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SUMMARY 
 
The formation of the vascular network in the embryo is a highly complex event that is 
controlled on multiple levels in a spatial and temporal manner. Initial formation takes 
place by vasculogenesis, i.e. the de novo formation of a primitive vessel network by 
mesodermal endothelial progenitor cells. Subsequent remodeling and expansion into 
a mature, diverse vasculature is undergone by angiogenesis, which refers to the 
proliferation of pre-existing endothelial cells. Both processes are controlled by a 
number of molecular signals such as receptor/ligand complexes, adhesion and matrix 
molecules as well as signaling intermediates that have been uncovered in the past 
years. However, the transcriptional mechanisms that regulate the initial differentiation 
of endothelial progenitor cells to mature tissue are not well-understood. We have 
used mouse embryonic endothelial progenitor cells (eEPCs) derived from E7.5 
embryos – when vascular structures begin to form - as an in vitro model to study the 
process of endothelial cell maturation. We found that Foxc1 and Foxc2, two 
members of the winged/helix Forkhead transcription factor family, are induced during 
cAMP-stimulated differentiation of eEPCs in vitro. Forkhead transcription factors 
comprise of a group of DNA binding proteins that act as trans-activators as well as 
trans-repressors at target gene cis-regulatory areas and are involved in a wide 
variety of biological processes in animals and fungi. Because Foxc1 and Foxc2 have 
been also implicated in cardiovascular development, we investigated their role during 
eEPC-differentiation.  The work described in this Ph.D. thesis provides evidence that 
Foxc1 contributes to the de novo activation of the vascular-specific gene Pecam-1 
(platelet endothelial adhesion molecule-1). In contrast, Foxc1 appears to down-
regulate Pecam-1 expression in mature endothelial cells.  In vitro promoter analysis 
revealed that the de novo activation of Pecam-1 in response to Foxc1 is mediated by 
a distal upstream regulatory element. Further analysis uncovered that Foxc1 does 
not bind to a bone fide Fox binding site, but to a microsatellite sequence consisting of 
repeats of the Fox binding site core ‘TTTGT’ motif.  Stepwise deletion of this repeat 
motif gradually reduces the ability of Foxc1 to activate the Pecam-1 promoter in vitro. 
Chromatin immunoprecipitation assays showed that Foxc1 protein has the capability 
to bind to the (TTTGT)n pentanucleotide repeat motif in the chromosomal context in 
vivo. Interestingly, the suppression of the Pecam-1 gene in adult endothelial cell lines 
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appears to be mediated by a different element immediately upstream from the 
transcription initiation site.  In summary, our study identified a new transcriptional 
control mechanism for the de novo Pecam-1 expression in immature embryonic 
EPCs, thus providing new insight into to the understanding of vascular specific gene 
expression.  
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1. INTRODUCTION 
 
1.1 The Vascular System  
 
As the first functional organ to develop in the embryo, the cardiovascular system 
plays a critical role during vertebrate development and homeostasis. Arising primarily 
from cells of mesodermal origin, it provides the embryonic tissues with oxygen and 
nutrients [1]. Blood vessels appear almost simultaneously during embryogenesis at 
different anatomical sites including the extraembryonic yolk sac membrane, the 
proximal lateral mesoderm and the allantois. Endothelial cells form the major 
compartment of the blood vessels where they line the innermost layer (luminal side) 
and are involved in multiple processes such as cell trafficking, nutrients and oxygen 
delivery, regulation of the vasomotor tone, maintenance of blood circulation as well 
as expansion of the vasculature through proliferation [2]. Endothelial cells contain 
distinctive morphological properties such as the presence of Weibel-Palade bodies 
and caveolae [3] as well as distinct molecular features, e.g. the expression of specific 
genes [4]. 
 
1.2 De novo formation of the vasculature – Vasculog enesis  
 
The initial event of blood vessel formation during embryonic development is called 
vasculogenesis, which describes the in situ and de novo assembly of vascular 
structures from differentiating progenitor cells [5]. Mesodermal cells migrate through 
the primitive streak and begin to differentiate to endothelial progenitor cells in lateral 
and posterior areas, such as the head mesenchyme and posterior lateral plate 
mesoderm. In particular, progenitor cells appear within the cranial region in a bilateral 
distribution along the midline and begin to form the pre-endocardial tubes [6]; these 
will later fuse and give rise to the endocardium (the inner layer) of the primitive 
embryonic heart and the major blood vessels [5, 7]. As development progresses, 
endothelial progenitor cells gradually appear in most areas of the intraembryonic 
mesoderm (except the notochord and the prechordal plate) in vascular “hot spots” 
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where they assemble into the primitive de novo vascular network of the embryo [8]. 
In parallel to intraembryonic vasculogenesis, the extraembryonic blood vessels form 
first in the yolk sac where cells within the inner, mesodermal layer assemble in 
clusters called blood islands [9].  The Flk-1+/Tal1+ cells in the blood islands 
differentiate at the perimeter into endothelial progenitors, whereas those in the center 
lose Flk-1 (or VEGFR2) expression and give rise to extraembryonic Flk-1-/Tal1+ 
hematopoietic precursors [6].  Morphogenetic observations and the close association 
of early blood and endothelial cells led to the idea of a common precursor for both 
endothelial and hematopoietic progenitor cells in the yolk sac, called the 
hemangioblast [9, 10]. 
 
1.3 Expansion and maturation of the vasculature – A ngiogenesis  
 
Whereas the primitive vascular plexus in the yolk sac and the major intra-embryonic 
vessels are formed by vasculogenesis, subsequent remodeling and expansion of the 
vasculature takes place by angiogenesis, i.e. the proliferation, sprouting and 
migration of pre-existing endothelial cells at the onset of embryonic circulation [11, 
12], yielding an extended network of arteries, veins, capillaries, and lymphatics. 
Several intra-embryonic tissues such as the kidney, thymus, brain, limb and choroid 
plexus are solely vascularized by angiogenesis, whereas certain endodermal tissues, 
such as lung or the liver undergo blood vessel formation by vasculogenesis [13, 14]. 
Angiogenesis also occurs by non-sprouting intussusceptive microvascular growth 
(IMG), i.e., the splitting of the existing vasculature by transluminal pillars or 
transendothelial bridges [15, 16].  
Vessel maturation is achieved by recruitment of supporting smooth muscle cells 
(SMCs) and pericytes and production of extracellular matrix (ECM) to stabilize the 
nascent vessels. Pericytes form a layer and surround the endothelium in capillaries 
and post-capillary venules, whereas large vessels, such as arteries, are surrounded 
by mural cells (SMCs), that form a multilayer around the elastic artery wall [17, 18]. 
Depending on their final localization during development, SMCs differ in their origin, 
e.g. the first SMCs in the embryo derive from mesoderm cells, pericytes in the 
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forebrain derive from neural crest cells and SMCs around vessels that lead to the 
heart originate from the epicardium (the outer layer of the heart) [19]. 
Under physiological conditions, the adult endothelium is quiescent and the majority of 
endothelial cells do not undergo cell division in postnatal life.  However, vascular 
remodeling and the pro-angiogenic activity do not entirely cease during adulthood but 
remain active during the pro-angiogenic activity in the corpus luteum during the 
female reproductive cycle [20, 21].  
 
1.4 The vasculature in disease states  
  
The vascular system plays a critical role in many human diseases. Abnormal 
remodeling of the vasculature can lead to psoriasis (hypervascularity of skin vessels) 
and pulmonary hypertension [22]. Increased vascularization can cause retinopathy 
(damage of the retina in the eye) [23] and rheumatoid arthritis. Atherosclerosis 
(occlusion of arteries) is an abnormal deposition of SMCs and mononuclear cells in 
the artery wall, mainly triggered through over-expressed inflammatory cytokines [24]. 
In addition, postnatal angiogenesis is activated during pathological conditions like 
wound healing or tissue ischemia. Moreover, tumor growth depends on the tumor’s 
ability to induce blood vessel growth through angiogenesis or vasculogenesis [12, 
25]. The main goals of clinical research in the field of vessel growth are to block 
vascularization in diseases like retinopathy or cancer and to enhance 
neovascularization in patients who suffered myocardial infarction and stroke or have 
peripheral vascular diseases. 
 
1.5 Characteristics of adult EPCs  
  
Postnatal blood vessel growth, for example during vascular disease states, mostly 
depends on the proliferation of mature, pre-existing endothelial cells or angiogenesis 
[12]. However, within the last years, numerous studies showed that mononuclear 
bone marrow or peripheral blood precursor cells have the potential to take part in the 
formation of new blood vessels, a process called adult or neo-vasculogenesis [12, 
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26, 27]. Those endothelial progenitor cells (EPCs) are characterized as CD34+/Flk-1+ 
cells. In the bone marrow, human EPCs also express CD133 (formerly AC133), a 
surface antigen of hematopoietic precursors, in contrast to circulating EPCs that have 
lower expression of CD133 [28-32]. However, no specific antigen profile has been 
uncovered to characterize EPCs as a distinct cell type from other mononuclear cells 
in the bone marrow and peripheral blood.  Past studies suggest that EPCs do not 
consist of a unique cell population but are probably derived from a subpopulation of 
mononuclear cells, which acquire endothelial characteristics when recruited to 
ischemic or angiogenic environments.  In accordance, EPCs also express myeloid 
monocytic markers like CD14 [33].   
 
1.6 EPC promote neovascularization  
 
Since the original publications about ten years ago, numerous studies demonstrated 
the potency of bone marrow mononuclear cells to differentiate to EPCs and then 
endothelial cells [28-30, 34-36].  By using various animal models of disease, these 
experiments provided evidence about the involvement of EPCs in blood vessel 
growth in ischemic myocardium [37-39], ischemic hindlimb [33-35, 40, 41], in cerebral 
ischemic tissue [42], or during tumor growth [43, 44].  Collectively, these studies 
showed that EPCs home specifically to areas of active angiogenesis, associate 
closely with the vascular wall and participate in vessel formation, mostly through the 
stimulation of angiogenesis and enhanced tissue recovery.  
The increasing importance of modulating vascular growth in clinical therapies during 
disease states has fostered intensive studies to uncover the molecular and cellular 
mechanisms that guide blood vessel growth during both, embryonic and postnatal 
vascularization. 
 
1.7 Molecular control of blood vessel formation  
 
Vascular formation is a complex, highly organized mechanism, relying on the correct 
spatial and temporal expression of specific sets of genes, that eventually result into 
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the formation of the vascular network [14, 45, 46]. Different molecular factors carry 
out distinct functions, such as endothelial growth stimulation or regulation of vessel 
maturation. Among them are e.g. extracellular ligands and their receptors, cell 
adhesion molecules, extracellular matrix components and intracellular signaling 
intermediates. The initiation of embryonic endothelial specification is driven by 
Fibroblast Growth Factor-2 (Fgf2) [47]. During subsequent vascular formation, three 
families of receptor tyrosine kinases and their ligands play major roles: the VEGF 
(Vascular Endothelial Growth Factor) family and their receptors [48, 49], the 
angiopoietins and their Tie receptors [50], and the ephrins and their Eph receptors 
[51].  
 
1.7.1 VEGF and VEGF-Receptors 
 
VEGF signaling is crucial to achieve a continued vascularization of the developing 
embryo, including organs such as heart and brain, as well as growth of the major 
blood vessels. The VEGF family consists of six members, VEGF-A – VEGF-E and 
PlGF (Placental Growth Factor). Three VEGF-receptor tyrosine kinases (VEGFR1-
VEGFR3) have been identified. VEGFR1 (Flt-1) and VEGFR2 (Flk-1) are expressed 
on the vascular endothelium, whereas VEGFR3 (Flt-4) is  restricted to lymphatic 
endothelium [52]. 
VEGF-A (usually termed VEGF) has the ability to induce proliferation, differentiation 
and migration of endothelial progenitor cells in vivo and in vitro and it is essential in 
both processes of vasculogenesis and angiogenesis [51]. Mutations of VEGF or 
VEGFR2 lead to early embryonic lethality. In the adult, lack of VEGF affects mainly 
wound healing or the ovarian corpus lutei [53]. The second VEGF receptor, Flt-1 
(VEGFR1) modulates VEGF signaling through Flk-1 (VEGFR2) and is involved in 
hemangioblast commitment. VEGF signaling is also modulated by the members of 
the neuropilin (NRP) family, which form a family of transmembrane proteins and bind 
members of the VEGF family, thus functioning as regulators of vasculogenesis [54]. 
Further, members of the neuropilin family differentially mark the arterial-venous 
system, with NRP-1 being expressed in arterial ECs, whereas NRP-2 is found on 
venous endothelium and later on lymphatic vessels [55]. 
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1.7.2 Angiopoietins and Tie-Receptors 
 
Angiopoietins, which comprise four secreted proteins (Ang1, Ang2, Ang3, and Ang4), 
and their receptors, the Ties (Tie-1 and Tie-2) function subsequent to the action of 
VEGF and have an important role in vessel maturation or destabilization by 
regulating processes such as endothelial sprouting, vessel wall remodeling and 
mural cell recruitment [50]. Ang1 counters the function of VEGF by promoting and 
maximizing the tight contact between ECs and underlying support cells, thus 
maintaining the quiescence and stabilization of the vessel [56]. In turn, a second Tie-
2 ligand - Ang2 - acts as a natural antagonist of Ang1 and leads to opposite effects 
like de-stabilization of the vessel wall [57].  
 
1.7.3 Ephrins and Eph Receptors 
 
Artery-vein cell fate is genetically programmed by numerous factors, including 
members of the Eph/ephrin family, which are expressed differentially in arterial and 
venous ECs. The Eph Family consists of at least 14 members and their counterparts, 
the ephrins, of at least 8 members. This receptor/ligand system stands out inasmuch 
that both, the receptor and its ligand must be membrane-bound to induce signaling 
into the cell [53]. Knockout studies showed that ephrinB2 and EphB4 are involved in 
the important specification of arterial and venous vessel identity, with EphB4 being 
expressed in veins whereas ephrinB2 marking arteries [58-60]. Mutations in both 
ephrin-B2 and Eph-B4 lead to embryonic lethality at E9.5, showing failure to remodel 
the primitive vascular plexus into arteries and veins.  
 
1.7.4 Extracellular Matrix and Cell Adhesion Molecules 
 
Matrix Metalloproteinases (MMPs) are zinc-dependent enzymes that partake in 
degrading the extracellular matrix during angiogenesis, thus permitting ECs to 
migrate into the surrounding tissue [45]. Their function is countered during vessel 
formation by circulating tissue-localized inhibitors of matrix metalloproteinases 
(TIMPs) [61]. 
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The assembly of migrating ECs into solid cords is established by cell-cell contacts 
through adhesion molecules, e.g. Pecam-1 (Platelet-Endothelial Cell Adhesion 
Molecule-1) [62] and members of the cadherin surface molecule family such as N-
cadherin (Neuronal-Cadherin) and VE-cadherin (Vascular endothelial-cadherin), 
which are expressed in ECs [63-65]. Integrins, a family of transmembrane proteins, 
mediate cell adhesion to proteins of the extracellular matrix and partake in the 
regulation of angiogenesis [66, 67], e.g. the integrin family member αvβ3 is expressed 
on angioblasts where it functions during EC maturation and vessel formation [68].  
Extracellular matrix molecules such as fibronectin support the formation of the basic 
vascular network [69]. During vessel maturation, fibronectin decreases and ECs 
synthesize collagen type IV and laminin that support the stability of the vascular 
tubes [70].   
 
1.7.5 Other signaling pathways involved in vascular development 
 
The Notch-Delta pathway is involved in driving the differentiation of the primitive 
vessel network toward a hierarchy of mature vascular beds and controls arterial cell 
fate as well as homeostatic functions of mature arteries [71, 72]. This pathway is a 
highly conserved mechanism comprising of four receptors (Notch 1-4) and five 
ligands (Jagged-1 and -2 and Delta-1,-3,-4), and all these factors have been shown 
to have expression patterns in different components such as arteries, veins, 
capillaries, and mural cells. Mutations in Notch receptors, ligands and downstream 
components lead to strong vascular defects [73]. 
 
During maturation of newly formed vessels, members of the transforming growth 
factor-beta (TGFβ) and platelet derived growth factor (PDGF) family inhibit 
proliferation and migration of ECs [18, 74]. PDGF-B is secreted by ECs in response 
to VEGF, and lack of PDGF-B leads to impaired pericyte recruitment [75]. Pleiotropic 
TGFβ-signaling consists of an essential role during vascular development, controlling 
EC migration as well as maturation [76].  
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1.7.6 Cytokines 
 
Several cytokines such as GM-CSF (Granulocyte-Monocyte Colony Stimulating 
Factor) or SDF-1 (Stromal Cell-Derived Factor-1) stimulate the migration of EPCs 
from the bone marrow to sites of neovascularization in adults [41, 77-79].  
 
1.7.7 Angiogenic inhibitors 
 
Besides numerous pro-angiogenic factors, several naturally occurring inhibitors of 
angiogenesis exist [45], among them thrombospondin, angiostatin or endostatin [80, 
81]. 
 
1.7.8 Haemodynamic forces 
  
Next to oxygen and genetic factors, the vascular system is shaped by the influence of 
haemodynamic forces, such as shear stress, i.e. the tangential, mechanical force 
acting upon the surface of the endothelium [14, 82]. Blood flow dynamics was shown 
to induce changes in vessel branching angles to allow optimization of flow, and shear 
stress has been suggested to be a driving force for the release of angiogenic signals 
[83]. 
 
1.8 Transcriptional control of vascular formation  
 
Besides extracellular signaling factors, surface receptors, and matrix molecules that 
have been described during blood vessel growth, factors also regulate vascular 
development on the transcriptional level and control the genetic regulation of 
endothelial differentiation. During development, transcription factors serve as master 
switches in activating the expression of tissue and cell-line specific genes. Unlike 
during developmental processes such as hematopoiesis or myogenesis, where a 
wide set of important transcriptional regulators have been uncovered in the past, only 
a few transcriptional regulators of vascular development are known to date [84].  
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1.8.1 Ets transcription factors 
 
The majority of the identified transcription factors during vascular development are 
activators of the expression of e.g. certain tyrosine kinase receptors like Tie1 and 
Tie2 or Flk-1 (VEGF receptor 2) and Flt-1 (VEGF receptor 1). Regulatory elements in 
the genomic regions of these genes were shown to contain binding sites for 
members of the Ets-family of transcription factors, e.g. Ets-1, Ets-2, and Fli-1 [85-89].  
For example, Tie1 and Tie2 were strongly activated by the Ets-family members 
NERF and ELF-1 [85, 86], with the latter one being strongly enriched in developing 
chicken embryos. In addition, the Ets-factor Fli-1 is enriched in the developing 
vasculature of zebrafish [88] and was shown to be a critical factor of vascular 
development in both, the zebrafish and E11.5 Fli-1 knockout mice, which display loss 
of vascular integrity [88, 89]. Ectopic expression of the transcription factor SCL/Tal1 
in zebrasfish mesoderm allowed identification of an important role of this gene in 
vasculogenesis, hematopoiesis and endothelial differentiation [90]. In addition, 
SCL/Tal1 is expressed in both, mouse and zebrafish embryos, where it can be 
detected in the developing vasculature [90, 91]. The Gata transcription factor family 
member Gata-2 was shown to be strongly expressed in endothelial cells and serves 
as an important regulator of the expression of vascular-specific genes, such as Flk-1, 
Icam-2 (Intercellular Adhesion Molecule-2), eNOS (endothelial nitric oxide synthase) 
and Pecam-1 [87, 92-94].  
 
1.8.2 Basic Helix-Loop-Helix Transcription Factors 
 
Basic Helix-Loop-Helix (bHLH) transcription factors are involved in the formation of 
the vasculature. The bHLH protein Tfeb was shown to be required for the 
vascularization of the placenta [95] and the transcription factor HESR1 is upregulated 
during vascular tube formation, where in turn it downregulates the expression of Flk-
1, thus lowering the responsiveness of ECs to VEGF, eventually resulting into 
increased vessel maturation [96]. 
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1.8.3 Homeobox Transcription Factors 
 
Capillary morphogenesis is under the partial control of the homeobox gene HoxB3, 
with ectopic overexpression of this gene resulting into increased capillary density in 
the chorioallantoic membrane of embryos [97, 98]. The related homeobox 
transcription factor HoxD3 was shown to regulate the expression levels of integrin 
αvβ3 on endothelial cells [99] and endothelial differentiation is enhanced after 
overexpression of the homeobox transcription factor gene hhex in zebrafish embryos 
[100].  
 
1.8.4 Further Transcription Factors 
 
Further transcription factors required for endothelial differentiation include the 
immediate-early gene Fra1 - an AP-1 transcription factor family member - whose 
deletion leads to a reduced number of endothelial cells in the placenta [101]. The 
zinc-finger transcription factor gene Vezf1 is expressed specifically in endothelial 
cells and their progenitors as well as ECs of the dorsal aorta, the branchial arch 
artery and the endocardium [102] and its expression co-localizes with Flk-1. The zink-
finger transcription factor gene LKLF is expressed in non-vascular and vascular cells, 
and its loss leads to abnormalities during the late stages of vascular formation [103]. 
 
1.8.5 Hypoxia and HIFα 
 
Hypoxia serves as a master stimulus in promoting the growth of new blood vessels, 
thereby inducing the expression of transcription factors that mediate this response. 
Among them is the bHLH-PAS domain transcription factor HIF1α (hypoxia inducible 
factor 1α) that mediates the expression of angiogenic genes, such as VEGF during 
low-oxygen conditions [104, 105].  
Signaling pathways that partake in the transcriptional induction of vascular and 
angiogenic genes involve the PI3-kinase (Phosphoinositide 3-kinases) pathway, that 
modulates VEGF induction by hypoxia. The catalytic subunit p110 induces HIF1α 
activity in response to hypoxia [106], and the mitogen-activated protein kinases p42 
and p44 have been shown to modulate HIF1α activity through phosphorylation [107]. 
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1.9 Embryonic endothelial progenitor cells (eEPCs) as a model system  
 
As mentioned above, bone marrow derived progenitor cells with endothelial potential 
partake in postnatal neovascularization processes. A number of endothelial lineages 
have been established in the past for in vitro studies to disclose the cellular 
processes of vessel development, including mature lines from diverse vascular beds 
of different species as well as CD34+ progenitor cells [4]. In order to gain further 
insight into the molecular mechanisms of endothelial cell growth and differentiation, 
our group took advantage of an embryonic endothelial progenitor (eEPC) line that 
was isolated by Hatzopoulos and coworkers [108].  
These cells were cultured from intra-embryonic egg cylinders of trypsin-dissociated 
mouse embryos at day 7.5 during midgestation, prior to the formation of the 
cardiovascular system. They represent a subpopulation of the first angioblasts in the 
embryo proper during development and show unlimited stem cell-like growth and 
properties of endothelial progenitor cells. Expression profile analysis indicates that 
these cells are derived from the embryonic proximal lateral mesoderm and represent 
an early pro-endocardial population. They express the stem-cell marker c-Kit as well 
as early endothelial markers like thrombomodulin and Tie2. In culture, they show a 
round to spindle-like shape and bind to GSL I B4 isolectin that interacts specifically 
with ECs and EPCs [109]. RNase protection assays - a method for gene expression 
studies - revealed that retinoic acid and cyclic adenosine monophosphate (cAMP) 
are capable to induce differentiation of these embryonic endothelial progenitor cells 
(eEPCs) toward more mature endothelial cells that express endothelium specific 
Flk-1 and vWF [109]. Furthermore, eEPCs can differentiate and form tube-like 
structures when plated in Matrigel (an extra-cellular matrix basement material) [109]. 
Taking together, the data showed that these embryonic mesodermal cells have the 
properties of EPCs and can differentiate into mature ECs. Interestingly, eEPCs do 
not express endothelial progenitor marker genes such as CD34 [40, 110] or Flk-1 
[111] before retinoic acid/cAMP treatment, but they show high levels of the 
endothelial surface protein Tie2. They display unlimited growth potential ex vivo with 
population doublings every 24 hours. Further, eEPCs were shown to retain their 
properties of endothelial progenitor cells after ex vivo culturing and they form 
vascular structures after injection into host chick embryos. Animal models showed 
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incorporation of eEPCs into the tumor microvasculature in lung carcinomas in mice 
[112] and eEPCs displayed intensive therapeutic potential inside damaged tissue in 
models of ischemic hind limb and myocardial infarction [113, 114]. Moreover, using 
eEPCs, it was shown that homing of progenitor cells from the circulation to the tumor 
vasculature is mediated by adhesive mechanisms that resemble the interaction of 
activated leukocytes with the vessel wall and involve ESL-1 (E-selectin ligand) and 
PSGL-1 (P-selectin ligand) expressed on eEPCs, and their respective receptors – E-
selectin and P-selectin – expressed on resident endothelial cells [112].  
In summary, embryonic EPCs have provided a new tool and allowed us to gain 
further insight into the molecular and cellular biology of endothelial progenitor cells 
and their behavior in postnatal vasculogenesis and organ vascularization.  
 
1.10 Foxc1 and Foxc2 are induced during eEPC in vitro differentiation  
 
In order to elucidate new vascular specific regulatory factors, the eEPC transcriptome 
was analyzed by means of Affymetrix GeneChip, which uncovered a number of 
genes induced or suppressed during in vitro differentiation. Among the induced 
genes were Foxc1 and Foxc2, two closely related members of the Forkhead/winged 
helix (Fox) transcription factor gene family [115, 116].  
 
1.11 Forkhead (Fox) Transcription Factors  
 
1.11.1 General characteristics of Fox Genes 
 
Fox genes encode a subclass of the helix-turn-helix class of transcription factors and 
comprise a monophyletic group of DNA binding proteins with an approximately 110-
amino acid conserved monomeric DNA binding domain [117], called the Fox 
(Forkhead) domain. The structure of the Fox domain is based on a helix-turn-helix 
core of three α-helices, flanked by two looped wings [118], giving Fox proteins the 
alternative name winged helix proteins, due to this butterfly-like three-dimensional 
structure [116, 119]. The Drosophila melanogaster forkhead gene and the rat Foxa1 
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gene were the first identified members of this gene family [120, 121] and since then, 
Fox genes have been identified in numerous species, ranging from yeast to 
mammals [115, 116]. Because of their wide functional variety in biological processes, 
there is no simplified scheme of a general function of all members of the Fox gene 
family. Fox transcription factors have been shown to act as trans-activators as well as 
trans-repressors and unlike most helix-turn-helix proteins, Fox proteins bind as 
monomers to an asymetric target sequence and are most likely to activate gene 
expression directly by opening up the chromatin structure close to the target gene 
locus [122]. In addition, little is known about the interactions of Fox proteins with the 
basic transcriptional machinery, although Foxf2 has been shown to interact with the 
general transcriptional regulators TBP and TFIIB in vitro [123].  
 
1.11.2 Nomenclature of Fox Genes 
 
Chordate Fox genes are divided into 17 subclasses, or clades, namely A-Q, based 
on the amino acid sequence of the conserved Fox (Forkhead) domain. Kaestner and 
coworkers revised the nomenclature system for Fox transcription factors, leading to a 
standardized name system that uses Fox (from Forkhead Box) as a root and divides 
the members into subfamilies [115]. Each member of a respective subfamily is further 
defined by a number, e.g. Foxa2 or Foxf1. This ensures a unified nomenclature 
between species and identifies orthologues family members between species. 
Comprehensive and updated information about Fox genes is available online under 
http://www.biology.pomona.edu/fox.html. 
 
1.11.3 Chromosomal organization of Fox genes 
 
Generally, Fox genes are distributed throughout the whole genome of a species and 
do not show any physical clustering. However, certain members of the human FOX 
gene family within the human genome show proximity, e.g. FOXQ1-FOXF2-FOXC1 
(on chromosome locus 6p25.3) or FOXC2-FOXF1-FOXL1 (locus 16q24.1), giving 
evidence for anchestreal intra-and inter-chromosomal gene duplications [124]. 
Ancient loci duplications, followed by sequence divergence, are thought to be 
responsible for the expansion of the Fox gene family. In some cases, the duplications 
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date back in evolution before the separation of zebrafish and coelacanths (jawed 
fish), as for Foxc1 and Foxc2, since these genes are present in both eukaryotic 
organisms [119]. Most of the vertebrate Fox genes have only a few small introns and 
some are even intronless, such as Foxc1, Foxc2, Foxd1, Foxd2 and Foxg1, whereas 
others such as Foxo1 and Foxo3 genes have large introns up to 130kb separating 
the Forkhead domain [116]. 
 
1.11.4 Fox Genes in Development 
 
Since the discovery of the first Fox gene, the biological importance of this gene family 
has become of significance because they partake in a wide variety of biological 
functions, e.g. cell cycle control, cell differentiation, metabolic control, and 
developmental processes such as the establishment of the body axis and the 
development of various tissues from all three germ layers [116, 119].  
For example, Foxh1 was shown to regulate the establishment of the left-right body 
axis in zebrafish and mouse embryos [125, 126] and mutations in Foxj1 lead to sinus 
inversus, i.e. abnormal laterality of the heart [127].  Hair development in mammals 
involves Foxq1 and Foxn1 and mutations in Foxq1 causes aberrant differentiation of 
the hair shaft [128] whereas Foxn1, that is specifically expressed in the skin and the 
thymic epithelium, leads to the nude phenotype in newborn mice, that is 
characterized by the absence of hair and severe immunodeficiencies [129, 130]. 
Impaired organogenesis also occurs in Foxi1 -/- mice, which display intense inner ear 
structural dysgenesis and severe hearing impairment [131], due to a lack of Foxi1 
expression in the ectodermal epithelium of the otic vesicle. Foxe3 is another Fox 
gene required for specification of ectodermal epithelia, where it controls the 
proliferation of ectodermal lens cells [132]. FoxA genes (Foxa1, Foxa2, Foxa3) are 
expressed in the vertebrate endoderm and formation of the epithelial gut tubes is 
impaired in Foxa2 -/- embryos [133, 134]. Other organs relying on Fox gene function 
involve the lung, where gene expression in the epithelium is controlled by Foxa1 and 
Foxa2 [135] and Foxj1 [127, 136, 137] as well as Foxp2 [138], which guide the 
specification of ciliated cells in the airway epithelium. In contrast, Foxf1 is expressed 
in the lateral plate mesoderm and the posterior primitive streak where it drives the 
separation of the lateral plate into splanchnic and somatic mesoderm [139, 140] and 
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Foxb1 deletions were shown to cause embryonic lethality with an open neural tube 
and dysgenesis of the caudal midbrain [141]. The development and differentiation of 
neuronal cells is controlled by several members of the Fox gene family such as 
Foxg1 that regulates the development of the cerebral hemispheres in the 
neuroectoderm, where it controls the proliferation of telenchephalic neuroepithelial 
cells [142, 143]. Foxd3 was shown to regulate and maintain the neural crest stem cell 
pool in zebrafish [144]. Adult myogenic stem cells require Foxk1 expression for 
proper cell cycle regulation and myogenic cell commitment [145].  
 
1.11.5 Fox Genes in Signaling Pathways  
 
Fox genes have been related to a number of important signaling pathways, where 
they function as downstream activators or repressors of transcription. Mammalian 
Foxh1 is involved in mediating TGFβ induced downstream responses during target 
gene activation. In addition, Foxh1 was shown to form a complex with smad2 and 
smad4, both intermediate signal transducers downstream of activin signaling, a 
member of the TGFβ superfamily [146-149]. Conversely, Foxg1 was shown to inhibit 
gene activation in response to TGFβ-type signaling [150, 151]. Sonic hedgehog 
signaling activates several mammalian Fox genes, such as Foxa2 in the floorplate of 
the neural tube or Foxc2 and Foxd2 in the presomitic mesoderm and Foxf1 
expression in the sclerotomes was shown to depend on Shh signaling from the 
notochord [152]. Foxl1 function was linked to Wnt/b-catenin/TCF signaling pathway in 
the intestinal mesenchyme [153]. 
Furthermore, FoxO genes have been linked to Akt/PKB (Protein Kinase B) signaling, 
where they are involved in cell cycle regulation. Phosphorylation by PI3K/PKB leads 
to arrest of the cell cycle entry in G1 [154] and Foxo4 was shown to be 
phosphorylated by Ras signaling, placing certain Fox proteins downstream from 
major signaling pathways [116, 154, 155]. Mammalian FoxM1 is activated upon the 
cell’s entry into the S-phase and has been implied in the regulation of DNA 
replication [156].  
Despite this wealth of information, the precise genetic program of Fox genes, 
including their regulators and downstream targets, yet has to be identified for most of 
the family members.  
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1.11.6 Fox Genes in Human Diseases 
 
Since Fox family members play pivotal functions during organogenesis and in the 
maintenance of physiological homeostasis, mutations or deletions in human FOX 
genes, e.g. in the case of FOXC1, FOXC2, FOXE1, FOXP2, lead to various human 
congenital disorders and malformations, such as skeletal, craniofacial, immune and 
circulatory defects. A majority of the known eight human disorders, that are caused 
by mutations in Fox genes, are autosomal dominantly inherited. The mutations 
frequently lie within the highly conserved Forkhead Domain, i.e. the DNA binding 
domain [116].  
 
In the human genome, FOXC1 lies in the 6p25 forkhead cluster and mutations of this 
gene cause Axenfeld-Rieger Syndrom, characterized by defects in eye development, 
eventually resulting into glaucoma [157-159]. Malformations of the anterior chamber 
of the eye have also been linked to mutations in FOXE3 [160] and mutations in 
FOXL2 and FOXC2 cause eyelid defects and lymphedema [161-165]. A fraction of 
primary endometrial and ovarian cancers exhibit FOXC1 inactivation, suggesting a 
tumor suppressor gene role for FOXC1 [166].  FOXL2 also has been implicated in 
premature ovarian failure [167], and FOXN1 deficiency causes T-cell 
immunodeficiency and skin disorders [168]. Speech and language disorders in 
humans have been linked to FOXP2 [169]. FOXA1 is overexpressed in esophageal 
and lung cancer [170], whereas FOXM1 expression levels were shown to be 
elevated in pancreatic cancer [171] and in basal cell carcinomas [172]. In acute 
lymphoid leukemia, fusion proteins consisting of the DNA binding domain of a certain 
transcription factor and the transactivation domain of FOXO3 or FOXO4 can cause 
oncogenic transformations [173-175]. 
There is increasing interest in disclosing the precise biological and molecular function 
of Fox gene family members, since a profound understanding of their role may lead 
to novel therapeutics as well as diagnosis and prevention of certain human genetic 
diseases. 
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1.11.7 Fox Genes in the Adult Organism 
 
Interestingly, many Fox genes show an expanded repertoire of functions in the adult 
organism, compared to embryonic life. Metabolic control in liver, lung, intestine and 
pancreatic tissues is one of the major functions of Fox genes in adult tissues, as it 
was shown for members of the FoxA subfamily, by the use of conditional knock out 
mice [135]. Likewise, a functional switch from embryonic control of morphogenesis to 
adult control of metabolism in adults is seen for Foxc2, which regulates metabolic 
efficiency in response to the energy content of the diet [176] and FoxO subfamily 
genes were shown to be involved in insulin/IGF signaling in the adult organism [116, 
155, 177]. 
 
1.12 The FoxC subfamily - Foxc1 and Foxc2  
 
Foxc1 and Foxc2 proteins have nearly identical DNA binding domains, suggesting 
that they were generated by a duplication event [115]. The role of the mouse Foxc1 
and Foxc2 genes during embryogenesis and the resulting phenotypes after gene 
knock out in mice was the subject of extensive research during the last years, 
implicating these two genes in cardiovascular development [178-181].   
 
1.12.1 Expression Patterns 
 
Initially, FoxC genes are expressed in a dorsoventral gradient and they display 
overlapping expression patterns in several embryonic tissues, e.g. the paraxial, 
cephalic, and nephrogenic mesoderm [180, 182]. In addition, FoxC transcripts are 
localized in the endothelium and the surrounding mesenchyme of the developing 
blood vessels and the heart [178, 179, 181, 183, 184] and both genes were shown to 
be expressed in the nuclei of endothelial and smooth muscle cells in the aorta of the 
developing embryo [180].  
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1.12.2 Abnormalities in FoxC mutant embryos 
 
For the most part, Foxc1 and Foxc2 are partially functionally redundant and display 
interactive roles during cardiac and renal morphogenesis, since compound 
heterozygous embryos (Foxc1 +/- ; Foxc2 +/-) have similar defects as single null 
mutant embryos, whereas compound null mutant embryos (Foxc1 -/- ; Foxc2-/-) 
display much more severe abnormalities. Most compound heterozygotes (Foxc1+/-
;Foxc2+/-) as well as single homozygotes (Foxc1 -/- or Foxc2 -/-) die pre-or 
perinatally with similar phenotypes, such as cardiovascular, multiple skeletal, 
urogenic, and ocular defects, as well as ventricular septal defects and pulmonary 
valve diplasia [178-180, 185-189]. However, blood vessels and somites form to a 
certain extent in those embryos, suggesting that Foxc1 and Foxc2 can compensate 
for each other to a certain degree in a dose-dependent function. Besides this, 
compound homozygote Foxc1, Foxc2 mice (Foxc1 -/- ; Foxc2 -/-) and compound 
heterozygous/homozygous embryos (Foxc1 +/- ; Foxc2 -/- or Foxc1 -/- ; Foxc2 +/-) 
die in utero with intensified malformations that are more severe than those of each 
single homozygous null embryo, undermining a dose-dependent function of the two 
transcription factors [180]. 
Blood vessels in embryos carrying Foxc1 and Foxc2 null mutations are disorganized 
vascular plexi without proper remodeling into a well-defined system of larger and 
smaller blood vessels, and compound Foxc1+/-;Foxc2-/- embryos display extensive 
defects in the morphology and remodeling in the head vasculature, and the number, 
size and organization of the branchial arch arteries is abnormal [180]. Further, the 
heart shows dysgenesis and is smaller than in wild type animals. In addition, FoxC 
transcription factors were shown to be involved in the regulation of arterial endothelial 
cell specification [181]. They directly activate transcription of the Notch ligand Dll4, a 
marker for arterial endothelium, through a Fox-binding site in the Dll4 promoter. 
Foxc1-/-;Foxc2-/- compound mutants have arteriovenous malformations and lack 
expression of arterial markers [181], making FoxC proteins important transcriptional 
regulators in arterial fate determination. Overlapping domains of expression have 
also been shown in the pro-epicardium, in cardiac neural crest cells and the 
endocardium, where a lack of Foxc1 and Foxc2 may affect the formation of the 
outflow tract cushions [190]. Because of its expression in cephalic neural crest 
derived mesechyme, Foxc1 mutations lead to hydrocephalus and defects in eye 
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development in the mutant embryo [187, 191] and craniofacial development is 
strongly impaired in these null mice, with maxilla and mandible, skull and facial gland 
developmental defects [188]. Foxc1 and Foxc2 were also shown to play a role in the 
specification of mesoderm to paraxial fate versus intermediate fate [178, 180, 185, 
187, 192], and double null mutants show a lack of paraxial mesoderm patterning and 
somite formation [180]. 
 
 
1.12.3 Foxc1 and Foxc2 - signaling pathways and target gene activation 
 
As for other members of the Fox gene family, little is known about the signaling 
pathways that interact with FoxC transcription factors downstream in the nucleus and 
so far, transcriptional target genes of FoxC proteins have lacked profound 
identification. Recent studies showed that the gene paraxis - a presumptive and 
definite paraxial mesoderm marker - contains several Fox binding sites in its 
promoter region [192], suggesting a direct regulation of that gene by Fox proteins. 
Foxc1 was shown to act as a TGFβ1 responsive gene in several human cancer cell 
lines and mesenchymal cells in Foxc1 null embryo lack proper differentiation into 
cartilage and do not response to added Bmp2 and TGFβ1 [187], showing that TGFβ 
family members can mediate their function involving members of the FoxC gene 
family. 
Further, Foxc1 was shown to regulate the proliferation of osteoprogenitor cells by 
controlling Bmp-driven expression of the homeobox transcription factors Msx2 during 
calvarial development [193], and the expression of Foxc1 in turn was shown to be 
regulated by FGF2 signaling [194]. Together, the proliferation of osteoprognitor cells 
is under strict genetic control of Bmp and Fgf signaling, and Foxc1 was identified as 
one of the downstream transcriptional regulators. Lack of activity of the T-box 
transcription factor Tbx1, a downstream target of FoxC proteins in the head 
mesenchyme, has been accounted for craniofacial defects and FoxC proteins were 
shown to function as intermediate factors in sonic hedgehog signaling during the 
transcriptional activation of Tbx1, that was identified as the first direct target gene of 
Foxc1 and Foxc2 during development [195]. Haploinsufficiency of Tbx1 is a major 
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factor of congenital cardiac and craniofacial defects, which are associated with 
DiGeorge syndrome, linking FoxC genes to that congenital disorder [195].  
 
1.13 Aims of the Ph.D. Project  
 
Because of the involvement of Foxc1 and Foxc2 in the development of the 
cardiovascular system and their induction during in vitro eEPC-differentiation, these 
two transcription factors were considered as interesting candidates to study 
transcriptional mechanisms during the transition from eEPCs to the mature 
endothelial cell phenotype. Since little is known about FoxC proteins regarding their 
direct transcriptional targets as well as the transcriptional regulation of endothelial-
specific gene expression, this Ph.D. thesis aimed in identifying new transcriptional 
targets of Foxc1 and Foxc2 in the vascular system, using embryonic EPCs as a 
cellular model system. The identification of mouse Pecam-1 as a Foxc1 target gene 
and the characterization of a distal 5’-flanking Foxc1 binding site are described 
herein. Further, core promoter areas and an enhancer from the 2nd intron of mouse 
Pecam-1 are characterized for their cis-regulatory activity in eEPCs, mature 
endothelial cells and non-endothelial lines.  
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2. MATERIAL and METHODS  
 
2.1 Tissue Culture  
2.1.1 Cell lines 
 
For the Ph.D. Thesis, the mouse embryonic endothelial progenitor cell (eEPC) lines 
FT4b, T17b, and T19b were used for all procedures. The isolation of eEPCs has 
been described previously by Hatzopoulos and coworkers [108]. In addition, bovine 
aortic endothelial cells (BAECs - American Type Culture Collection, Manassas, VA, 
USA), pancreatic endothelial cells (MS1-ECs - American Type Culture Collection), 
cardiac endothelial cells (H5V-ECs - kind gift from Bin Zhou, Vanderbilt University, 
Nashville, TN, USA – described in [196]), CGR8 mouse embryonic stem cells 
(FunGenES Consortium), NIH mouse 3T3 fibroblasts and green monkey (fibroblast-
like) kidney Cos7 cells (American Type Culture Collection) were used for the project.  
Embryonic EPCs were cultured on coated plates (0.1% porcine skin gelatin - Sigma-
Aldrich, St. Louis, MS, USA) to enhance attachment of the cells to the surface, and 
passaged every 3-4 days onto new plates. BAECs, MS1-ECs, H5V-ECs, Cos7 cells, 
and 3T3 fibroblasts were cultured on 0.1% gelatin-coated plates and passaged every 
5-6 days (or when the cell layer reached a density of around 100%). During growth, 
the cells were washed with 1X PBS (137 mM NaCl, 2,7 mM KCl, 4.3 mM Na2HPO4, 
1,4 mM KH2PO4, - Sigma-Aldrich) and supplied with fresh medium if the medium 
color turned into orange, indicating a pH below 7.5. 
ES cells were supplied with fresh medium daily to continuously provide active 
leukemia inhibitory factor (LIF) and prevent premature differentiation. They were 
cultured on 0.2% gelatin-coated plates (pre-coated for at least 3 hours) and 
passaged every 2-3 days (or before growing to a density of more than 70%, since a 
higher density can induce differentiation and thus cause the loss of pluripotency of 
the ES cells) onto fresh plates.  Tissue culture work was carried out in a sterile tissue 
culture bank (Clean Air Technik BV, Woerden, The Netherlands and NUAIRE 
Biological Safety Cabinets, Plymouth, MN, USA) and all cell lineages were incubated 
at 37°C, 5% CO 2, 21% O2 in a CO2 Water Jacketed Incubator (Thermo Forma, 
Marietta, OH, USA) and cultured on standard tissue culture plastic plates (NUNC 
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Brand Products, Nalgen Nunc International, Denmark or Sarstedt Inc., Newton, NC, 
USA).  
 
 
2.1.2 Tissue culture media 
 
Embryonic EPCs were maintained in DULBECCO´S Minimal Essential Medium 
(DMEM) (4.5 g/Liter Glucose, Mediatech Inc., Herndon, VA, USA or GIBCO 
Invitrogen Corporation, Carlsbad, CA, USA) supplemented with 20% heat-inactivated 
Fetal Bovine Serum (55°C - 30 min, GIBCO Invitrogen ), 1x Penicillin/Streptomycin 
(100x Stock - 10.000 units/ml Penicillin, 10 mg/ml Streptomycin, Mediatech or GIBCO 
Invitrogen), 2 mM L-Glutamine (Mediatech or GIBCO Invitrogen), 25 mM HEPES pH 
7.5 (Mediatech), 1x MEM non-essential amino acids (Mediatech or GIBCO 
Invitrogen), and 0.1 mM β-Mercaptoethanol (Sigma-Aldrich).  
BAECs, MS1-ECs, H5V-ECs, Cos7, and NIH 3T3 fibroblasts were maintained in 
DMEM (4.5 g/Liter Glucose) supplemented with 10% Fetal Bovine Serum, 1X 
Penicillin/Streptomycin and 2 mM L-Glutamine.  
CGR8 ES cells were maintained in Glasgow Minimal Essential Medium (GMEM, 
Sigma-Aldrich) supplemented with 10% Fetal Bovine Serum, 2 mM L-Glutamine, 
0.05 mM β-Mercaptoethanol, and 5x104 units Leukemia Inhibitory Factor (LIF, 
Chemicon Millipore Corporation, Billerica, MA, USA).  
Prepared tissue culture media were filter-sterilized using a 0.2 µm pore size SFCA 
Serum Filter Unit (Nalgene Filtration Products, Nalgene Nunc International, 
Rochester, NY, USA). 
 
 
2.1.3 Passage of cell cultures 
 
The split ratios for cell lines were as follows: FT4b,T17b, and T19b eEPCs -1:20 for 
3-4 days; MS1-ECs - 1:10 for 5-6 days; H5V-ECs - 1:5 for 5-6 days; BAECs - 1:10 for 
5-6 days; CGR8 ES cells - 1:5 for 3-4 days; Cos7 cells - 1:10 for 5-6 days; 3T3 
fibroblasts - 1:10 for 5-6 days. Before splitting, the cell layer was washed with 5 ml 
(60 mm plates) or 10 ml (100 mm plates) 1X PBS. To detach cells from plates, the 
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cell layer was incubated for 10 minutes with 1-2 ml of 0.05% Trypsin-EDTA (GIBCO 
Invitrogen). Trypsinization was stopped with serum through the addition of the 
respective growth medium. The cell suspension was then spun at 250 g for 5 min to 
pellet the cells. The supernatant was removed and cells were resuspended in the 
corresponding fresh growth medium and plated onto freshly gelatin-coated plates.  
 
 
2.1.4 Freezing and thawing of cell lines 
 
All cell lines were frozen in 90% FBS and 10% Dimethylsulfoxide (DMSO - Sigma-
Aldrich).  First, 1-2x106 cells were washed with 1X PBS, trypzinised, resuspended 
and then spun down (as described above). The supernatant was removed and the 
cells were resuspended in 4°C cold FBS. Subsequently, DMSO was added to a final 
concentration of 10%.  One ml of the cell suspension was then pipetted into a 
cryovial (Nalgene Nunc), stored at -20°C for 2 hours and subsequently transferred to 
-80°C for 2 days. Finally, the frozen cells were long-term stored in liquid nitrogen 
(around -196°C). To thaw frozen cell stocks, a cryovial was warmed quickly in a 37°C 
water bath until the cells were thawed. Immediately after, the cells were gently 
pipetted onto a 100 mm plate containing 25 ml of pre-warmed (37°C) tissue culture 
growth medium. Cells were then incubated overnight and washed with 1X PBS the 
following day and supplied with fresh growth medium for further culturing.  
 
2.1.5 Transfection of cell lines 
 
Transfection is a technique that allows the transfer of nucleic acids into eukaryotic 
cells. To this end, cell lines were transfected with the reagent Lipofectamine 2000 
(Invitrogen Corporation, Carlsbad, CA, USA), according to the manufacturer’s 
instructions. Lipofecatamine is a cationic liposome reagent that facilitates the contact 
and fusion of the negatively charged nucleic acid molecules with the phospholipid cell 
membrane, which also carries a negative net charge [197]. Upon mixture, the DNA 
molecule binds to a positively charged head group of the liposome containing 
nitrogen atoms, that interact with the negative phosphate backbone of the nucleic 
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acid as well as with the negatively charged cell membrane, thus providing a linker to 
overcome the electrostatic repulsion between the DNA and the cell membrane. The 
fusion with the cell membrane is carried out by neutral hydrocarbon chains, that are 
linked to the positively charged head group in the liposomes. After fusion, the nucleic 
acid-liposome complex penetrates the cell and is also carried into the core by 
merging with the nuclear membrane, thus exposing the DNA to nuclear proteins, 
allowing efficient transcription of e.g. genes cloned into expression plasmids. Nucleic 
acids can eventually integrate into the host genome, resulting into genetically 
engineered stable cell lines. 
In this project, transfection was carried out using a 2-fold excess of µg Lipofecatime 
2000 compared to µg of plasmid DNA. E.g., for transfection of a 60 mm cell culture 
plate (about 3-5x106 cells), 8 µg of plasmid DNA was dissolved in 1 ml of OPTIMEM 
medium (Invitrogen), i.e. a modified minimal essential medium (MEM) that only 
contains minimal protein levels (insulin and transferrin at 15 µg/ml), but has a 
formulation that allows cells to survive under serum-deprived conditions for several 
hours. Transfections have to be carried out in a low-serum environment, since serum 
lipoproteins can interfere with the liposomes. Next to the DNA/OPTIMEM mix, a 
second mixture containing 1 ml OPTIMEM and 16 µg of Lipofectamine 2000 
(liposomes) was set up and incubated for 5 min at room temperature before both 
mixtures were combined by gentle mixing and incubated for 30 min at room 
temperature. Finally, the combined mixture was given onto the cells and incubated 
for 6 hours at 37ºC, followed by addition of 5 ml of regular growth medium to the 
plate. The cells were then grown further for 24 hours before they were used for 
downstream applications.  
 
2.2 Molecular biology techniques  
2.2.1 Total RNA isolation 
 
The RNA isolation procedure was carried out using the QIAGEN RNeasy® Kit 
(QIAGEN Corporation, Valencia, CA, USA), which is based on a silica-gel membrane 
system that binds RNA molecules with a length of more than 200bp (RNeasy® Mini 
Handbook, QIAGEN). Cell lysis occurs in the presence of the denaturing agent 
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isothiocyanate, which also inactivates RNases, thus preventing an enzymatic 
degradation of RNA. The purification step is based on the highly specific binding of 
larger RNA molecules, such as mRNA to the membrane, whereas smaller RNAs, e.g. 
tRNA, are efficiently washed away, together with other contaminants. The binding of 
RNA is also enhanced by the presence of ethanol. After binding and washing with 
ethanol-containing washing buffers, the bound RNA is eluted with H2O and can be 
used for further processing.  
Generally, for RNA isolation, cell monolayers on plates (around 5x106 cells) were 
lyzed in 700 µl RLT Lysis buffer (RNeasy Kit). DNA digestion (with RNase-Free 
DNase Set, QIAGEN) was performed to avoid contamination of isolated RNA with 
genomic DNA. The RNA was eluted in 40-50 µl RNase-free water (QIAGEN) and 
stored at -80°C for future use. RNA concentrations were measured at an OD260 using 
an Eppendorf BioPhotometer (Eppendorf Corporation, Hamburg, Germany).  
 
 
2.2.2 Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) 
 
RT-PCR is a technique to measure expression levels of gene transcripts. In a first 
step, cDNA is synthesized by Reverse Transcription (RT) using RNA as a template. 
The molecular reaction is carried out by enzymes called reverse transcriptases, 
which are RNA-dependant DNA polymerases derived from retroviruses such as the 
moloney murine leukemia virus [198]. Single-stranded RNA is thereby transcribed 
into complementary DNA (cDNA), using specific deoxyoligonucleotides, such as 
oligo(dT), as primers for the enzymatic reaction. The derived single-strand cDNA 
subsequently serves as template for amplification by Polymerase Chain Reaction 
(PCR).  
The steps for RT-PCR were carried out in an Eppendorf Thermomixer (Eppendorf 
Corporation) in 1.5 ml tubes. First, 3 µg of RNA were added to autoclaved ddH2O to 
a total volume of 15 µl. Then, 3,75 µl of 80 ng/µl oligo(dT)15 primer (Promega 
Corporation, Madison, WI, USA) were added to the mixture. The tubes were 
incubated at 65°C for 5 min to open up secondary RN A structures and allow the 
primers to bind to the polyA tails of mRNA molecules. Afterwards, the tubes were put 
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on ice immediately to avoid refolding of the RNA. Then 11,25 µl of RT-Mix was added 
to the tubes. RT-Mix contained: 
4,5 µl  NX buffer (0.4 M KCl, 0.1 M Tris-HCl pH 8,4, 20 mM MgCl2, 2% Tween20, all 
from Sigma-Aldrich), 1.5 µl dNTPs (20mM stock - Amersham Biosciences 
Piscataway, NJ, USA), 3 µl of 0.1 M β-mercaptoethanol (Sigma-Aldrich), 10 U 
RNasin (40 U/µl - Promega), 100 units M-MLV Reverse Transcriptase (200 U/µl - 
Invitrogen). The entire mixture was incubated at 37°C for 55 min, followed by a 
second incubation step at 95°C for 5 min to inactiv ate the enzyme and stop further 
reaction. Finally, 270 µl autoclaved ddH2O was added to the reaction to obtain a final 
cDNA volume of 300 µl at a concentration of about 10 ng/µl. The cDNA was then 
stored at -20°C for future use. 
 
2.2.3 Polymerase Chain Reaction (PCR) 
 
Polymerase Chain Reaction (PCR) is a powerful technique that allows the 
exponential in vitro amplification of a specific region of a template DNA strand [199]. 
In typical applications, DNA fragments up to the size of 10 kb are amplified. A PCR 
reaction is divided into cycles that consist of three steps, i.e. (1) denaturation of the 
DNA double helix at around 95°C; (2) primer anneali ng between 55-65°C; (3) 
elongation of the polymerase reaction at 72°C. The cycles are preceded by a 
denaturation step at around 95°C for several minute s to assure proper opening of the 
DNA double helix. At the end of the cyclic program, a 5-7 min elongation step is 
performed before the enzymatic reaction is stopped. The thermostable Taq DNA 
polymerase from the hot springs thermophilic bacterium Thermus aquaticus resists 
the high denaturation temperatures, thus allowing the reaction to be performed 
without the requirement to add fresh enzyme during each thermocyclic amplification.  
PCR amplification was carried out using 20 ng cDNA as template derived from RT-
PCR reactions. Oligodeoxynucleotide primer pairs (2 µl) were added to a final 
concentration of 0.5 µM, together with 0.2 µl deoxynucleotide 5’-triphosphate (dNTP) 
mix (20 mM of each dNTP – Amersham Biosciences), 2 µl of 10X PCR reaction 
buffer (0.1 M Tris-HCl pH 8.4, 0.5 M KCl, 15 mM MgCl2, all from Sigma-Aldrich), 1 µl 
DMSO (Sigma-Aldrich) and 1 U Taq DNA polymerase (Promega). The reaction 
mixture was filled up with ddH2O to 20 µl and amplified with a MJ Research PTC-100 
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Thermo Cycler (Bio-Rad Laboratories, Hercules, CA, USA). The primer sequences 
and their corresponding thermocyclic program were as follows: Aldolase forward 5’-
AGCTGTCTGACATCGCTCACCG-3’, reverse 5’-CACATACTGGCAGCGCTTCAAG-
3’ (24 cycles – 65ºC annealing); Pecam-1 forward 
5’-GTTCAGCGAGATCCTGAGGGT-3’ (35 cycles – 60ºC annealing), reverse 
5’-GAGGACACTTCCACTTCTGTGTATTC-3’; Foxc1 forward 
5’-GCAGTGAAGGACAAGGAGGAGAAG-3’, reverse 
5’-TGGAGGCAGCGAGTAGTCGG-3’ (35 cycles – 65ºC annealing); Foxc2 forward 
5’-CTCTTACGACTGCACCAAATACTG-3’, reverse 
5’-GAATCTCCACAGAAGTCATTAGGG-3’ (35 cycles – 65ºC annealing); Foxa2 
forward 5’-AGGAGTGTACTCCAGGCCTATTATG-3’, reverse 
5’-GTCCGGTACACCAGACTCTTACAT-3’ (35 cycles – 60ºC annealing). Shown are 
the sequences for the primarily used RT-PCR primers. A complete list of all primers 
used in RT-PCR is given in the supplemental file ‘primer_sequences.pdf’.  
 
2.2.4 PCR Primer Design 
 
Primers were designed using the online primer3 tool (http://fokker.wi.mit.edu/cgi-
bin/primer3/primer3_www.cgi). This program allows optimal design of 
oligonucleotides for PCR by selecting a large number of criteria that specify the 
working conditions of the primer. Primers were designed to contain the following 
criteria: an annealing temperature between 60-65ºC, a length between 20-25 bp; a 
PCR amplification product of variable length between 150-800 bp. For cDNA 
amplification and gene expression studies, if possible, primers were designed to bind 
in areas representing different exons of the transcript, such enabling the distinction 
between amplified cDNA and possible impurities of genomic DNA that would also 
serve as template. Primers were ordered from MWG Biotech (Ebersberg, Germany) 
or Integrated DNA Technologies (Coralville, IA, USA).  
 
2.2.5 DNA Sequencing 
 
To date, the chain-termination method developed by Frederick Sanger is the 
standard choice for the sequencing of DNA. The principle of this enzymatic reaction 
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is based on the use of dideoxynucleotide triphosphates (ddNTPs) that function as 
nucleic acid chain terminators [200]. The original described method uses single-
stranded DNA to be sequenced as template. Modern protocols also use double-
stranded DNA that has been denaturated using e.g. alkali, as template. A special 
DNA polymerase, e.g. E.coli DNA polymerase I, initiates the synthesis of a 
complementary strand, starting from an oligodeoxynucelotide primer that binds at the 
3’-end of the template DNA strand. The key of the reaction lies in the separation into 
four separate sequencing reactions, that all contain the standard deoxynucelotides, 
i.e. dATP, dCTP, dGTP, dTTP. In addition, each reaction contains one of four 
dideoxynucelotides (ddATP, ddCTP, ddGTP, ddTTP), that lack the 3’-OH group 
required for the enzymatic formation of the phosphodiester bond between two 
nucleotides during the polymerization of the DNA strand. Thus, the incorporation of a 
dideoxynucelotide into the elongating DNA strand causes the termination of the 
polymerization reaction and yields multiple DNA fragments of various, random 
lengths. The elongated DNA fragments are then separated according to their length 
by gel electrophoresis using denaturing polyacrylamid gels, and each of the four 
separate sequencing reactions (containing one of the four ddNTPs) is run in an 
individual lane. The DNA molecules are visualized through the use of e.g. 
fluorescence-labeled oligodeoxynucleotide primers during the polymerization 
reaction. The terminal nucleotide base on the template strand is similar to the 
dideoxynucelotide used in the individual sequencing reaction and the relative 
positions of the DNA bands in the gel are used to assemble the nucleotide sequence 
of the template DNA strand. Modern automated DNA sequencers use a single 
reaction with all four dideoxy terminator nucleotides at the same time, and with 
different fluorescent colors on each of them, usually red, green, blue and yellow. The 
resulting fragments are subsequently separated by electrophoresis, and an ultraviolet 
laser determines the color of the DNA molecules.  The complete sequence is then 
automatically assembled by the computer.  In this project, DNA sequencing of 
plasmid DNA and PCR amplification products was carried out by commercial 
sequencing centers (MWG Biotech, Ebersberg, Germany and Genhunter 
Corporation, Nashville, TN, USA). 
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2.2.6 Plasmid DNA preparation 
 
For high amount preparations, plasmid DNA was purified using the commercially 
available DNA Maxi Prep Kit from QIAGEN. Plasmids were isolated from E.coli DH5α 
cultures grown in LB culture medium (10 g Tryptone, 5 g Yeast extract, 10 g NaCl, all 
from Sigma-Aldrich, - filled up with ddH2O to 1 liter). Bacteria cultures were grown for 
12-14 hours (OD600 of about 4.0) at 37ºC under shaking (225 rpm) in the presence of 
the appropriate selective antibiotics (100 µg/ml Ampicillin, or 50 µg/ml Kanamycin – 
Sigma-Aldrich), based on the antibiotic resistance gene on the plasmid backbone. 
Overnight cultures for plasmid DNA Maxi Preps (100 ml total volume) were 
inoculated from frozen DH5α 15%-glycerol stocks (850 µl E.coli suspension, 150 µl 
glycerol – Sigma-Aldrich) containing the respective plasmid. The stocks were kept at 
-80ºC for long-term storage. Alternatively, Maxi Prep cultures were inoculated with 
200 µl E.coli starter culture that was grown in LB medium for 8-9 hours from a single 
agar plate colony. After growth, E.coli Maxi Prep cultures were centrifuged for 20 min 
at 3000 g and 4ºC to pellet the cells, and then subjected to plasmid isolation.  
In the Maxi Prep, the plasmid DNA is purified trough binding to an anion-exchange 
resin column, under low-salt and low-pH conditions. Lysis of bacteria is based on the 
alkaline lysis method of Birnboim and Doly, involving a NaOH/SDS (sodium dodecyl 
sulfate) buffer [201]. Subsequent purification involves the removal of RNA -that is 
fragmented by RNase digestion during the bacteria pellet resuspension - and other 
low-weight molecules through washing steps with medium-salt buffers (QIAGEN), 
that in turn allows the plasmid DNA to remain bound to the anion-exchange matrix. In 
a step that precedes the medium-salt buffer washes, the alkaline lysis is neutralized 
by potassium acetate, resulting into the precipitation of cell membrane bound 
genomic DNA, proteins and larger cellular debris.  
After washing, elution of plasmid DNA from the column is facilitated by high-salt 
buffers (QIAGEN), followed by isopropanol precipitation, resulting into pure pelleted 
plasmid DNA that is re-dissolved in TE buffer (10 mM Tris-HCl pH 8.0, 1 mM EDTA – 
Sigma-Aldrich) and stored at -20ºC for future use.  
In accordance, Mini-Prep plasmid DNA purification during cloning procedures was 
carried out with the QIAprep Spin Miniprep Kit (QIAGEN), and cell lysis as well as 
plasmid DNA purification is based on analogous steps as described for the Maxi-
Prep plasmid DNA purification (QIAprep Spin Miniprep Kit Handbook). E.coli cultures 
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for Mini Preps were inoculated by picking single colonies from freshly streaked LB 
agar plates (as described below), followed by growth for 12-14 hours at 37ºC and 
225 rpm shaking.   
The optical density (OD) of E.coli suspensions was measured at a wavelength of 600 
nm (OD600) using an Eppendorf BioPhotometer (Eppendorf Corporation).  
 
2.2.7 Transformation of CaCl2-competent DH5α E.coli 
 
Through transformation, foreign DNA can be introduced into bacteria cells that were 
rendered competent by exposure to calcium ions [202]. Uptake of plasmid DNA 
occurs during a heat-shock that enables the nucleic acid to efficiently penetrate the 
cells. To generate calcium competent E.coli cells, LB growth medium (200 ml) was 
inoculated with 3 ml of a DH5α overnight starter culture and grown to an OD600 of 0.4 
(early to mid-log phase) at 37ºC, followed by a cooling step for 15 min on ice. The 
cells were pelleted by centrifugation (3000 g, 10 min, 4ºC) and the pellet was 
resuspended in 80 ml of Tfb1 buffer (pH 5.8 - 30 mM KOAc, 100 mM RbCl2, 10 mM 
CaCl2, 50 mM MnCl2, 15 % Glycerin, all from Sigma-Aldrich) and incubated for 15 
min on ice, followed by centrifugation. The pellet was then resuspended in 8 ml of 
TfbII buffer (pH 6.5 - 10 mM MOPS, 75 mM CaCl2, 10 mM RbCl2, 15% Glycerin), 
followed by another incubation step for 15 min on ice. The suspension was aliquoted 
(50 µl) into prechilled 1.5 ml tubes and frozen immediately at -80ºC for future 
transformations.  
Transformations were carried out with 50 µl aliquots of competent DH5α E.coli cells. 
In brief, the cells were thawed on ice and 0.1-0.5 µg of plasmid DNA was added to 
the thawed cell suspension, followed by an incubation step for 30 min on ice. E.coli 
cells were then heat-shocked at 42ºC for 45 sec, followed by an immediate 
incubation on ice for 2 min. To grow, 900 µl of non-selective LB growth medium was 
added and the E.coli cells were incubated at 37ºC for 1 hour under shaking (1200 
rpm) to recover and to allow transcription and synthesis of antiobiotic-resistance 
genes. Subsequently, 100 µl of the suspension was plated onto LB agar plates (2% 
agar, Sigma-Aldrich) containing the appropriate selective antibiotics (100 µg/ml 
Ampicillin or 50 µg/ml Kanamycin). The agar plates were grown inverted at 37ºC for 
12-14 hours and then checked for the presence of colonies.  
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2.2.8 DNA restriction digests  
 
DNA restriction endonucleases (or restriction enzymes) are procaryotic enzymes that 
catalyze specific reactions on the DNA in a sequence-specific manner and protect 
the bacteria host cell from viral infections by degrading viral DNA [203]. Their 
discovery has marked a revolutionary change in molecular biology, and today, their 
use to cleave DNA at defined positions into specific fragments is one of the most 
common procedures in molecular biology and genetic engineering. The majority of 
restriction endonucleases used in molecular biology applications belong to the type II 
and most members of this type II recognize a short nucleotide sequence (4-6 
nucleotides in length) on the DNA and cleave the double helix within the recognized 
sequence. The recognition sequence is mostly palindromic, i.e. the sequence on one 
DNA strand is the same in 5’ to 3’ direction as on the complementary strand. Different 
restriction endonucleases that recognize the same target sequence are referred to as 
isoschizomeres. Other type II restriction endonucleases cleave the DNA outside of 
their recognition sequence on one side. The cleavage of the double helix results into 
3’-hydroxyl on one side and a 5’-phospahte residue on the other side of the cut and 
some restriction endonucleases leave blunt ends after cleaving, whereas others 
cleave the double helix in a staggered manner, yielding cohesive ends with single-
stranded 5’ or 3’ overhangs.  
All restriction endonucleases were from NEB (New Enland Biolabs Incorporation, 
Ipswich, MA, USA) and were used according to the manufacturer’s instructions. In 
general, restriction digests in this project were set up in a total volume of 20-50 µl. 
The mixture contained purified template DNA dissolved in ddH2O or TE buffer, 
together with 5 µl of the appropriate 10X enzyme buffer (containing MgCl2 - NEB), 0.5 
µl of 100X bovine serum albumine solution (10 mg/ml - NEB) and an 5-fold excess of 
restriction enzyme units compared to µg of DNA (with enzyme volume not exceeding 
10% of the total reaction volume). Reaction mixtures were incubated for 1 hour or 
longer at 37ºC or the appropriate temperature for certain restriction endonucleases, 
according to the manufacturer’s instructions.  
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2.2.9 DNA ligation  
 
Whereas restriction endonucleases cleave the double helix, DNA ligases catalyze the 
ligation of two blunt- or cohesive-end DNA fragments through the formation of 
phosphodiester bonds between adjacent 5’-phospahte and 3’-hydroxyl termini in the 
double helix. Commonly, T4 DNA ligase – a product of the bacteriophage T4 - is 
used for molecular biology applications and catalyzes the formation of 
phosphodiester bonds by use of ATP as cofactor [204].  
DNA ligation was carried out according to the manufacturer’s instruction (NEB). 
Typically, the enzymatic reaction had a total volume of 20 µl, containing 2 µl of 10X 
enzyme buffer (0.5 M Tris-HCl pH 7.5, 0.1 M MgCl2, 10 mM ATP, 250 µg/ml BSA - 
NEB), and 400 U of T4 DNA ligase (NEB). Ligation was carried out at 16ºC for 12 
hours, with a 10-fold molar excess of DNA insert fragment compared to plasmid DNA 
backbone to assure a high efficiency of insertion.   
 
2.2.10 Plasmid Constructs 
 
Foxc1, Foxc2 and Foxa2 expression plasmids (CMV-Foxc1, CMV-Foxc2, and CMV-
Foxa2) are based on the pcDNA3 backbone (Invitrogen) and were kindly provided by 
Tom Kume (Vanderbilt University). The cloned cDNA sequences were as follows: 
Foxc1, +415 to +2779 based on ENSEMBL Genome Browser Transcript ID 
ENSMUST00000062292; Foxc2, +373 to +2704 based on Ensembl Genome 
Browser Transcript ID ENSMUST00000054691; Foxa2, +112 to +1970 based on 
Ensembl Genome Browser Transcript ID ENSMUST00000047315 
(http://www.ensembl.org). 
Pecam-1 promoter-luciferase plasmids pGL2-mp (minimal promoter), pGL2-lpp, (long 
proximal promoter), pGL2-5’3.5kb/mp (distal 5’-flanking 3.5kb fragment and minimal 
promoter), and pGL2-I2-4.5kb/mp (2nd intron 4.5kb fragment and minimal promoter) 
were kindly provided by Dr. Scott Baldwin (Vanderbilt University – further description 
in RESULTS). The cloned genomic sequences (relative and absolute nucleotide 
numbers) were as follows: plasmid pGL2-mp - relative -88 to +57 / absolute 
106,531,458 to 106,531,315; plasmid pGL2-lpp - relative -280 to +57 / absolute 
106,531,651 to 106,531,315; plasmid pGL2-5’3.5kb/mp – relative -13,597 to -10,063 
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/ absolute 106,544,967  to 106,541,433 (distal 5’-flanking 3.5kb fragment); plasmid 
pGL2-I2-4.5kb/mp -relative +5,849 to +10,273 / absolute 106,525,521 - 106,521,098 
(2nd intron 4.5kb fragment). For all promoter-luciferase plasmids, the relative 
nucleotide numbers refer to the transcription initiation site of mouse Pecam-1. 
Absolute nucleotide numbering was obtained from the UCSC Bioinformatics 
Database, with the transcription initiation site at nucleotide position 106,531,371 on 
chromosome 11 (descending nucleotide numbers).  
Promoter-Luciferase-plasmids pGL2-5’1kb(A)/mp (distal 5’-flanking 1kb fragment and 
minimal promoter), pGL2-5’1kb(B)/mp (distal 5’-flanking 1kb fragment and minimal 
promoter), and pGL2-5’1.5kb/mp (distal 5’-flanking 1.5kb fragment and minimal 
promoter) were generated by PCR using pGL2-5’3.5kb/mp as DNA template. The 
PCR reaction contained 100 ng template DNA, 5 µl 10X Pfu buffer (Promega), 0.5 µl 
dNTPs (20 mM each dNTP – Amersham Biosciences), 2 µl primer mix (5 µM each 
primer), and 2 U Pfu Polymerase (Promega), all filled up with H2O to 50 µl. Pfu 
Polymerase is a DNA polymerase that has 3’ to 5’ exonuclease activity 
(proofreading), thus resulting into high fidelity amplification of the DNA template. 
Amplification was carried out as follows: initial denaturation (95ºC – 2 min), 35 cycles 
(95ºC – 30 sec, 60ºC – 30 sec, 74ºC – 2 min), final elongation (74ºC – 5 min).  
The cloned genomic sequences were as follows: plasmid pGL2-5’1kb(A)/mp– relative 
-13,597 to -12,547 / absolute 106,544,967 - 106,543,917 (distal 5’-flanking 1kb 
fragment); plasmid pGL2-5’1kb(B)/mp - relative -12,568 to -11,499 / absolute 
106,543,939 - 106,542,870 (distal 5’-flanking 1kb fragment); pGL2-5’1.5kb/mp – 
relative -11,520 to -10,063 / absolute 106,542,891 – 106,541,433 (distal 5’-flanking 
1.5kb fragment).  
The primers were as follows: plasmid pGL2-5’1kb(A)/mp forward 
5’-ggggtaccGAGCTCATGGTTTGGTTTCT-3’, reverse 
5’-cgacgcgtCACTTATAGTAAAACCACCTG-3’; pGL2-5’1kb(B)/mp forward 
5’-ggggtaccCAGGTGGTTTTACTATAAGTG-3’, reverse 
5’-cgacgcgtGTCAGTGTCCCTGACTGATG-3’; pGL2-5’1.5kb/mp forward 
5’-ggggtaccCATCAGTCAGGGACACTGAC-3’, reverse 
5’-cgacgcgtGAGCTCTCCTGAGCGTGAAG-3’; lower-case nucleotides indicate 
restriction sites added for cloning purposes. Fragments were cloned into pGL2-mp 
using KpnI (in the forward primer) and MluI (in the reverse primer).  
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Mutated promoter-luciferase-plasmids pGL2-5’1.5kbD1/mp, pGL2-5’1.5kbD2/mp, 
pGL2-5’1.5kbD3/mp, and pGL2-5’1.5kbD4/mp were generated by in vitro site-
directed mutagenesis, using the QuikChange II Site-Directed Mutagenesis Kit 
(Stratagene Corporation, La Jolla, CA, USA) and pGL2-5’1.5kb/mp as DNA template. 
Site-directed mutagenesis is a technique to selectively manipulate a nucleotide 
sequence by creating a mutation at a defined site on a DNA molecule [205]. Whereas 
conventional mutagenesis protocols require the presence of single-stranded DNA as 
template, the method used in this project allows to directly mutate supercoiled 
double-stranded plasmid DNA. The key of this technique lies in the use of two 
complementary oligodeoxynucleotide primers, that both carry the desired mutation 
and anneal to the same sequence on the opposite strands of the template plasmid 
DNA. The mutations in the primers can consist of single nucleotide point mutations or 
even larger insertions or deletions. In case of a deletion to be inserted into the 
plasmid, the primers consist of two “nucleotide arms” (around 20 bp in length) that 
represent the sequence on either side of the deletion. During amplification, the 
parental plasmid DNA forms a loop between the two “nucleotide arms” and is not 
integrated into the newly polymerized DNA, thus resulting into a deletion that is 
carried on during the amplification. 
 
The protocols were according to the manufacturer’s instructions (Stratagene). In 
brief, the template plasmid DNA was amplified by PCR consisting of an initial 
denaturation step (95ºC - 1 min), 18 cycles (95ºC - 50 sec; 60ºC - 50 sec; 68ºC - 7.5 
min), and a final elongation step (68ºC – 7 min). The PCR mixture contained 5 µl of 
10X reaction buffer (Stratagene), 50 ng of template DNA, 125 ng of 5’- and 3’-PCR 
primer  (described below), 1 µl of 20 mM dNTP Mix (Amersham Biosciences), 3 µl of 
QuickSolution (Stratagene), filled up with H2O to 50 µl total. PfuUltra HF DNA 
polymerase (2.5 U - Stratagene) was then added to the mixture and following 
amplification, the samples were cooled down on ice and incubated with 10 U/µl DpnI 
(Stratagene) for 1 hour at 37ºC. DpnI is a restriction endonuclease that requires the 
presence of N6-methyladenine within its recognition sequence (5’-Gm6ATC-3’) to 
cleave DNA [206]. Thus, it specifically digests the methylated parental DNA (pGL2-
5’1.5kb/mp) derived from E.coli Maxi Preps but has no affinity for non-methylated 
DNA, which is generated during the mutagenesis PCR reaction. An aliquot of 45 µl 
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XL10-Gold competent E.coli cells (Stratagene) was incubated with 2 µl 
β-Mercaptoethanol (Stratagene) for 10 min on ice and subsequently 2 µl of the DpnI-
treated DNA was added to the mixture, followed by 30 min incubation on ice and a 30 
sec heat-shock at 42ºC. After another 2 min incubation on ice, 500 µl of NZY+ broth 
(10 g NZ amine, 5 g yeast extract, 5 g NaCl, 12.5 ml 1 M MgCl2, 12.5 ml 1 M MgSO4, 
10 ml 2 M glucose – ddH2O to 1 liter) was added and the cells were grown for 1 hour 
at 37ºC under shaking (225 rpm), followed by plating on LB-agar plates (2% agar - 
100 µg/ml ampicillin) and grown until colonies were visible. Colonies were picked, 
grown in LB-medium, and subjected to plasmid DNA Mini Preps and DNA 
sequencing to check for the presence of the deletion. 
Primers used for the individual deletions were as follows: plasmid pGL2-
5’1.5kbD1/mp (deletion relative -11,495 to -11020; deletion absolute 106,542,865 to 
106,542,390) 5’-cagggacactgactttgCCTAGGATGGGCACC-3’ and 
5’-GGTGCCCATCCTAGGcaaagtcagtgtccctg-3’; plasmid pGL2-5’1.5kbD2/mp 
(deletion relative -11,495 to -10,884; deletion absolute 106,542,865 to 106,542,254) 
5’-cagtcagggacactgactttgGTTTGTTAAATGTTC-3’ and 
5’-GAACATTTAACAAACcaaagtcagtgtccctgactg-3’; plasmid pGL2-5’1.5kbD3/mp 
(deletion relative -11,495 to -10,741; deletion absolute 106,542,865 to 106,542,111) 
5’-cagggacactgactttgGTTAGTTAAATGTTCCC-3’ and 
5’-GGGAACATTTAACTAACcaaagtcagtgtccctg-3’ ; plasmid pGL2-5’1.5kbD4/mp 
(deletion relative -11,495 to -10,458; deletion absolute 106,542,865 to 106,541,828) 
5’-cagggacactgactttgGGTCTGATCCTCCTG-3’ and 
5’-CAGGAGGATCAGACCcaaagtcagtgtccctg-3’. The nucleotides in lower case letters 
indicate the “primer-arm” on one side of the deletion, whereas the upper-case letters 
indicate the “primer-arm” on the other side. 
The complete sequences of the cloned promoter and cDNA inserts are given in the 
supplemental file ‘plasmid_sequences.pdf’. 
 
 
2.2.11 Agarose gel electrophoresis 
 
Agarose is a gelatinous polymer isolated from red algae and its use in agarose gel 
electrophoresis is an effective technique for the separation of nucleic acid fragments 
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of different sizes. During electrophoresis, the negatively charged nucleic acid 
molecules migrate toward the positive electrode of the electrophoresis unit and are 
separated according to their size, with smaller fragments migrating faster through the 
polymerized gel [207].  
DNA amplification products from conventional PCR and LightCycler runs were 
separated in 1.5% agarose gels (ultraPURE agarose, Invitrogen), run in horizontal 
electrophoresis chambers (Bio-Rad Laboratories, Hercules, CA, USA) in 1X TBE 
electrophoresis buffer (0.089 M Tris-borate, 2 mM EDTA, 0.02% ethidium bromide - 
Sigma-Aldrich). The size of DNA fragments was determined using a 100 basepair 
ladder (Amersham Biosciences), which contains DNA fragments of known size, as 
molecular marker. After electrophoresis, the DNA bands were visualized under UV 
light at a wavelength of 254 nm and agarose gels were then photographed using a 
Polaroid camera or a Bio-Rad Gel Documentation system (Bio-Rad). 
 
2.2.12 Ethanol Precipitation of DNA 
 
DNA was purified by Ethanol precipitation. For this purpose, sodium acetate pH 5.2 
(Sigma-Aldrich) was added to a total volume of 10% to the DNA solution, together 
with 2 volumes of ice-cold 100% Ethanol and mixed thoroughly. Next, the mixture 
was incubated for 30 min at -20ºC to precipitate the DNA and subsequently 
centrifuged at 15.000 g for 10 min. The DNA pellet was washed twice with ice-cold 
70% ethanol, each time followed by a 5 min centrifugation step at 15.000 g. 
Following, the pellet was air-dried for 5 min at room temperature and subsequently 
dissolved in 20-30 µl ddH2O or TE buffer.  
 
 
2.3 Quantitative Real-Time Amplification (qPCR)  
 
2.3.1 LightCycler Real-Time PCR System 
 
 
Embryonic EPC chromatin for chromatin immunoprecipitation (ChIP) analysis was 
amplified taking advantage of the Roche Advanced LightCycler System (Roche 
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Diagnostics) using the LightCycler FastStart DNA Master SYBR Green I Kit and 
LightCycler glass capillaries as reaction vessel. The LightCycler System is a powerful 
tool that allows monitoring real-time amplification of reverse transcribed mRNA [208]. 
Compared with conventional PCR, real-time amplification is much more sensitive, 
since the amount of PCR amplicons is continuously monitored during every 
amplification cycle, allowing accurate quantification of PCR products. Furthermore, 
no agarose gels, which lack sensitivity, are necessary for quantification. A real-time 
PCR system is based upon the detection and quantification of a fluorescent reporter 
dye, e.g. SYBR Green I [209]. This dye is incorporated into the double stranded DNA 
helix and, upon intercalation, emits green fluorescence at a wavelength of 530 nm. 
Since unbound dye only emits minimal background fluorescence, the increased 
signal is in direct proportion to the amount of doubled-stranded PCR product in a 
reaction. In addition, the LightCycler System takes advantage of a thermostable 
recombinant Taq Polymerase, that does not display any activity below 75ºC and 
allows to perform a hot-start PCR reaction, that avoids the creation of unspecific PCR 
amplification products.  
The concentration of cDNA can be determined relatively to a standard curve. As an 
example, a cDNA pool that is known to contain a certain transcript was amplified with 
the respective primer pair at a high cycle number and at different temperatures to find 
optimal primer working conditions. Subsequently, 10 µl of amplified cDNA was taken 
out from every capillary and run on an agarose gel to verify the proper length of the 
amplification product and thus the specificity of the amplification reaction. In addition, 
a melting curve calculated by the LightCycler Software 3.0 (Roche Diagnostics) 
indicates the purity and specificity of the amplification as monitored in real-time. 
During melting curve analysis, the PCR reaction is slowly but continuously heated to 
95ºC, resulting into denaturation of the DNA double helix and decrease of the SYBR 
Green I fluorescence signal. The decrease in activity from the bound SYBR Green of 
each PCR amplicon is presented as a melting curve, and the presence of a single 
peak indicates the specific amplification of the desired PCR product, alongside with a 
specific band in an agarose gel.  In turn, non-specific amplicons and primer dimers 
are indicated by multiple peaks in the melting curve analysis.   
Amplified cDNA that shows the right length and a proper melting curve without minor 
peaks was then used for a dilution series. For this, 1:103 and 1:105 dilutions of 
amplified cDNA are prepared with RS2 RNA as carrier (Roche Diagnostics GmbH, 
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Mannheim, Germany) and 1:107 and 1:109 dilutions are prepared in autoclaved 
ddH2O. Carrier RNA avoids the adhesion of template cDNA to the wall of the reaction 
capillary, thus assuring a higher quality of the analysis. During the main amplification 
of all cDNA samples with a certain primer pair, the corresponding dilutions are re-
amplified and their concentrations are set to a relative value in the LightCycler 
software before the amplification. E.g., the 103 dilution can be set to a value of 106, 
the 105 dilution to a value of 104, the 107 dilution to a value of 102 and the 109 dilution 
to a value of 1. On the basis of these four relative values, a standard curve is 
calculated by the LightCycler software and the relative cDNA concentrations from all 
samples are then referenced by the software to these standard curves.  
 
2.3.2 iQ5 Real-Time PCR System 
 
Real-time quantification of gene transcript levels was also carried out using the Bio-
Rad iQ5 Real-Time PCR system and the iQ SYBR Green Supermix (Bio-Rad 
Laboratories, Hercules, CA, USA).  Like the LightCycler, this system as well uses the 
fluorescent dye SYBR green I and the key of the real-time quantification method is 
the same as the one described above for the LightCycler system.  
In brief, 1 µl of cDNA was combined with 2 µl primer mix (5 µM each), 7 µl ddH2O 
and 10 µl iQ SYBR Green Supermix (2X – containing 100 mM KCl, 40 mM Tris-
HCl pH 8.4, 0.4 mM dNTPs, 50 U/ml iTaq Polymerase, 6 mM MgCl2, SYBR Green I, 
20 nM fluorescein) to obtain a whole reaction volume of 20 µl. The quantitative real-
time PCR (qPCR) reactions were carried out in 96-well twin.tec PCR plates 
(Eppendorf).  
The relative gene expression levels obtained with the iQ5 qPCR system were 
calculated using the 2-∆∆CT method [210]. In brief, the method is a way to calculate the 
relative amount of a gene transcript in a given sample as well as relative changes in 
gene expression without the need to create a standard curve. The amount of cDNA 
(mRNA) added to the reaction is normalized to an endogenous reference (internal 
control gene), typically a housekeeping gene such as β-actin, Gapdh, or rRNA. In 
addition, the transcript levels are presented as fold-change relative to an untreated 
control sample, also called the calibrator, which is arbitrarily chosen for each qPCR 
reaction. The CT value indicates the threshold cycle during the PCR reaction, i.e. the 
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number of cycles at which the target sequence is present as a certain copy number 
and reached a fixed threshold. The data analysis is based on the equation:  
∆∆CT = (CT,sample-CT,internal-control)time/sampleX – (CT,sample-CT,internal-control)time/sample0 
The first part of the equation calculates the ∆CT value of a treated sample or a 
sample at a specific experimental time point by subtracting the corresponding CT 
value of the internal control gene (i.e. Gapdh) from the CT value of the specific gene 
of interest, giving ∆CT, time/sampleX. The second part of the equation gives the ∆CT value 
of the calibrator sample, e.g. an untreated control sample or a sample at time point 
zero in an experiment, giving ∆CT, time/sample0.  The ∆∆CT value is obtained by 
subtracting ∆CT, time/sample0  from ∆CT, time/sampleX,. The amount of target gene transcript 
is then given by the term 2-∆∆CT.  
The 2-∆∆CT value of the untreated control sample (calibrator) is 1, since ∆∆CT for the 
calibrator sample is 0 and 20 equals 1. All other samples are calculated relative to the 
arbitrary value of the untreated control sample. A detailed description of the 
mathematical derivation of the 2-∆∆CT method and further applications have been 
described by Livak & Schmittgen [210]. 
The cDNA was amplified using the following primers: β-actin forward 5’-
CTACGAGGGCTATGCTCTCCC-3’, reverse 5’-CCGGACTCATCGTACTCCTGC-3’;  
Gapdh forward 5’-CTCACTCAAGATTGTCAGCAATG-3’, reverse 5’-
GAGGGAGATGCTCAGTGTTGG-3’;  
Cxcr4 forward 5’-GATTGGTCTTCCTGCCCACCA-3’, reverse 5’-
CAGTAACAGGAGAGGATGACG-3’;  
Icam-1 forward 5’-GGAGACGCAGAGGACCTTAACAG-3’ reverse 5’-
CATCTCCTGTTTGACAGACTTCACC-3’;  
Pecam-1 5’-forward AGACATGGAATACCAGTGCAGAG-3’, reverse 5’-
ACAGGATGGAAATCACAACTTCAT-3’.  
The iQ5 qPCR parameters for all primers were as follows: heat-activation of the hot-
start iTaq Polymerase (55°C – 2 min), initial denat uration of DNA (95°C – 3 min), 45 
amplification cycles (94°C – 20 sec, 62°C – 30 sec,  data collection and real-time 
analysis, 72°C - 1 min), denaturation (95°C - 1 min ), incubation (55°C - 1 min), 
melting curve analysis (55°C to 94.5°C - 0.5°C incr ement - 15 sec each), final cooling 
(4°C). The data were analyzed with the iQ5 Optical System Software (Version 2.0  - 
Bio-Rad).  
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2.4 Fluorescence Activated Cell Sorting (FACS) Anal ysis  
FACS analysis is a technique for examining and counting cells in a suspension. For 
example, it is used to detect surface proteins on eukaryotic cells and to quantify their 
amount through the binding of primary antibodies – directed against a specific protein 
- that in turn are recognized by secondary fluorescencently-labeled antibodies [211]. 
FACS analysis was performed using the BECTON DICKINSON Flow Cytometer 
FACSCalibur System (BD Biosciences, San Jose, USA). Data were analyzed with 
the CellQuest Software 3.3 (BD Biosciences). Primary antibodies recognizing mouse 
antigens were detected with red R-phycoerythrin-conjugated AffiniPure F(ab`)2 
fragment donkey anti-rat IgG (Jackson Laboratories, Bar Harbor, ME, USA). The 
surface protein levels were quantified using two-dimensional dot plot analysis for 
double-stained eEPCs (red phycoerythrin and EGFP positive eEPCs). A dot plot is 
usually divided into four quadrants: lower left (LL), lower right (LR), upper left (UL) 
and upper right (UR). The settings in the software were chosen that the x-axis shows 
cells that emit a green fluorescence EGFP signal whereas the y-axis shows cells that 
are positive for red fluorescence phycoerythrin (PE), which is conjugated to the 
secondary antibody. Cells that are negative for both colors are located in the LL 
quadrant. Cells that only emit an EGFP signal accumulate in the LR quadrant. Only 
cells that are positive for both signals locate in the UR quadrants and indicate 
presence of the respective surface protein. Cells occasionally show only a red PE 
signal in the UL quadrant. These cells are eEPCs that express the gene of interest 
but lost EGFP expression. Summarizing the percentages of gated cells in the UL and 
UR leads to the total percentage of cells that express the protein of interest. By 
comparing this percentage to the control (stained with isotype antibody that does not 
bind to the cells) it is possible to conclude whether a protein is present on the cell 
surface.  
For FACS analysis, eEPCs were plated at a density of 2x105 cells/ml into 6-well 
tissue culture plates and transiently transfected with 8 µg of Foxc1-expression 
plasmid or pcDNA3 as negative control. Additionally, 8 µg of pBK-CMV-EGFP were 
transfected into the cells. After 24 hours, the cells were washed with 1X PBS and 
detached from plates by incubation with 5 mM EDTA (Sigma-Aldrich) at 37°C for 20-
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30 min. After successful detaching, the suspension was centrifuged at 250 g for 
2 min to pellet the cells, that were subsequently washed with 4 ml ice-cold FACS 
buffer (4% bovine serum albumin, ICN Biomedicals, Solon, OH, USA and 0.1% 
sodium azide, Sigma-Aldrich, both diluted in 1X PBS), centrifuged again and finally 
resuspended in 2 ml fresh ice-cold FACS buffer. About 2x105 cells of this suspension 
were used for incubation with each primary antibody, at a final antibody concentration 
of 5 µg/ml. Cells were incubated 30 min at 4oC with anti-mouse Pecam-1 rat-
monoclonal (Mec 13.3), rat IgG Isotype, or anti-mouse Tie2 rat-monoclonal primary 
antibody (all BD Pharmingen, Heidelberg, Germany) and subsequently washed twice 
with 400 µl ice-cold FACS buffer. R-phycoerythrin-conjugated donkey-anti-rat 
secondary antibody (Jackson Laboratories, Bar Harbor, ME, USA) was added to the 
cell suspension at a final concentration of 5 µg/ml and incubated for 30 min at 4oC 
(protected from light), followed by two washing steps with 400 µl ice-cold FACS 
buffer. Finally, the cells were fixed in 400 µl 1% paraformaldehyde (Sigma-Aldrich) 
and subjected to FACS analysis.  
 
2.5 Microscopy and Fluorescence Microscopy  
Microscopy and fluorescence microscopy were carried out using a NIKON Eclipse 
TE2000-U Microscope (Nikon, Tokyo, Japan). Fluorescence emission by cells was 
observed by means of a NIKON Super High Pressure Mercury Lamp at a wavelength 
of 480 nm for excitation of EGFP and at 550 nm for Cy3. Cells were photographed 
using a NIKON F90X camera (Nikon, Tokyo, Japan).  
 
2.6 Immunofluorescence  
Immunofluorescence is a way to detect proteins in tissue sections, based on the 
binding of primary monoclonal or polyclonal antibodies to their respective antigens. 
As in FACS analysis, secondary antibodies, conjugated with a fluorescence dye, bind 
to the primary antibodies. The fluorescence signal is observed using fluorescence 
microscopy. 
Mouse tissues were cryopreserved in OCT Tissue Tek (Sakura Finetek, Torrance, 
CA, USA) and stored at -80°C for further work. Tiss ue sectioning was carried out with 
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a JUNG FRIGOCUT 2800E Cryostat (Leica Microsystem Vertrieb GmbH, Bensheim, 
Germany). All sections had a thickness of 10 µm.  
Prior to the antibody staining, the issues sections were fixed in a 1:1 
acetone/methanol solution (Sigma-Aldrich) at 4°C fo r 5 min. The sections were then 
surrounded with a PapPen (SCI Science Services, Munich, Germany) and washed 
5x with 1X PBS for 10 min each, followed by a blocking step for 1 hour with blocking 
buffer (1% bovine serum albumin and 0.05% Saponin, Sigma-Aldrich, in 1X PBS) at 
room temperature to prevent unspecific antibody binding to the tissue sections. Rat 
anti-Pecam-1 monoclonal antibody (BD Biosciences Pharmingen, Heidelberg, 
Germany) was added to the sections at a concentration of 5 µg/ml and incubated 
overnight at 4°C. After this step, the sections wer e washed 5x with 1X PBS  for 10 
min each and subsequently incubated with a Cy3-conjugated donkey anti-rat IgG 
secondary antibody (Jackson ImmunoResearch Laboratories Inc., West Grove, PA, 
USA) for 1 hour at room temperature. Finally, the sections were again washed 5x 
with 1X PBS for 10 min each, air-dried for a short time, mounted with VECTASHIELD 
Mounting Medium (Vector Laboratories, Burlingame, CA, USA) and photographed 
under fluorescence light at a wavelength of 550 nm. The sections were also sealed 
with nail polish for long-term storage.   
 
 
2.7 Promoter-Luciferase Assays  
 
The Firefly luciferase gene is a molecular genetic tool to identify and study the 
presence and activity of regulatory elements in gene promoter areas, as well as to 
investigate their interaction with trans-regulatory factors. In general, luciferase 
reporter assays are commonly used to investigate the regulation of eukaryotic gene 
expression. 
Firefly luciferase is a 61kDa monomeric protein synthesized by the firefly beetle. It 
catalyzes the oxidation of beetle luciferin into oxyluciferin in a reaction requiring the 
presence of O2, ATP and Mg
2+ ions. As a result, ATP is hydrolyzed into AMP and 
PPi, and energy is emitted in the form of photons [212]. The key principle of the 
assay lies in the quantification of promoter activity through the amount of luciferase 
Material and Methods 
 45
mRNA transcribed, which is proportional to the luminescence that is emitted during 
the reaction catalyzed by translated luciferase protein. A certain promoter fragment is 
cloned in front of the luciferase gene that is part of a reporter plasmid. The construct 
is transfected into a cell line where the activity of the cloned promoter area is to be 
studied. This way, the intensity of the emitted luminescence is directly correlated to 
the activity of a genetic regulatory element cloned upstream of the luciferase gene.  
For the project, the Dual-Luciferase Reporter Assay System (Promega) was used. 
The system takes advantage of the simultaneous expression of two distinct reporter 
genes in the transfected cells. The activities of Firefly luciferase and of a second 
luciferase enzyme derived from the sea pansy (Renilla Reniformis) [213] are 
measured together from a single sample.  Renilla luciferase is a 36kDa monomeric 
protein and catalyzes the oxidation of coelenterazine to coelenteramide with 
simultaneous emission of photons. The two luciferase enzymes use distinct 
substrates and emit different wavelength fluorescent light,                                                                                                                                                                                                                
allowing to measure sequentially the activity of either enzyme. The advantage of the 
co-expression of two reporter genes lies in its high accuracy, allowing to rule out 
variability such as differences in transfection efficiency, cell numbers, or cell lysis 
efficiency. The activity of the experimental reporter gene (Firefly luciferase under the 
control of a promoter area of interest) is thereby normalized to the activity of the 
Renilla luciferase reporter gene, which is under the control of the constitutively active 
Herpes Simplex Virus thymidine kinase (HSV-tk) promoter.  
 
In this project, eEPCs, BAECs, MS1-ECs, Cos7, and ES cells were plated at a 
density of 1x105-5x105 cells/ml into 24-well plates (Falcon) and subjected to 
transfection with 0.3 µg pGL2 promoter-luciferase plasmid (section 2.2.10) and 0.03 
µg HSV-tk-Renilla-luciferase plasmid (Promega) to correct for experimental 
variabilities. For co-transfections, the cells were additionally transfected with 2.4 µg 
Fox-expression plasmid (CMV-Foxc1, CMV-Foxc2, CMV-Foxa2) or basic pcDNA3 
(Invitrogen) as control plasmid. After 24 hours, the growth medium was removed and 
the cells were washed with 1X PBS, followed by lysis using the 5X Passive Lysis 
buffer provided in the Dual Luciferase Kit (Promega). Per well, 100 µl of diluted (1X) 
Passive Lysis buffer was added and the plates were shaken subsequently for 15 min 
at room temperature on an orbital shaker to assure efficient lysis. Following lysis, the 
luciferase activity was measured according to the manufacturer’s instructions 
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(Promega). In brief, 20 µl of cell lysate was combined with 20 µl of luciferase assay 
reagent II containing the substrate for Firefly luciferase, followed by measuring of the 
luminescence, using a Monolight 2010 Luminometer. Afterwards, the firefly 
luminescence was quenched by adding Stop & Glo Reagent that simultaneously 
activates the Renilla luciferase activity. The Firefly luciferase values are then 
normalized to the Renilla luciferase values from the same sample. All luciferase 
assays were performed in triplicates and replicated at least twice to obtain a 
statistically significant data set.  
 
2.8 Western Blot  
 
Western Blot is used to detect a specific protein in a cell or tissue homogenate (or 
extract) [214]. The principle of the method lies in the separation of denaturated 
proteins, usually depending on their size (i.e., the length of the polypeptide chain), 
using gel electrophoresis and polyacrylamide gels under denaturating conditions. 
Initially, the protein extract is denaturated and solubilized by SDS (sodium 
dodecylsulfate). Typically, SDS-PAGE (polyacrylamide gel-electrophoresis) is used to 
separate the proteins. It maintains them in a denaturated state preventing formation 
of secondary and tertiary structures. In addition, the negatively charged SDS causes 
the proteins to adopt an overall negative net charge and thus allows their separation 
during electrophoresis, where they migrate toward the positive anode. Smaller 
proteins migrate faster through the polyacrylamide gel. Following, the proteins are 
electrophoretically transferred to a positively charged nitrocellulose membrane, 
causing irreversible binding. During transfer, the membrane is placed on the anode 
side of a transfer unit, resulting into a “pulling” of the negatively charged antigens 
onto the membrane. To prevent unspecific binding of antibodies during the 
subsequent stages, the membrane is blocked by a diluted protein solution – usually 
non-fat dry milk powder - that blocks binding sides on the membrane where no 
antigens are bound. The specific antigen of interest is detected by a primary antibody 
that in turn is recognized by a secondary antibody directed against the species-
specific part of the primary antibody. The secondary antibody itself is conjugated to a 
reporter enzyme such as horseradish peroxidase that catalyzes a detectable 
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chemiluminscent reaction visualized on X-ray films. Alternatively, the secondary 
antibody can carry a radioactive label for detection purposes.  
For Western Blots in this project, protein lysates were generated from embryonic 
EPCs using the NE-PER Nuclear and Cytoplasmic Extraction Reagents Kit (Pierce 
Biotechnology), according to the manufacturer’s instructions. In brief, cytoplasmic 
contents are released by disruption of the cell membranes. In a next step, the intact 
nuclei are recovered from the cytoplasmic extract by centrifugation, and nuclear 
proteins are extracted through lysis of the nuclei. The use of pure nuclear extract 
without the presence of cytoplasmic components elevates the quality to study 
interactions of DNA and nuclear proteins. To assure the stability of the nuclear 
extract, a proteinase inhibitor cocktail tablet (Roche Diagnostics, Indianapolis, IN, 
USA) was added to the extraction reagents (provided by Pierce Biotechnology) and 
the nuclear and cytoplasmic extracts were stored at -80ºC for further applications. 
 
The total protein concentrations of the cell lysates were determined using the BCA 
Protein Assay Reagent Kit (Pierce Biotechnology). This assay allows colorimetric 
quantification of protein amounts by the reduction of Cu2+ to Cu+ by chelation of 
cupric ions through proteins in an alkaline environment (i.e. the biuret reaction or 
assay) [215]. The light blue to violet chelated complex absorbs light at 540 nm and 
the intensity of the colored signal is in proportion to the amount of peptides in the 
mixture, with four to six peptide bonds forming a complex with one cupric ion. For 
Western Blot, 3 µg of protein lysate were incubated together with 4 µl of 5X loading 
buffer (250 mM Tris-HCl pH 6.8, 500 mM DTT, 10% SDS, 20% Glycerin, 2% 
Bromphenol blue) in a total volume of 20 µl for 10 min at 70ºC to unfold the 
polypeptide chains, followed by electrophoresis using NUPage 4-12% Bis-Tris 
polyacryamide gels (Invitrogen) and a vertical gel electrophoresis unit (Hoefer 
Pharmacia Biotech Inc., San Francisco, CA, USA) at 85 V for 2 hours in running 
buffer (24 mM Tris-Base, 192 mM glycin, 3.4 mM SDS, pH 7.4) Next to the protein 
samples, a molecular weight ladder (SeeBlue Plus2 Prestained Standard - 
Invitrogen) was run. Following electrophoresis, a Hybond-ECL nitrocellulose 
membrane (Amersham Biosciences) was placed onto the gel and the complex was 
covered on both sides with blotting paper (VWR International, West Chester, PA, 
USA) and a transfer sponge on the outside (VWR). The whole complex was soaked 
in transfer buffer (48 mM Tris-Base, 39 mM glycine, 0.038% SDS, 20% methanol 
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pH 8 - Sigma-Aldrich) and placed into a transfer unit (Hoefer), followed by 
electrophoretic blotting at 60 V for 2 hours in transfer buffer. Subsequently, the 
membrane was incubated for 1 hour in 5% non-fat dry milk powder (Nestle 
Corporation) at room temperature under shaking at 100 rpm, followed by incubation 
with the primary antibody for 12 hours at 4ºC or 1 hour at room temperature. The 
membrane was incubated with goat polyclonal anti-Foxc1 or goat polyclonal anti-
Foxc2 (Abcam Incorporation, Cambridge, MA, USA – both at a concentration of 0.5 
µg/ml, diluted in 5% non-fat dry milk powder) or mouse monoclonal anti-β-Actin 
(Santa Cruz Biotechnology, Santa Cruz, CA, USA). Following incubation, the 
membrane was washed 5x with PBST buffer (PBS, 0.05% Tween20 - Sigma-Aldrich) 
for 10 min each and subsequently incubated with a secondary antibody (0.2 µg/ml in 
5% non-fat milk powder) directed against the Fc part of mouse or goat antibodies and 
conjugated with horseradish peroxidase (Santa Cruz). After incubation for 2 h at 
room temperature under shaking at 100 rpm, the membrane was washed 5x with 
PBST buffer, followed by the development of chemiluminescent light reaction, using 
the ECL Western Blotting Analysis System (Amersham). This kit provides the 
substrate reagent and buffers for the horseradish peroxidase enzyme and allows to 
develop a light reaction that was subsequently detected using a X-ray film (CL-X 
Posure Film, Pierce Biotechnology).  
Horseradish peroxidase catalyzes the oxidation of chemiluminescent substrates such 
as luminol in the presence of H2O2 [216], and this enzymatic activity is then 
visualized on X-ray films. 
 
 
 
2.9 Chromatin Immunoprecipiation  
 
Chromatin immunoprecipiation (ChIP) assay is a technique to study DNA-protein 
interactions in vivo [217]. Unlike plasmid promoter assays or band-shift experiments, 
where binding to synthetic DNA loci (e.g. plasmid DNA) is studied, ChIP allows to 
assess the binding of a protein to a DNA sequence on the chromosome. The 
principle of this method lies in a reversible cross-linking of all DNA-associated protein 
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to the chromatin, by the means of gentle formaldehyde fixation of cultured cells. The 
chromatin is then isolated through cell lysis, followed by nuclei purification and lysis. 
As a key step, the chromatin is fragmented by sonication into small pieces (around 
200-1000 bp in length). The obtained DNA-protein complexes are then 
immunoprecipitated using antibodies directed against the proteins of interest, 
followed by purification of the DNA-protein-antibody complex using protein A or G 
agarose beads that bind the Fc part of immunoglobulins. Thus, any DNA sequence 
that is specifically cross-linked to the protein of interest precipitates as part of the 
chromatin-protein complex. This immunoprecipitate complex is then purified and the 
cross-link is reversed, thus liberating the DNA. Finally, the identity of the isolated 
DNA fragments is uncovered by means of PCR. DNA regions that have associated 
with a specific protein are amplified, as indicated by a positive PCR signal. 
For ChIP experiments in this project, 4x107 eEPCs were transfected with 50 µg CMV-
Foxc1 plasmid. Following transfection, the cells were washed 3x with 1X PBS 
24 hours later and fixed for 10 min at 37ºC in 1% formaldehyde, followed by 3 wash 
steps with ice-cold 1X PBS. The cells were then scratched from the plates using 500 
µl ice-cold 1X PBS per 100 mm plate and spun down (1500 g, 5 min, 4ºC). Hypotonic 
buffer Mendez A (10 mM Hepes pH 7.9, 10 mM KCl, 1.5 mM MgCl2, 0.34 M sucrose, 
10% glycerin, Roche protease inhibitor cocktail tablet) was added to the pellet for 
resuspension. Lysis was carried out by addition of Triton-X (0.04% final 
concentration), followed by an incubation step for 10 min on ice. The samples were 
spun down (1300 g, 4 min, 4ºC), resulting into separation of nuclear and cytoplasmic 
proteins. After two wash steps with ice-cold 1X PBS, the pellet was dissolved in 
2.3 ml LSB (0.1M NaCl, 10 mM Tris-HCl pH 7.4, 0.1% NP-40, 1 mM EDTA – Sigma-
Aldrich) and the nuclei were lysed by addition of 300 µl 20% Sarkosyl. Next, the 
chromatin was gently transferred onto a 40 ml LSB-sucrose cushion (100 mM 
sucrose) and centrifuged  (2500 g, 10 min, 4ºC) to separate soluble protein from 
chromatin bound protein.  The supernatant was removed and the chromatin was 
resuspended in 2 ml TE buffer (containing a Roche protease inhibitor cocktail tablet), 
followed by sonication (Branson sonifier, Danbury, CT, USA - 250-D, 50% amplitude, 
2 x 50 sec in 1 second intervals). Finally, the chromatin concentration was measured 
at OD260. 
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For immunoprecipitation, 10 µg of goat anti-Foxc1 polyclonal antibody (Abcam) or 
10 µg of Goat Isotype IgG (Jacksons Laboratories) as control was added to 500 µg 
sonicated chromatin and incubated at 4ºC for 12-16 hours.  50 µl of protein G 
agarose/salmon-sperm DNA beads (50 % slurry – Upstate Millipore Corporation, 
Billerica, MA, USA) were added and the mixture was incubated (2 hours, 4ºC) 
followed by a quick spin to pellet the beads. The supernatant was removed and the 
beats were resuspended in RIPA buffer (150 mM NaCl, 0.1% SDS, 0.5% DOC, 
1% NP-40, 50 mM Tris-HCl pH 8.0) and transferred to Poly-Prep chromatography 
columns (Bio-Rad) where they were rinsed with 20 ml RIPA buffer, 20 ml LiCl buffer 
(250 mM LiCl, 0.5% NP-40, 0.5% DOC, 1 mM EDTA, 10 mM Tris-HCl, pH 8.0), and 
20 ml TE buffer. Subsequently, the columns were sealed and the beads were 
transferred with 1 ml TE buffer to a microfuge tube. Following a quick spin, the 
immunoprecipitated chromatin was eluted in 200 µl TE buffer / 10% SDS under 
shaking for 10 min at 37ºC, followed by a second elution at room temperature. The 
supernatant was transferred into new tubes and 200 µl TE buffer was added to dilute 
the SDS. The mixture was incubated at 65ºC for 2 hours to reverse-cross-link the 
immunoprecipitate, followed by Proteinase K (Roche Diagnostics) digest (45ºC, 
overnight) to degrade the antibodies and proteins. Finally, the chromatin was purified 
by Phenol / Chloroform / Isoamylalcohol extraction and subsequent ethanol 
precipitation. All protocols for ChIP analysis were based on a protocol by Gerhardt et 
al. [218]. 
The purified eEPC chromatin was amplified with the following primers: Foxc1 binding 
sites forward 5’-CAGAGTCCTAAGTTTCACATCCCTA-3’ , reverse 
5’-GTCAGGAGGATCAGACCTTTAAAAC-3’; Negative control promoter site forward 
5’-GCAGAGAACAAAAACCTGAGTTGGT-3’, reverse 
5’-CTGACTTTGGTGGTCTTTTCTCGTT-3’. The amplifications were carried out 
using the LightCycler system (described in section 2.3.1). The amplification products 
were run on 1.5% agarose gels for evaluation without real-time quantification. The 
LightCycler PCR Mix for amplification of ChIP-derived chromatin contained 13.1 µl 
ddH20, 2.4 µl 25 mM MgCl2 (Roche Diagnostics), 0.5 µl primer Mix (5 µM each), 2 µl 
LightCycler Fast Start Enzyme (Roche Diagnostics), and 2 µl template DNA. The 
PCR parameters for Foxc1 binding site primers and negative control promoter primer 
were as follows: 50 amplification cycles (95ºC - 10 sec, 5 cycles 62ºC annealing, 5 
cycles 60ºC annealing, 40 cycles 58ºC annealing - all 10 sec, 72ºC - 45 sec). 
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Densitometric analysis of the ChIP-PCR agarose gel bands to quantitate the relative 
amount of amplicon was carried out with the Bio-Rad Gel Documentation System 
Software (Bio-Rad).  
 
  
2.10 Online Databases and Bioinformatics Programs  
 
Sequence screening for individual transcription factor binding sites in selected 
genomic sequences was carried out with the MatInspector program from Genomatix 
(Genomatix Software Incorporation, Munich, Germany – http://www.genomatix.de), 
that allows the identification of cis-regulatory elements embedded in nucleotide 
motifs by means of a large library of weight matrices [219]. 
Alignment of the genomic sequence of the mouse Pecam-1 locus with the 
corresponding human Pecam-1 sequence was performed using the DiAlignTF 
program from Genomatix [220]. The program combines sequence alignments with 
the identification of conserved transcription factor binding sites within aligned 
orthologous sequences, thus achieving a higher degree of confidence regarding the 
biological functionality of identified transcription factor binding sites.   The genomic 
sequences used for the MatInspector and DiAlignTF programs were derived from the 
NCBI Entrez Gene WebViewer (http://www.ncbi.nlm.nih.gov/sites/entrez - see 
RESULTS for details). 
 
The nucleotide numbering used to indicate the relative position of the different 
genomic fragments of the mouse Pecam-1 locus where calculated by alignment of 
those sequences with the genomic sequences from the UCSC Bioinformatics 
Database, which displays the positions in absolute nucleotide numbering on the 
respective chromosome. Alignments were performed with the Blat Search Genome 
tool from the UCSC Bioinformatics Database. The numbers were then calculated 
relative to the transcription initiation site of Pecam-1, as indicated by the UCSC 
Bioinformatics Database.  
The nucleotide sequences of Pecam-1 transcripts were obtained from the NCBI 
Nucleotide Database (http://www.ncbi.nlm.nih.gov/). The accession numbers for the 
mRNAs are mentioned in the RESULTS section. The nucleotide sequences from the 
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Pecam-1 genomic areas cloned for promoter-luciferase assays were obtained from 
Dr. Scott Baldwin and coworkers (Vanderbilt University – personal communication).  
The display of homology areas between the mouse and human Pecam-1 locus was 
based on the output parameters of the DiAlignTF program (Genomatix).  The 
alignment of 20kb of the 5’-flanking genomic sequence was subdivided into 2,000 
data points (each representing a block of 10 nucleotides) and the relative nucleotide 
homology within the sequence blocks was indicated according to the output value of 
the alignment, with ‘0’ indicating no similarity and ‘10’ representing maximal similarity 
of a pairwise nucleotide alignment.  
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3. RESULTS 
 
3.1 Expression of Fox genes in eEPCs  
 
Previous in vivo studies in our laboratory showed that eEPCs possess the ability to 
migrate to areas of active tumor growth and contribute to the neovascularization 
process by incorporating into the endothelial layer and by forming microvascular 
sprouts [112]. Alongside with these events, eEPCs shift their phenotype to a more 
mature endothelial cell type. However, the rate of incorporation and overall 
contribution to the tumor’s microvascular network was rather low (around 3% of the 
total tumor vessel density was composed of eEPCs). In order to understand the 
molecular controls behind the eEPC-differentiation and to genetically manipulate this 
process, we aimed at identifying transcriptional regulators that are involved in eEPC 
differentiation. Previous Affymetrix microarray analysis, comparing the transcriptome 
of eEPCs before and after cAMP/retinoic acid-mediated differentiation, had identified 
induction of FoxC genes. Specifically, the transcript levels of Foxc1 and Foxc2 
increased 4-6 fold after cAMP-induced differentiation of eEPCs (data not shown). 
Based on this finding, we focused on the Forkhead transcription factor family 
members Foxc1 and Foxc2, since these two genes had been previously implicated in 
the development of the cardiovascular system in the past [180].  
 
As a first step, the transcript levels of Foxc1 and Foxc2 in eEPCs were evaluated 
directly by RT-PCR to gauge expression levels of the two genes.  In agreement with 
the microarray data, I found that expression of both genes was induced after in vitro 
differentiation of eEPCs with 0.5 mM cyclic AMP (Fig. 1). Among further genes, 
cAMP induced the expression of the endothelial-specific genes Flk-1 and vWF as 
well as of E-selectin and P-selectin (Fig. 1) two genes that are expressed on the 
endothelium and are involved in leukocyte migration [221]. The data showed that 
cAMP is capable of inducing the shift of eEPCs toward a more mature endothelial 
phenotype.  
Since the two transcriptional regulators Foxc1 and Foxc2 belong to a wider family of 
transcription factors, the expression profile of 29 members of the mouse Fox gene 
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family was screened by RT-PCR in order to test if this effect is unique to members of 
the FoxC subfamily. As a positive control, the expression profile of the selected Fox 
genes was assessed in parallel using E12.5 whole embryo RNA including 
intraembryonic RNA as well as Yolk Sac RNA (E12.5).  
 
 
Alongside, the expression profile of the orthologue human FOX genes was screened 
in human umbilical vein endothelial cells (HUVECs), which in contrast to eEPCs 
represent a mature endothelial line  (Table 1). The number of active Fox genes in 
whole embryonic tissue (n=27) was much higher compared to eEPC (n=8) and 
HUVEC (n=6) lines (Table 1, Fig. 2). The number of active Fox genes in eEPCs was 
slightly higher as in HUVECs. However the expression of FOXB2, FOXJ2, and 
FOXQ1 in HUVECs was not tested. The stimulation of eEPCs with cAMP induced the 
expression of 12 further members of the Fox gene family (Table 1 and Fig. 2), 
indicating that embryonic endothelial progenitors may employ Fox genes as 
important transcriptional regulators during and after the differentiation process. In 
turn, four Fox genes, namely Foxf2, Foxj2, Foxo1, and Foxq1 had decreased gene 
expression levels after eEPCs were differentiated, indicating that some Fox genes 
may also have specialized functions during the undifferentiated progenitor cell state.  
- before differentiation
+  after differentiationFoxc1
- +
Aldolase
cAMP
Flk-1
vWF
E-selectin
P-selectin
Foxc2
Figure 1 . Induction of FoxC genes upon eEPC-differentiation. Embryonic EPCs were incubated 
with 0.5 mM cAMP for 24 hours. Untreated eEPCs were used as control. Total RNA was 
isolated from control (-) and cAMP-treated cells (+) and reverse transcribed into cDNA and 
amplified by PCR. The results show induction of Foxc1 and Foxc2 gene expression during 
cAMP-induced eEPC differentiation; cAMP also induces the expression of endothelial-genes 
such as Flk-1 and vWF, as well as members of the selectin family, such as E-selectin and P-
selectin. RT-PCR were carried out with RNA from 3 different experiments and repeated twice 
(n=9). Shown is a representative result.  
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Fox Gene E12.5 Embryo eEPCs eEPCs + cAMP HUVECs
Foxa1 + - + +
Foxa2 + + increased -
Foxa3 + - - -
Foxb1 + - + -
Foxb2 + - + not tested
Foxc1 + - + +
Foxc2 + - + -
Foxd1 + - + -
Foxd2 + - - -
Foxd4 + - + -
Foxf1 + - + -
Foxf2 + + decreased -
Foxg1 + - + -
Foxh1 + - - -
Foxi1 + - - -
Foxj1 + - - -
Foxj2 + + decreased not tested
Foxk1 + - - +
Foxl1 + - + -
Foxm1 + - + -
Foxn1 - - - -
Foxn2 + + + +
Foxo1 + + decreased -
Foxo3 + + + +
Foxo4 + + increased -
Foxp1 + - - +
Foxp2 + - - -
Foxp3 - - + -
Foxq1 + + decreased not tested
Total 27 8 20 6
Table 1.  Expression analysis of Fox genes. Expression of 29 members of the mouse and 
human Fox transcription factor family was analyzed using RNA from E12.5 whole embryos, 
undifferentiated and cAMP-differentiated eEPCs as well as HUVECs. RNA was reverse 
transcribed into cDNA and amplified with gene-specific primers; (+) indicates detected 
transcript; (-) indicates no detected transcript; after differentiation of eEPCs, the expression 
levels of four Fox genes decreased and those of two Fox genes increased; twelve Fox gene 
family members were induced during eEPC-differentiation and the expression levels of two 
Fox genes was not affected; Gene expression anlaysis is based on agarose-gel 
electrophoresis. PCRs were carried out three times. 
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3.2 Foxc1 and Foxc2 regulate expression of Pecam-1 in eEPCs  
 
The upregulation of FoxC genes during differentiation of eEPCs suggested that they 
might play a role in the endothelial maturation process. To answer this question, 
Foxc1, Foxc2, and Foxa2 (the last as a control) genes were over-expressed to 
monitor changes in the expression levels of known endothelial-specific genes. In this 
experiment, undifferentiated eEPCs were transfected with expression plasmids 
encoding either Foxc1 or Foxc2 full-length cDNAs under the control of the CMV 
promoter (CMV-Foxc1 or CMV-Foxc2). To assure that Foxc1 and Foxc2 proteins 
were translated from the plasmid-encoded mRNA, Western Blot analysis was 
performed with nuclear protein extract from transfected eEPCs (Fig. 3). The assay 
showed high amounts of synthesized FoxC protein, confirming efficient over-
expression of the transgenes.  
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Figure 2. Fox gene expression. The chart shows the number of expressed Fox 
transcription factors in the different tissues and cell lines tested; cAMP-
treatment of eEPCs strongly augments the number of expressed Fox genes.  
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In a next step, the expression profiles of a variety of endothelial-specific effector 
genes (e.g., Pecam-1, Icam-1, eNOS, vWF), transcriptional regulators (e.g. Sox 
genes, Id genes, members of the Gata-family, KLF factors, Egr-1 and members of 
the Fox gene family), signaling ligands and their respective receptors (e.g., TGFβ 
family members, Ephrin/Eph family members, Integrins, Wnt family members, 
chemokines and chemokine receptors) as well as extracellular matrix molecules 
(matrix metalloproteinases and their inhibitors) were tested for potential 
responsiveness to FoxC genes by RT-PCR using gene-specific primers. A complete 
list of the examined genes is shown in the Supplemental Table at the end ot the 
document. Whereas expression levels of most tested genes were not affected by 
Foxc1 or Foxc2, Pecam-1 (Platelet Endothelial Cell Adhesion Molecule-1) was 
specifically induced by Foxc1, but not by Foxc2 (Fig. 4A). Another adhesion 
molecule, Icam-1 (Intercellular Adhesion Molecule-1) responded to both FoxC 
proteins, an effect that was also seen for the chemokine receptor Cxcr4 (Fig. 4A). 
Quantitative real-time PCR confirmed the gene induction in response to Foxc1. As 
shown in Figure 4B, Pecam-1 transcript levels were elevated by 5.5-fold, and Icam-1 
and Cxcr4 expression increased 3.5-fold and 6.5-fold, respectively. In contrast, the 
expression of genes expressed in the vascular system such as Flk-1 and Flt-1, as 
well as members of the ephrin/Eph family (ephrinB2 and EphB4), did not respond to 
overexpression of either Foxc1 or Foxc2 (Fig. 4A). These findings suggest that Foxc1 
and Foxc2 may play a role in the genetic regulation of genes encoding for surface 
proteins that are involved in the recruitment of circulating cells during inflammatory 
conditions.   
Figure 3.  Western Blot with eEPC protein lysates showing high amounts of Foxc1 and 
Foxc2 proteins after transient transfection with CMV-Foxc1, CMV-Foxc2 or empty pcDNA3 
(control); β-actin was used as internal control.  
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Figure 4.  Embryonic EPC gene expression profile after transient Foxc1 and Foxc2 expression.  A) 5x106
cells were transiently transfected with CMV-Foxc1 and/or CMV-Foxc2 expression plasmids. Basic pcDNA3 
vector was used as control. Total RNA was isolated 24 hours after transfection and subsequently reverse 
transcribed into cDNA and amplified by gene specific PCR primers. Pecam-1 expression responses to 
Foxc1. Icam-1 and Cxcr4 transcript levels are induced by either FoxC protein. Vascular genes like Flk-1
and Flt-1 or ephrinB2 and EphB4 are not affected by Foxc1 and Foxc2. Aldolase was used as 
normalization control. Transfections were repeated at least three times with RNA from at least two 
independent experiments. Shown is a representative result. B) Quantitative real-time PCR (qPCR) depicts 
the fold-induction of mRNA levels after expression of Foxc1 in eEPCs. The transcript levels of Cxcr4, 
Icam-1, and Pecam-1 show an about 6.5-fold, 3.5-fold, and 5.5-fold increase, respectively, in response to 
Foxc1 (black bars). The relative mRNA levels were calculated using the 2-∆∆CT method and normalized to 
β-actin expression as internal control; qPCRs were carried out in triplicates with mRNA from at least two 
independent experiments. (n > 6). The expression levels in control cells (gray bars) was set to an arbitrary 
value of 1 and the fold induction of gene expression in response to Foxc1 was calculated accordingly. The 
standard deviation is indicated for the CMV-Foxc1 transfected samples (black bars).    
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To test if Pecam-1 gene induction leads to higher levels of Pecam-1 protein on the 
eEPC cell membrane, we performed Fluorescence Activated Cell Sorting (FACS) 
using antibodies recognizing Pecam-1. I detected very low levels of Pecam-1 protein 
on the surface of undifferentiated eEPCs, in accordance with the mRNA results (Fig. 
5). In Foxc1-expressing eEPCs, Pecam-1 surface molecule quantity shows an 
approximately 6-fold increase (from 3% to 19% Pecam-1-positive cells), 
demonstrating that the Foxc1-induced Pecam-1 mRNA expression in eEPCs leads to 
increased Pecam-1 protein levels (Fig. 5).  
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Figure 5.  Two color dot plot FACS Analysis of EGFP-positive eEPCs, as described in Material and 
Methods. 10x5 eEPCs were incubated with an anti-Pecam-1 rat monoclonal antibody and with an anti-Tie2 
rat monoclonal antibody, and a rat IgG Isopotype control. The endothelial-specific marker Tie2 served as 
the positive control; the signal from the Isotype IgG antibody was set as a negative control. Cells were 
labeled with a donkey anti-rat secondary antibody conjugated with the red dye Phycoerythrin. Cells in the 
upper row dot plots show control (pcDNA3 transfected) eEPCs. Bottom row dot plots indicate CMV-Foxc1 
transiently transfected eEPCs. The total percentage of double-positive cells is indicated for each dot plot.  
Pecam-1 surface protein levels show an approximately 6-fold increase after Foxc1 expression. Tie2 
positive cells make up to 92% of the total counted eEPC population. X-axis shows EGFP-positive cells; y-
axis indicates Phycoerythrin (PE)-positive cells.  
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3.3 Pecam-1 as an endothelial target gene of Foxc1  
 
Pecam-1 is a 130kDa type I transmembrane surface protein that belongs to the 
immunoglobulin (Ig) superfamily of cell adhesion molecules [62]. Its expression is 
restricted to endothelial cells and certain hematopoietic cells and it has been 
implicated as a critical mediator of leukocyte transendothelial migration to sites of 
acute inflammation. In addition, it is found in the inner cell mass of the blastocyst, 
which gives rise to embryonic stem (ES) cells  [222]. 
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Figure 6.  Expression of Pecam-1.  A) 10 µm mouse liver sections were stained with a rat anti-Pecam-1 
monoclonal antibody. Cy3-conjugated donkey-anti-rat antibody was used to detect bound primary anti-
Pecam-1 antibody on the tissue section. The liver microvasculature stains intensely for the endothelial 
marker Pecam-1. B) RT-PCR shows induction of Pecam-1 expression during cAMP-induced in vitro
differentiation of eEPCs. Aldolase was used for normalization. (-) control eEPCs; (+) cAMP-
differentiated eEPCs (0.5 mM cAMP). C) Quantitative real-time PCR (qPCR) indicates an about 4-fold 
increase in Pecam-1 transcript levels after cAMP-induced eEPC-differentiation (black bar). The relative 
mRNA levels were calculated using the 2-∆∆CT method and normalized to Gapdh expression as internal 
control; qPCRs were carried out in triplicates with mRNA from three independent experiments. (n = 9). 
The expression levels in control cells (gray bar) was set to an arbitrary value of 1 and the fold induction 
of gene expression in response to cAMP was calculated accordingly. The standard deviation is
indicated for the cAMP-treated sample (black bar).    
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Because of its high expression in the endothelium, Pecam-1 is widely used as 
marker for endothelial cells (Fig. 6A). In addition, like Foxc1 and Foxc2, Pecam-1 
expression is induced during in vitro differentiation by cAMP, indicating an 
involvement during the maturation toward a differentiated endothelial phenotype (Fig. 
6B). The level of Pecam-1 induction was about 4-fold, as quantified by qPCR (Fig. 
6C), and thus similar to that seen after Foxc1 expression in eEPCs (Fig. 4B).   
The results described above show that Pecam-1 expression is specifically 
upregulated after Foxc1 expression in eEPCs (Fig. 4). To test if Pecam-1 is a direct 
target of Foxc1 and in order to identify the putative transcriptional regulatory 
elements, we undertook a detailed analysis of the Pecam-1 promoter response to 
FoxC factors in eEPCs and mature endothelial cells. 
  
3.4 Cis-regulatory areas of the Pecam-1 promoter  
 
The mouse Pecam-1 gene is located on band qE1 of chromosome 11, spanning a 
range of almost 60kb (based on Ensembl Genome Browser – 
http://www.ensembl.org). In an attempt to identify genomic areas of the Pecam-1 
locus that are bound by Foxc1, this study took advantage of Pecam-1-promoter-
luciferase plasmids kindly provided by Dr. Scott Baldwin and co-workers (Vanderbilt 
University). In the past, proximal and distal, as well as intronic areas, of the mouse 
Pecam-1 locus have been analyzed for the presence of cis-regulatory elements by 
the group of Dr. Baldwin (unpublished data in preparation). Among others, four 
different genomic fragments of the Pecam-1 locus were subcloned into the pGL2 
promoter firefly-luciferase plasmids.   
 
These four constructs are: 1) the minimal promoter elements derived from the 
transcriptional start site of mouse Pecam-1 (pGL2-mp;  -88 to +57); 2) the long 
proximal promoter sequences (pGL2-lpp; -280 to +57); 3) a distal 5’-flanking 3.5kb-
fragment (-13,597 to -10,063) in combination with the minimal promoter (pGL2-5’-
3.5kb/mp); and 4) a 4.5kb fragment from the second intron  (+10,273 to +5,849) in 
combination with the minimal promoter (pGL2-I2-4.5kb/mp) (Fig. 7,8) (see Material 
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and Methods for further details).  The latter two fragments showed the highest 
transcriptional activity regarding 5’-flanking and intronic sequences, respectively, in 
isolated endothelial cells and transient transgenic mouse embryos (Dr. Baldwin, 
personal communication).  
 
 
 
3.5 Pecam-1 promoter and enhancer analysis in different cell l ines  
 
As a first step, the four promoter plasmids (Fig. 8) were analyzed for their ability to 
drive Pecam-1 expression in eEPCs and mature endothelial lines as well as in non-
endothelial cells. In parallel to the Pecam-1 promoter studies, Pecam-1 expression 
levels were evaluated by conventional RT-PCR to obtain an overview of endogenous 
Pecam-1 gene expression in the corresponding cell lines.  
 
 
Pecam-1 Gene Locus - Chromosome 11
Minimal Promoter (-88 to +57)   
Proximal Promoter (-280 to +57)
Intron-2 4.5kb-fragment + Minimal Promoter  
Exon-1 (+1 to +262)
Exon-3
Exon-2 (+354 to +380)
Intron-2 (15kb)
4.5kb
3.5kb
4.5kb
Intron-1 (+263 to +353)
5‘-flanking area
-10,063
+5,849 +10,273
A
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Figure 7.   Mouse Pecam-1 gene locus. A) Schematic overview of the 5’-flanking region and 
exons 1-3 of the mouse Pecam-1 locus on band qE1 of chromosome 11. The transcription 
initiation site (TIS) is at +1. B) Pecam-1 promoter constructs. Overview of areas of the Pecam-
1 locus (in alignment with the diagram in A) that were cloned for promoter analysis and the 
identification of putative Foxc1-response elements. The location of the selected areas are 
directly upstream of the transcription start (minimal promoter sequence from -88 to +57), long 
proximal promoter sequence (from -280 to +57) as well as a 3.5kb fragment located distal in 
the 5’ flanking area of Pecam-1 (-13,597 to -10,063) and a 4.5kb fragment located within the 
second intron (+5,849 to +10,273). All nucleotide numbering is relative to the TIS (+1) and is 
based on the UCSC Genome Bioinformatics Database (http://www.genome.ucsc.edu). 
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As shown, Pecam-1 transcripts are detectable at high levels in mature pancreatic 
endothelial cells (MS1-ECs), cardiac endothelial cells (H5V-ECs) and bovine aortic 
endothelial cells (BAECs) but not in undifferentiated eEPCs, mouse fibroblasts (3T3) 
and Cos7 cells. As reported previously [222], we detected that undifferentiated 
embryonic stem (ES) cells express Pecam-1 (Fig. 9B).  
 
These results show that Pecam-1 is specifically expressed in mature endothelial cells 
and embryonic stem cells. To test which genomic area drives Pecam-1 expression 
and to assess if all areas are equally active in Pecam-1-expressing cells, Pecam-1 
promoter activity in eEPCs, MS1-ECs, and BAECs as well as in ES cells and Cos7 
cells was measured after transient transfection with the Pecam-1 promoter reporter 
plasmids (Fig. 9A). The minimal promoter (pGL2-mp) showed low activity only in 
BAECs, whereas the long proximal promoter (pGL2-lpp) drove reporter activity in 
BAECs and ES cells.  
 
Firefly Luciferase
4.5kb
3.5kb Luciferase
Luciferase
Luciferase
-88 to +57
-280 to +57
-88 to +57
-13,597 to -10,063
-88 to +57
+ 10,273 to +5,849 
Luciferase
3) pGL2-5’3.5kb/mp
2) pGL2-lpp
4) pGL2-I2-4.5kb/mp
1) pGL2-mp
Figure 8.   Outline of Pecam-1 promoter plasmids. Schematic structure of the four Pecam-1 
promoter plasmids cloned in front of the Firefly Luciferase gene inside the pGL2 vector. The 
plasmids contain the 1) minimal promoter sequence  (pGL2-mp / -88 to +57); 2) long proximal 
promoter sequence (pGL2-lpp / -280 to +57); 3) distal 5’-3.5kb fragment + minimal promoter 
(pGL2-5’3.5kb/mp / -13,597 to -10,063); 4) 2nd intron 4.5kb-fragment + minimal promoter (pGL2-
I2-4.5kb/mp / +10,273 to +5,849 ). The nucleotide numbering is relative to the transcription 
initiation site (+1) and is based on the UCSC Genome Bioinformatics Database 
(http://www.genome.ucsc.edu). 
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The enhancer from the 2nd intron (pGL2-I2-4.5kb/mp) displayed high activity in 
BAECs, and moderate activity in ES cells and pancreatic microvascular endothelial 
cells (MS1-ECs), thus suggesting that this regulatory element might be primary 
responsible to drive Pecam-1 expression in endothelial cells of larger vessels. The 
distal 5’-flanking enhancer (pGL2-5’3.5kb/mp) did not display extra activity. In 
accordance with endogenous Pecam-1 expression levels, no reporter gene activity 
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Figure 9.  Pecam-1 expression analysis A) For promoter analysis, eEPCs, BAECs, MS1-ECs, ES 
cells, and Cos7 cells were transiently transfected with 0.3 µg of Pecam-1 promoter plasmids (outline 
in Fig. 7). Ten ng  of the HSV-tk-Renilla plasmid were co-transfected for normalization, as described 
in Material and Methods. Luciferase activity was measured 24 hours after transfection. The 
luciferase activity derived from pGL2-I2-4.5kb/mp in BAECs was set to an arbitrary value of 1 and all 
other values were normalized accordingly. Pecam-1 expression is driven by pGL2-I2-4.5kb/mp in 
BAECs (purple bars), MS1-ECs (orange bars), and ES cells (green bars).  Embryonic EPCs (black 
bars) and Cos7 (white bars) cells do not display promoter activity. Luciferase assays were carried 
out in triplicates and repeated at least once and bars represent average values (n > 6). The standard 
deviation is indicated for each bar. B) RT-PCR analysis shows expression of Pecam-1 in BAECs, 
MS1-ECs, H5V-ECs, and ES cells but not in eEPCs and 3T3 fibroblasts. RNA was isolated from at 
least three different experiments and PCR was repeated at least twice. Aldolase was used as 
normalization control. Shown is a representative result.  
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was seen in immature eEPCs and Cos7 cells, for all four reporter plasmid (Fig. 9A). 
Taken together, the data suggest that different genomic areas contribute in the 
transcriptional regulation of Pecam-1 expression, depending on the origin of the cell 
lines. 
 
3.6 Foxc1 activates transcription through the 5’-fl anking 3.5kb-fragment  
 
The results showed that no promoter/enhancer fragment was active in 
undifferentiated eEPCs.  
 
 
 
 
Figure 10 . Pecam-1 promoter activation in eEPCs by Foxc1. 5x105 eEPCs were transiently 
transfected with 2.4 µg of CMV-Foxc1 (black bars) or pcDNA3 (gray bars) together with 0.3 µg of 
Pecam-1 promoter plasmids and 10 ng of HSV-tk-Renilla to normalize, as described in Material 
and Methods. Luciferase activity was measured 24 hours after transfection. Luciferase activity 
derived from the co-transfections with pGL2-5’3.5kb/mp and CMV-Foxc1 was set to an arbitrary 
value of 1 and the values derived from the other co-transfections were normalized accordingly. 
Foxc1 activates the Pecam-1 promoter through pGL2-5’3.5kb/mp. Fold increase or decrease in 
response to Foxc1 is shown for each bar. Luciferase assays were carried out in triplicates and 
repeated at least twice and bars represent average values (n > 9). The standard deviation is 
indicated for each bar.  
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To test if the putative Foxc1-responsive elements reside within the tested genomic 
areas, the cells were co-transfected with the promoter plasmids and a Foxc1-
expression (CMV-Foxc1) plasmid. As shown in Figure 10, a strong activation of 
reporter gene transcription through the 5’-flanking 3.5kb-fragment (pGL2-5’3.5kb/mp) 
was observed after Foxc1 expression, showing a 3.6-fold higher activity compared to 
control, empty-vector transfected eEPCs that do not express Foxc1 (Fig. 10). 
Transcriptional activation of the reporter gene by Foxc1 was neither seen for the 
proximal (pGL2-lpp) and minimal promoter area (pGL2-mp) nor with the intronic 
4.5kb-fragment (pGL2-I2-4.5kb/mp), where the background activity even dropped 
about 4-fold after Foxc1 expression in the cell. Similar, a drop of the relative reporter 
activity was seen in the promoter plasmids containing the proximal and minimal 
promoter sequences (about 2-fold in each case). Since the effect is not seen with the 
empty vector transfection, it is ruled out that this suppression is due to competition for 
a limited pool of transcription factors between co-transfected plasmids. Instead, it 
appears that Foxc1 protein overexpression might be interfering with the general 
transcriptional machinery. The around 3.5-fold induction after Foxc1 binding is in 
accordance with the increase in Pecam-1 mRNA and protein levels after Foxc1 
expression in eEPCs (Fig 4B, 5). Additionally, Pecam-1 levels increase about the 
same fold after eEPCs are induced to differentiate with cAMP and retinoic acid.  In 
conclusion, these data support the notion that a cis-acting regulatory site within the 
5’-flanking 3.5kb-fragment is driving Pecam-1 expression after Foxc1 expression in 
eEPCs.  
 
 
3.7 The distal 5’-flanking 3.5kb-fragment responds specifically to Foxc1  
 
To test if the transactivation of Pecam-1 in eEPCs through the distal upstream 
element is specific to Foxc1, the cells were co-transfected with the pGL2-5’3.5kb/mp 
promoter plasmid and pGL2-mp as control, together with the CMV-Foxc1, CMV-
Foxc2, or CMV-Foxa2 expression plasmids. Gain of function studies showed that 
Pecam-1 expression in eEPCs was specifically activated by Foxc1 but not by the 
Results 
 67
closely related transcription factor Foxc2 or the family member Foxa2 after transient 
transfection of eEPCs. (Fig. 11A). Thus, the ability of these three Fox transcription 
factors to activate target gene expression through the 5’-flanking 3.5kb-fragment was 
compared.  
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Figure 11.  Pecam-1 induction is specific for Foxc1. A) 5x106 eEPCs were transiently transfected 
with 8 µg of CMV-Foxc1, CMV-Foxc2, CMV-Foxa2, or pcDNA3 (control) followed by RNA isolation 
after 24 hours and RT-PCR. Foxc1, but not Foxc2 and Foxa2 activates expression of Pecam-1 in 
eEPCs. Aldolase is shown as normalization control. B) eEPCs were transiently transfected with 
2.4 µg of CMV-Foxc1, CMV-Foxc2, CMV-Foxa2, or pcDNA3, together with 0.3 µg of pGL2-mp 
(gray bars) or pGL2-5’3.5kb/mp (black bars) and 10 ng of HSV-tk-Renilla to normalize, followed by 
luciferase assays after 24 hours. Luciferase activity derived from the co-transfections with pGL2-
5’3.5kb/mp and CMV-Foxc1 was set to an arbitrary value of 1 and all other luciferase values were 
normalized accordingly. The fold activity of reporter expression from pGL2-5’3.5kb/mp compared 
to pGL2-mp is shown for each co-transfection. The 3.5kb fragment (pGL2-5’3.5kb/mp) is induced 
by Foxc1. Luciferase assays were carried out in triplicates and repeated at least twice and bars 
represent average values (n > 9). The standard deviation is indicated for each bar.  
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As shown, the transcriptional activation was specific for Foxc1 (11-fold over the 
minimal promoter), since both Foxc2 (1.75-fold over minimal promoter) and Foxa2 
(2.12-fold over minimal promoter) had a minimal effect (Fig. 11B), thus not reaching a 
significant induction, similar as in control eEPCs (pcDNA3 transfected). These data 
confirmed the RT-PCR studies that showed induction of endogenous Pecam-1 
expression in eEPCs only through Foxc1.  
 
 
3.8 Foxc1 activates transcription specifically in e EPCs 
 
In eEPCs, the induction of Pecam-1 after Foxc1 expression is regulated through the 
5’-flanking 3.5kb-fragment (pGL2-5’3.5kb/mp). The response of this putative control 
element to Foxc1 was also investigated in BAECs as well as in non-endothelial cells 
(ES cells and Cos7 cells) (Fig. 12A). After transient co-transfections of CMV-Foxc1 
plasmid and Pecam-1 promoter plasmids, I found that Foxc1 did not trans-activate 
reporter gene expression in BAECs and Cos7 cells (Fig. 12A), showing that the 
transcriptional activation through Foxc1 specifically takes place in eEPCs (about 3.5-
fold induction compared to control cells – Fig. 10). This suggests that the effect of 
Foxc1 on Pecam-1 expression might be cell-context specific (Fig. 12A). The basal 
signal of pGL2-5’3.5kb/mp was even lowered in BAECs (about 11-fold), ES cells 
(about 5-fold) and in Cos7 cells (about 1.5-fold) after expression of Foxc1, compared 
to control (pcDNA3 transfected) cells. Lowered reporter activity was seen for all 
promoter plasmids in response to Foxc1 expression in these cells (data not shown), 
possibly indicating a general suppression activity of the basic Pecam-1 promoter.  
 
In accordance, Pecam-1 transcript levels were decreased in response to Foxc1-
overexpression in mature pancreatic endothelial cells (about 4-fold) and ES cells 
(about 2-fold), as shown by qPCR (Fig. 12B).  
In addition, attempts to assess reporter gene activation through pGL2-5’3.5kb/mp 
upon Foxc1 expression in pancreatic (MS1-ECs) and cardiac (H5V-ECs) endothelial 
cells did not work well, possibly because these cells are hard to transfect efficiently, 
especially with a combination of several plasmids. A number of different techniques 
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did not result into the desired transfection efficiency that would have allowed the 
monitoring of the Pecam-1 promoter plasmid activity after co-transfection with the 
CMV-Fox expression plasmids.  
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Figure 12. Legend next page 
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3.9 Endogenous Pecam-1 RNA analysis matches promoter activation studies  
 
To corroborate the promoter studies, activation of endogenous Pecam-1 expression 
in response to Foxc1 was studied. Figure 13 summarizes the data, showing that 
Pecam-1 transcript levels are elevated only in eEPCs after Foxc1 expression.  
 
In contrast, mature endothelial lines (MS1-ECs, H5V-ECs, BAECs), which express 
constitutively high levels of Pecam-1, do not upregulate Pecam-1 expression after 
transient transfection of CMV-Foxc1 plasmid. Undifferentiated ES cells express 
Pecam-1, but - like in mature endothelial cells - transcript levels are not influenced by 
the presence of Foxc1 in the cells (Fig. 13). Non-endothelial lines such as Cos7 cells 
and 3T3 mouse fibroblasts do not express Pecam-1, and no de novo activation is 
seen after Foxc1 expression is induced. Thus, it appears that endogenous 
upregulation of Pecam-1 after Foxc1 induction is confined to embryonic EPCs 
indicating that the Pecam-1 response is cell-context specific.  
 
 
 
 
Figure 12.  A) Pecam-1 transactivation by Foxc1 is specific for eEPCs. 1x105  BAECs, ES cells, or 
Cos7 cells were transiently transfected with 2.4 µg of CMV-Foxc1 (black bars) or pcDNA3 (gray 
bars) together with 0.3 µg of pGL2-mp or pGL2-5’3.5kb/mp and 10 ng of HSV-tk-Renilla to 
normalize, followed by luciferase assays after 24 hours. Luciferase activity derived from the co-
transfections with pGL2-5’ 3.5kb/mp and CMV-Foxc1 was set to an arbitrary value of 1 and all other 
luciferase values were normalized accordingly. Note that luciferase values are normalized 
independently for each cell line and values in the charts do not represent absolute luciferase units. 
BAECs, ES cells, or Cos7 cells do not activate reporter expression through pGL2-5’3.5kb/mp in 
response to Foxc1 (black bars). Luciferase assays were carried out in triplicates and repeated at 
least twice and bars represent average values (n > 9). The standard deviation is indicated for each 
bar. B) Quantitative Real-Time PCR (qPCR) shows a decrease in endogenous Pecam-1 mRNA 
levels in MS1-ECs and ES cells after overexpression of Foxc1. 5x106 MS1-ECs or ES cells were 
transiently transfected with 8 µg of  CMV-Foxc1 plasmid (black bars) or pcDNA3 as control (gray 
bars). Cells were lysed 24 hours after transfection and total RNA was subjected to RT-PCR, 
followed by qPCR. Endogenous Pecam-1 mRNA levels decrease about 4-fold (MS1-ECs) or about 
2-fold (ES cells) in response to Foxc1 expression. The mRNA level in CMV-Foxc1-transfected cells 
was set to an arbitrary value of 1 and the mRNA level in control cells was normalized accordingly for 
each cell line. The relative mRNA levels for each sample were calculated using the 2-∆∆CT method 
and normalized to β-actin expression; qPCRs were carried out in triplicates with mRNA from two 
independent experiments. (n = 6). The standard deviation is indicated for the control samples (gray 
bars).    
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3.10 Dose-dependent activation of the Pecam-1 promoter by Foxc1  
 
In a new round of transfection experiments in eEPCs, a stepwise decrease of the 
amount of Foxc1-expression vector – from a 4-fold molar excess compared to 
reporter plasmid pGL2-5’3.5kb/mp, to a 2-fold molar excess and to an equimolar 
amount - resulted in a consistent drop of the reporter gene activity from 100% to 76% 
and to 35%, respectively (Fig. 14). Thus, the activation of reporter expression 
through the 5’-flanking 3.5kb-fragment in response to Foxc1 is dose-dependent and 
Pancreatic ECs
BAECs
Cardiac ECseEPCs
ES cells
CMV-Foxc1 - +
-
- + - +CMV-Foxc1
Pecam-1
Aldolase
- + - +
3T3
- +
Foxc1
Pecam-1
Aldolase
Foxc1
Figure 13.  Foxc1 induction of the endogenous Pecam-1 gene is restricted to eEPCs. 5x106
eEPCs, MS1-ECs, H5V-ECs, ES cells, BAECs, or 3T3 fibroblasts were transiently transfected with 
8 µg of CMV-Foxc1 (+) or pcDNA3. (-). Cells were lysed 24 hours after transfection and total RNA 
was subjected to RT-PCR. Foxc1 activates Pecam-1 expression only in undifferentiated eEPCs. 
BAECs, MS1-ECs, H5V-ECs, and ES cells express high Pecam-1 and the expression levels are 
not elevated in response to Foxc1. Fibroblasts (3T3) do not express Pecam-1. Aldolase is shown 
as normalization control. RNA was isolated from at least three different experiments and PCR was 
repeated at least twice. Shown is a representative result.  
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requiring relatively high Foxc1 expression levels.  This result suggests that Foxc1, or 
an intermediate, might act through a weak binding site. 
 
 
3.11 Activation of the Pecam-1 promoter takes place in multiple, independently 
isolated eEPC clones  
 
Embryonic EPCs are primary cell lines isolated from single or pools of mouse E7.5 
embryos. To ensure that the observed induction of Pecam-1 by Foxc1 does not 
depend on the cell isolation, the promoter/enhancer analysis was performed in three 
independently isolated eEPC lines, namely T17b, T19b and FT4b. After transient 
transfection with the Pecam-1 promoter plasmids (outlined above in Fig. 8) and CMV-
Foxc1, reporter gene activation through pGL2-5’3.5kb/mp was seen in all three 
different eEPC clones, resulting into a 3,67, 3,72 and 4,01-fold induction after Foxc1 
expression as compared to control eEPCs (pcDNA3 transfected; Fig. 15). The results 
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Figure 14.   Responsiveness of pGL2-5’3.5kb/mp to Foxc1 in eEPCs is dose dependent. 5x105
eEPCs were transiently transfected with 0.3 µg of pGL2-5’3.5kb/mp and 10 ng of HSV-tk-
Renilla to normalize, together  with CMV-Foxc1 at 4-fold, 2-fold and equal molar amounts,
followed by luciferase assays after 24 hours. Luciferase activity derived from the co-
transfections with CMV-Foxc1 in an equimolar amount was set to an arbitrary value of 1 and all 
other luciferase values were normalized accordingly. The reporter gene activity decreases in 
correlation with lowered CMV-Foxc1 amounts. The relative luciferase values are shown above 
each bar. Luciferase assays were carried out in triplicates and repeated once with bars 
representing average values (n = 6). The standard deviation is indicated for each bar.  
Results 
 73
showed that Pecam-1 upregulation in response to Foxc1 is taking place at 
comparable levels in independently isolated eEPC lines. 
 
 
 
3.12 Pecam-1 promoter activity – Summary  
 
In summary, Foxc1 activates a 3.5kb-fragment located in the distal 5’-flanking area of 
Pecam-1 and induces transcription in embryonic endothelial progenitor cells (Fig. 
16).  In contrast, mature endothelial lines, such as bovine aortic cells, pancreatic ECs 
and cardiac ECs drive high endogenous levels of Pecam-1 expression through 
regulatory sequences located within the 4.5kb-intronic fragment. Exogenous Foxc1 
protein does not affect expression in mature endothelial cells. ES cells display 
moderate activity of the proximal promoter located directly upstream of the Pecam-1 
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Figure 15.  Pecam-1 activation by Foxc1 takes places in different eEPC clones. 5x105 cells from 
three independent eEPC clones (T17b, FT4b, T19b) were transiently transfected with 2.4 µg of 
CMV-Foxc1 (black bars) or pcDNA3 (gray bars) together with 0.3 µg of pGL2-5’3.5kb/mp and 10 
ng of HSV-tk-Renilla to normalize, followed by luciferase assays after 24 hours. Luciferase activity 
derived from the co-transfections with pGL2-5’3.5kb/mp and CMV-Foxc1 was set to an arbitrary 
value of 1 for each clone and corresponding control luciferase values were normalized 
accordingly. The fold activation of reporter expression through pGL2-5’3.5kb/mp in response to 
Foxc1 is indicated for each clone. Luciferase assays were carried out in triplicates and repeated 
once, and bars represent average values (n = 6). The standard deviation is indicated for each bar.  
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transcription start and, as with mature endothelial cells, gain of Foxc1 function does 
not increase Pecam-1 expression nor does it induce luciferase activity of the 
promoter/enhancer constructs. The promoter elements have no activity in Cos7 cells, 
regardless of Foxc1, in accordance with the fact that Cos7 cells represent a Pecam-1 
negative non-endothelial cell population [223].  
 
 
 
3.13 Localization of Foxc1-responsive sites  
 
Next, the 5’-flanking 3.5kb-fragment (-13,597 to -10,063) was scrutinized for putative 
sites responding directly or indirectly to Foxc1. Using PCR amplification, the whole 
3.5kb-fragment was separated into three pieces (-13,597 to -12,547; -12,568 to -
Foxc1 Exon-3Intron-2 -15kb
4.5kb
Foxc1 GoF - eEPCs
B
Exon-3Intron-2-15kb
4.5kb
Pancreatic ECs / Cardiac ECs / BAECs
C
Exon-3Intron-2 (15kb)-15kb
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Undifferentiated ES Cells
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Exon-3Intron-2 (15kb)-15kb
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Exon 1 (+1 to +262)
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Exon 2 (+354 to +380)
Intron-2 -15kb
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Intron 1 (+263 to +353)
No Pecam-1 expression - eEPCs
A
Figure 16 . Summary of Pecam-1 Promoter regulation in different cell types. A) Undifferentiated 
eEPCs do not show cis-regulatory activity of the distal 5’-flanking 3.5kb fragment (gray box), the 
proximal promoter areas (around Exon-1), or the 4.5kb fragment (black-white striped box) in the 
second intron. B) Gene transcription is activated through the distal 5’-flanking 3.5kb fragment after 
Foxc1 expression C) Mature endothelial cells (pancreatic ECs, cardiac ECs, bovine aortic ECs) 
have high endogenous Pecam-1 expression driven by the 4.5kb fragment located within the 
second intron (gray triangle). The activity of the intronic enhancer is independent of Foxc1. D)
Undifferentiated ES cells drive Pecam-1 expression through the proximal promoter area as well as 
through the intronic 4.5kb fragment (gray triangles). E) Cos7 kidney cells do not express  Pecam-1
and display no activity of the different promoter elements, regardless of Foxc1 expression. All 
inactive promoter elements are indicated by a black circled X; GoF = Gain of Funtion. 
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11,499; -11,520 to -10,063), which were sub-cloned into the luciferase reporter vector 
upstream from minimal promoter regulatory sequences (-88 to +57), yielding the 
promoter plasmids pGL2-5’1kb(A)/mp (-13,597 to -12,547), pGL2-5’1kb(B)/mp (-
12,568 to -11,499), and pGL2-5’1.5kb/mp (-11,520 to -10,063)( Fig. 17A).  
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Figure 17. Legend next page 
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We then tested the ability of Foxc1 to induce the activity of the three sub-fragments in 
eEPCs. The results showed that the ca. 1.5kb-long sequence derived from the 3’-part 
of the 3.5kb-fragment (pGL2-5’1.5kb/mp) - distal to the Pecam-1 transcription start - 
responded to Foxc1 leading to about 5-fold increase in luciferase activity compared 
to control, empty vector-transfected, cells (Fig. 17B). In contrast, the remaining 2kb-
long sequence, which is sub-divided into two fragments about 1kb in length (pGL2-
5’1kb(A)/mp and pGL2-5’1kb(B)/mp), does not respond to Foxc1, and reporter gene 
activity even drops about 10- and 7-fold, respectively, compared to control cells. The 
data indicate that putative Foxc1 regulatory elements are located within the 1.5kb-
fragment. As with the intact 3.5kb fragment, activation of reporter gene expression 
through pGL2-5’1.5kb/mp was only seen in response to Foxc1, but not to Foxc2 
(which led to approximately 2-fold decrease in activity compared to control cells) (Fig. 
17B).   
 
3.14 Analysis of the Pecam-1 promoter using Bioinformatic Tools  
 
The responsiveness of the 1.5kb-sub-fragment within the distal element raised the 
possibility that this might be due to direct binding in this area.  To test this idea, I 
analyzed the nucleotide sequence using the NCBI Nucleotide database 
(http://www.ncbi.nlm.nih.gov/) as well as the UCSC Bioinformatics Database 
(http://www.genome.ucsc.edu/) for putative, consensus Fox binding sites. 
Figure 17.  Localization of Foxc1 binding sites within the 3.5kb upstream element.  A) The distal 5’-
flanking 3.5kb-fragment inside pGL2-5’3.5kb/mp was divided into three fragments, followed by sub-
cloning into pGL2-mp, yielding promoter plasmids pGL2-5’1kb(A)/mp (-13,597 to -12,547),  pGL2-
5’1kb(B)/mp (-12,568 to -11,499) and pGL2-5’1.5kb/mp (-11,520 to 10,063). Details are described in 
Material and Methods. B) 5x105 eEPCs were transiently transfected with 2.4 µg of CMV-Foxc1 (black
bars), CMV-Foxc2 (white bars), or pcDNA3 (gray bars), together with 0.3 µg of pGL2-5’1kb(A)/mp, 
pGL2-5’1kb(B)/mp, and pGL2-5’1.5kb/mp and 10 ng HSV-tk-Renilla to normalize. Luciferase activity 
derived from the co-transfections with pGL2-5’1.5kb/mp and CMV-Foxc1 was set to an arbitrary value 
of 1 and all other luciferase values were normalized accordingly. pGL2-5’1.5kb/mp responds to Foxc1 
and drives reporter gene expression. No reporter transcription through pGL2-5’1.5kb/mp is seen in 
CMV-Foxc2 or pcDNA3 transfected cells. The fold-change in response to Foxc1 or Foxc2 is indicated 
for each bar. Luciferase assays were carried out in triplicates and repeated at least three times and 
bars represent average values (n > 9). The standard deviation is indicated for each bar. All nucleotide 
numbering is relative to the transcription initiation site (+1) and is based on the numbering system of 
the UCSC Genome Bioinformatics Database (http://www.genome.ucsc.edu). 
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This analysis showed that the genomic 1.5kb-fragment (-11,520 to -10,063) contains 
two non-connected stretches of ‘TTTGT’ pentanucleotide repeats (‘ACAAA’ in 
Exon-1
Exon-3
Exon-2
Intron-2
-15kb
Intron-1
5Ō-flanking area
-11497 TGAAAGTTTTGCCTTTTGAAAGGATGGGTTATCCAGGAGGCCTAACCCTATGTAAAAAGG
-11437 CAGTTTAGGGTTCAGACACAGCCAGCAATCAGCCCCGAGGTTAGCACT GTAGAATTAAG
-11377 GAGAGAATAGGTAGCCGGTGCCATGTGAAGGAGATGAGTTAGATCTAATGTGTTGGCTTG
-11317 GCTTGGAGAAGCAGCACTGCTTGTCATTGGAACCAGTTGCATGTA G GACAGGAGCTTT
-11257 GACCTGGGAGCAATGTCATCCCATGGTCAACACCCTTCTCTATAA C GCATGCCCATGT
-11197 TATTCCTGCATCCCAGACACCATAAGTCCGTGGCTGCTTCCATGCTT AACCAGGATTAT
-11137 AATAGGGTTACAAGTCTGGGGCTGAGTGCAGGAATTATTAACAGGGTTGAAATTGTTAG
-11077 GTGGTGGTGGTGGTGGGGTCTCGGTTAACCCCCCAAGCAGAGTCCT AGTTTCACATCCC
-11017 TAGGATGGGCACCAATACTGGTT TGTTAAATGTTCCTTTTTTTGGTTTTTTTTTTTTTT
-10957 TGG TTTGTTTGTTAAATGTTCCTTTTTGTTTGTTTGTTAAATGTTCCTTTTTGTTTTT
-10897 TGTTTTGTTTGTTTGTTTGTTAAATGTTCTTTTTTGTTTTTTGTTTGTTAAATTTTCCC
-10837 TT TTTGTTTGTTTGTTAAATGTTCCTTTTTTGTTTGTTTGTTAAATGTTCCTTTGTTTG
-10777 TTTGTTAAATGTTCCTTTTTGTTTGTTTGTTTGTTTGTTAGTTAAATGTTCCCTTTT
-10717 TGTTTGTTTGTTAAATGTTCCTTTTTGTTTGTTTGTTAAATGTTCCTGTTTGTTTGTT
-10657 TGTTTGTTTGTTAAATGTTCCCTTTTTTTTGGTTTGTTTGTTAAATGTTCCTTTTTGTT
-10597 TGTTTGTTTGTTAAATGTTCCTTTTTGTTTGTTTGTTTGTTAAATGTTCCTTTTTGTT
-10537 TGTTTGTTTGTTAAATGTTCCTTTTTGTTTTGTTTTGGTTTTTTGTTTGTTTGTTTGTT
-10477 AAATGTTAAATGGTTTTAAAGGTCTGATCCTCCTGACTCCACAAGAGCTGAGATTGCACG
-10417 GGTGAACCGCCACGCCAGTTTGCAGGAT TTTTGGATGGAACGCAGGACGCTGTGCATGC
-10357 TAGGGGTTTCGAGTTTTTGTTTTGTTTGTTAAATGTTCCTTTTTTGTTTGTTTTTTGT
-10297 TAAATGTTCCTTTTTTTGTTTTGTTTTGGTTTTTTTGTTTGTTTGTTAAATGTTCCTTT
-10237 T TTTGTTTGTTTGTTAAATGTTCCTTTTTGTTTGTTTGTTTGTTTGTTTGCCAATACTG
-10177 GTTTTGGTCACTGCAGTTGGTACTAGTGGCTGAGGGACAAGCATATAATTTTTCCCTTG
-10117 AAACCTCTGTGAAAAACATTTAGCTGTTGAGGGGGCTTCACGCTCAGGAGAGCTC
Fox Consensus Binding Site
5’-WTTYRTTTRW-3’
W = A or T
R = A or G
Y = C or T
A
B
5‘-flanking area
Figure 18.  The Foxc1-response element contains multiple Foxc1 “core” binding sites. A) The 
distal 5’-flanking 1.5kb-fragment (-11,520 to -10,063 - gray box) of mouse Pecam-1 contains a 
block of 61 ‘TTTGT’ pentanucleotide repeats , spanning from -10,995 to -10,478. A second, 
shorter block of 20 ‘TTTGT’ pentanucleotide repeats is located immediately downstream and 
spans from  -10,390 to -10,188. Shown is the nucleotide sequence from -11,497 to -10,063. All 
nucleotide numbering is relative to the transcription initiation site (+1) of Pecam-1
(http://www.genome.ucsc.edu). The pentanucleotide repeats are shown in bold and are 
separated by short stretches of nucleotides. B) Consensus Fox binding site (see text for details). 
The pentanucleotide ‘TTTGT’ is part of the consensus sequence. 
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reverse orientation), spanning from -10,995 to -10,478 and -10,390 to -10,188 (Fig. 
18A). Interestingly, the pentanucleotide sequence ‘TTTGT’ is the core of the Fox 
transcription factor binding site consensus sequence, which is defined as 5’-
WTTYRTTTRW-3’ (W = A or T; R = A or G; Y = C or T) [224]. Within the repetitive 
blocks found within the Pecam-1 distal element, the single ‘TTTGT’ repeats are 
separated by short stretches of nucleotides. The presence of a microsatellite repeat 
containing the core sequence of the Fox binding site raised the possibility that this 
(TTTGT)n microsatellite repeat motif could function as a remote cis-regulatory site 
that is able to bind the transcription factor Foxc1 and take part in the transcriptional 
activation of the Pecam-1 gene.   
 
3.15 The (TTTGT)n motif is found at the human PECAM-1 locus  
 
The unusual sequence arrangement within the mouse Pecam-1 distal element 
prompted us to search if the microsatellite repeat motif is found in other species 
besides mouse. To this end, the sequence of the 1.5kb-fragment embracing the 
repeat motif was further analyzed with bioinformatics tools.  
 
Using the Genomatix DiAlignTF software [220], an alignment of 20kb of the 5’-
flanking sequence of the mouse Pecam-1 gene displays several areas of cross 
species homology with the corresponding human genomic sequence of Pecam-1. 
The area that contains the (TTTGT)n motif within the mouse genomic sequence only 
aligns over a short distance with that of the human sequence (Fig. 19), indicating that 
a sequence block (-10,231 to -10,193) of the mouse (TTTGT)n microsatellite repeat 
displays moderate cross-species homology to a TG-rich sequence around 16kb 
upstream of the human PECAM-1 gene (Fig 19). A second homology peak within the 
area of the microsatellite motif (-10,440 to -10,402) indicates a low cross-species 
homology stretch that is located between the major and minor block of ‘TTTGT’ 
repeats. However, the major parts of the two sequence blocks containing the 
(TTTGT)n repeat motif are not conserved between mouse and human, as seen by the 
absence of a homology histogram (Fig. 19). In contrast, the proximal promoter areas 
located directly upstream of the transcriptional start site of Pecam-1 are strongly 
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conserved between the orthologue sequences (Fig. 19). In addition, various 
histograms indicating moderate to high homology can be found throughout the 20kb 
5’-flanking sequence and - in addition to the proximal promoter areas - an area 
displaying very high cross-species homology to the human sequence is found around 
19kb upstream of the mouse Pecam-1 transcription initiation site (Fig. 19).  
 
 
Although we did not attempt to further analyze potential transcription factor binding 
sites, it is very well possible that these homology areas contain cis-regulatory motifs 
that may partake in the activation or repression of Pecam-1 expression.  
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Figure 19 . Cross Species homology upstream of the Pecam-1 locus. Alignment of the respective 
Pecam-1 genomic sequence of mouse and human. Homology areas between the two species are 
indicated by the histograms. The area containing the two blocks of ‘TTTGT’ repeats (-10,995 to -10,478 
and -10,390 to -10,188) at the mouse 5’-flanking locus is indicated by the horizontal bar. A short stretch 
of low cross-species homology is seen in the area of the mouse ‘TTTGT’ microsatellite repeat (-10,231 
to -10,193 - ‘TTTGT’ repeats in bold) as indicated by the vertical empty arrow. The neighbouring 
homology peak to the immediate left (-10,440 to -10,402) indicates a low cross-species homology area 
that is positioned between the major and minor block of ‘TTTGT’ repeats. The ‘TTTGT’ repeats are not 
conserved at the human Pecam-1 locus, but rather represented by a TG-rich sequence motif, as 
indicated by the alignment below the graphic (‘T’ and ‘G’ in italic and underlined). The asterix and the 
horizontal arrow indicate the start of transcription (+1) of the mouse Pecam-1 gene - strong cross-
species sequence homology is found in the area surrounding the transcription initiation site, and various 
homology areas of different intensity are present throughout the 20kb 5’-flanking area. The alignment 
was performed by means of the genomatix “DiAlignTF” Tool (http://www.genomatix.de), using the 
nucleotide sequences derived from the NCBI Entrez Gene MapViewer 
(http://www.ncbi.nlm.nih.gov/sites/entrez).The relative degree of cross-species homology is indicated 
on the y-axis and is based on the output of the DiAlignTF sequence alignment, ranging from ‘0’ (no 
homology) to ‘10’ (very high homology). The overall nucleotide similarity of the two aligned sequences 
was calculated as 7% by the DiAlignTF program.  All nucleotide numbering is relative to the transcription 
initiation site (+1) of the mouse Pecam-1 gene and is based on the NCBI Entrez Gene MapViewer 
sequence. 
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Using the MatInspector software [219], the 40kb 5’-flanking genomic sequence of the  
human PECAM-1 locus was screened for the presence of potential Foxc1 binding 
sites and/or ‘TTTGT’ repeat motifs, as found at the mouse Pecam-1 locus. As shown 
in Figure 20, the analysis picked several areas at the human locus that contain 
blocks of ‘TTTGT’ repeats, ranging from two up to six repeat units.  
 
 
 
 
The MatInspector analysis identified those repeats as Forkhead binding site with 
‘CAAA’ (reverse for ‘TTTG’) as core sequence. Likewise, the major block of ‘TTTGT’ 
repeats in the mouse sequence is identified by the software to contain numerous 
Forkhead binding sites with the same core sequence, thus allowing us to make the 
claim that the identified repeats in the human locus may serve as regulatory motifs 
and potential Foxc1 binding sites during human PECAM-1 expression.  
 
The number of repeat units was lower at the human locus than at the mouse locus. 
Our analysis showed that the human PECAM-1 5’-flanking area contains an overall 
of nine short blocks of ‘TTTGT’ repeats identified by the software, indicating a total of 
45 ‘TTTGT’ repeat units. However the repeat blocks were distributed over a range of 
14kb (from around -33kb to -19kb) in the 5’-flanking area of the human PECAM-1 
gene. All identified ‘TTTGT’ sequence repeats and their corresponding nucleotide 
positions in relation to the human PECAM-1 transcription initiation site are listed in 
Table 2. 
+1
-35kb -30kb -25kb -20kb -15kb -10kb -5kb-40kb
Human Pecam-1 5’-flanking area
6 5 6 6 6 4
4
42 PECAM-12
Figure 20.  The human PECAM-1 locus contains various short (TTTGT)n repeat motifs. A) The 5’-
flanking sequence (40kb) of the human PECAM-1 gene was screened for putative Forkhead 
Transcription Factor binding sites using the genomatix MatInspector Software 
(http://www.genomatix.de). The schematic graphic depicts areas containing ‘TTTGT’ repeats (black 
boxes) that were identified by the software as Forkhead binding sites. The upstream area between -
33kb and -19kb contains several blocks of ‘TTTGT’ repeats. The number of single repeat units of each 
block is shown above the boxes, indicating a total of 45 identified repeat units. The width of the boxes 
reflects the total length of the sequence stretch embracing the repeats units. 
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To further verify the possibility that the (TTTGT)n repeat motifs serve as putative cis-
regulatory sites at the human PECAM-1 locus, an experimentally verified Foxc1 
binding site at the mouse Tbx1 locus that was shown to be involved as cis-regulatory 
element in the expression of Tbx1 [195], was identified by the MatInspector software 
as Forkhead binding site with ‘CAAA’ as core binding site (data not shown), as seen 
for the (TTTGT)n repeat motifs at the mouse and human Pecam-1 locus. This 
strengthened our assumption that, like in the mouse, transcriptional control of the 
human PECAM-1 gene may involve the randomly distributed (TTTGT)n repeat motifs 
(Fig. 20). 
 
 
3.16 Deletion of the repeat motif abolishes promote r activity  
 
To test the notion that the (TTTGT)n repeat motif has cis-acting regulatory activity, 
the 1.5kb-fragment (pGL2-5’1.5kb/mp) containing the microsatellite sequence was 
deleted stepwise from the 5’-end using site-directed PCR mutagenesis, as described 
in Material and Methods. Figure 21 summarizes the obtained data, showing that a 
decrease in reporter gene activity correlated with a stepwise deletion of the (TTTGT)n 
repeats. A deletion of 612bp (-11,495 to -10,884) from the 1.5kb fragment 
encompassing 10 ‘TTTGT’ repeats (promoter plasmid pGL2-5’1.5kbD2/mp) or 755bp 
(-11,495 to -10,741) with 28 ‘TTTGT’ repeats (promoter plasmid pGL2-
Repeat Units Position
6 -32,941
5 -31,569
6 -30,221
6 27,885
6 -27,372
4 -25,541
2 -24,720
2 -20,005
4 -19,884
4 -19,435
Table 2 . Listing of ‘TTTGT’ repeats in the distal 5’-flanking area of the human PECAM-1 gene. 
The left column shows the number of single repeat units; right column indicates the first nucleotide 
position of each repeat motif. 
Results 
 82
5’1.5kbD3/mp), or 1038bp (-11,495 to -10,458) covering the major block of 61 
‘TTTGT’ repeats (promoter plasmid pGL2-5’1.5kbD4/mp)  led to a decrease of 
reporter activity of 20% and 49% and 73%, respectively.  
 
 
 
 
Still, an activity of 27% of the original pGL2-5’1.5kb/mp promoter plasmid remained 
after the major block of ‘TTTGT’ repeats was deleted. The minor second block 
containing 20 ‘TTTGT’ repeats (-10,390 to -10,188) appears to be able to drive 
transcriptional activity compared to the minimal promoter alone (pGL2-mp) (Fig. 21). 
In addition, a deletion comprising 476bp (-11,495 to -11,020) of the sequence 
5’
pGL2-5’1.5kbD4/mp
5’ 3’
5’
3’
pGL2-5’1.5kbD2/mp
5’ pGL2-5’1.5kbD3/mp
3’
5’
3’pGL2-5’1.5kbD1/mp
0 0.2 0.4 0.6 0.8 1 1.2
relative luciferase activity
pGL2-5’ 1.5kb/mp WT-sequence 3’
Luciferase
-88 to +57
pGL2-5’1.5kb/mp
1
0.85
0.51
0.27
pGL2-mp
0.80
Figure 21.  Deletion analysis of the Foxc1-responsive repetitive element. The (TTTGT)n repeat motif 
was deleted stepwise as described in Materials and Methods, using pGL2-5’1.5kb/mp (-11,520 to -
10,063) as DNA template. 5x105 eEPCs were transfected with 0.3 µg of pGL2-5’1.5kb/mp, pGL2-
5’1.5kbD1/mp (deletion -11,495 to -11,020 - no TTTGT repeats), pGL2-5’1.5kbD2/mp (deletion -
11,495 to -10,884  - 10 TTTGT repeats), pGL2-5’1.5kbD3/mp (deletion -11,495 to -10,741 - 28 
TTTGT repeats), pGL2-5’1.5kbD4/mp (deletion -11,495 to -10,458 - all 61 TTTGT repeats) or pGL2-
mp, together with 2.4 µg of CMV-Foxc1 (black bars) or pcDNA3 (data not shown). Sequential 
deletion of the (TTTGT)n repeats results into a stepwise decrease of 20%,  49% or 73% of reporter 
gene activity in response to Foxc1. Deletion of the sequence upstream of the (TTTGT)n repeat motif 
results into a decrease of 15% of reporter gene activity. pGL2-mp was used as control. The black 
boxes indicate the major block of ‘TTTGT’ repeats (-10,995 to -10,478). The white box indicates the 
minor ‘TTTGT’ repeat block  (-10,390 to -10,118) that was not deleted. The luciferase signal derived 
from the co-transfections of CMV-Foxc1 with pGL2-5’1.5kb/mp was set to an arbitrary value of 1 and 
all others values were normalized accordingly. Luciferase assays were carried out in triplicates and 
repeated twice and bars represent average values (n = 9). The standard deviation is indicated for 
each bar.  
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upstream of the (TTTGT)n repeat motif (promoter plasmid pGL2-5’1.5kbD1/mp) leads 
to a decrease of 15% of the luciferase activity, possibly caused by the removal of 
positive regulatory elements in that area which may respond to eEPC-nuclear 
protein. In brief, the data show that the (TTTGT)n repeat motif is responsible of 
driving reporter gene transcription in response to Foxc1 expression and has cis-
acting regulatory activity. 
 
 
3.17 Foxc1 binds the (TTTGT) n motif on native chromatin  
 
In the previous experiments, Foxc1 protein was shown to bind the (TTTGT)n repeat 
motif on a promoter plasmid in vitro. To examine if this interaction can take place in 
vivo, the binding of Foxc1 protein at the chromosomal Pecam-1 locus was analyzed 
using chromatin immunoprecipitation (ChIP) analysis. As shown in Figure 22, PCR 
primers were used to amplify a 599bp fragment (-11,039 to -10,441) that contains the 
major block of the 61 ‘TTTGT’ repeats (-10,995 to -10,478) in the distal 5’-flanking 
area of mouse Pecam-1 (Fig. 22A). The primers amplified sonicated eEPC chromatin 
that was precipitated with an anti-Foxc1 goat polyclonal antibody (Fig. 22B), but no 
amplification took place on chromatin precipitated with a goat Isotype IgG control 
antibody. The Input DNA sample (sonicated total eEPC chromatin) showed a positive 
control signal, whereas the PCR reaction with no template chromatin (H2O) was 
negative and proved the specificity of the PCR reaction. In addition, eEPC chromatin 
was amplified with a primer pair that spans a 171bp sequence  upstream of the 
repeat motif (-13,021 to -12,851) and served as negative non-binding control site for 
Foxc1 in the distal 5’-flanking area of Pecam-1.  No amplification of anti-Foxc1 goat 
polyclonal antibody-precipitated chromatin was seen in the PCR with these primers 
(Fig. 22B).  
 
In addition, goat Isotype IgG antibody-precipitated chromatin and Input DNA showed 
no PCR signal and a positive signal, respectively. Finally, control PCR (no template 
chromatin) did not yield a PCR product, indicating the specificity of the observed 
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amplicons. In order to increase the interpretation of the experiment, the PCR bands 
were evaluated by means of agarose gel densitometry.  
 
Figure 22. Legend next page 
 
(TTTGT)n repeat motif area
Non-Foxc1 responsive area 
-11497 TGAAAGTTTTGCCTTTTGAAAGGATGGGTTATCCAGGAGGCCTAACCCTATGTAAAAAGG
-11437 CAGTTTAGGGTTCAGACACAGCCAGCAATCAGCCCCGAGGTTAGCACT GTAGAATTAAG
-11377 GAGAGAATAGGTAGCCGGTGCCATGTGAAGGAGATGAGTTAGATCTAATGTGTTGGCTTG
-11317 GCTTGGAGAAGCAGCACTGCTTGTCATTGGAACCAGTTGCATGTA G GACAGGAGCTTT
-11257 GACCTGGGAGCAATGTCATCCCATGGTCAACACCCTTCTCTATAA C GCATGCCCATGT
-11197 TATTCCTGCATCCCAGACACCATAAGTCCGTGGCTGCTTCCATGCTT AACCAGGATTAT
-11137 AATAGGGTTACAAGTCTGGGGCTGAGTGCAGGAATTATTAACAGGGTTGAAATTGTTAG
-11077 GTGGTGGTGGTGGTGGGGTCTCGGTTAACCCCCCAAGAGA TCCTAAGTTTCACATCCC
-11017 TAGGATGGGCACCAATACTGGTTTTGTTAAATGTTCCTTTTTTTGGTTTTTTTTTTTTTT
-10957 TGG TTTGTTTGTTAAATGTTCCTTTTTGTTTGTTTGTTAAATGTTCCTTTTTGTTTTT
-10897 TGTTTTGTTTGTTTGTTTGTTAAATGTTCTTTTTTGTTTTTTGTTTGTTAAATTTTCCC
-10837 TT TTTGTTTGTTTGTTAAATGTTCCTTTTTTGTTTGTTTGTTAAATGTTCCTTTGTTTG
-10777 TTTGTTAAATGTTCCTTTTTGTTTGTTTGTTTGTTTGTTAGTTAAATGTTCCCTTTT
-10717 TGTTTGTTTGTTAAATGTTCCTTTTTGTTTGTTTGTTAAATGTTCCTGTTTGTTTGTT
-10657 TGTTTGTTTGTTAAATGTTCCCTTTTTTTTGGTTTGTTTGTTAAATGTTCCTTTTTGTT
-10597 TGTTTGTTTGTTAAATGTTCCTTTTTGTTTGTTTGTTTGTTAAATGTTCCTTTTTGTT
-10537 TGTTTGTTTGTTAAATGTTCCTTTTTGTTTTGTTTTGGTTTTTTGTTTGTTTGTTTGTT
-10477 AAATGTTAAATGGTTTTAAAGGTCTGATCCTCCTGACTC ACAAGAGCTGAGATTGCACG
-10417 GGTGAACCGCCACGCCAGTTTGCAGGAT TTTTGGATGGAACGCAGGACGCTGTGCATGC
-10357 TAGGGGTTTCGAGTTTTTGTTTTGTTTGTTAAATGTTCCTTTTTTGTTTGTTTTTTGT
-10297 TAAATGTTCCTTTTTTTGTTTTGTTTTGGTTTTTTTGTTTGTTTGTTAAATGTTCCTTT
-10237 T TTTGTTTGTTTGTTAAATGTTCCTTTTTGTTTGTTTGTTTGTTTGTTTGCCAATACTG
-10177 GTTTTGGTCACTGCAGTTGGTACTAGTGGCTGAGGGACAAGCATATAATTTTTCCCTTG
-10117 AAACCTCTGTGAAAAACATTTAGCTGTTGAGGGGGCTTCACGCTCAGGAGAGCTC
A
IgG 
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Anti 
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Input H 2O
1
2
B
0
0,2
0,4
0,6
0,8
1
1,2
IgG Isotype Anti-Foxc1 Input
0
0,2
0,4
0,6
0,8
1
1,2
IgG Isotype Anti-Foxc1 Input
(TTTGT)n repeat motif area Non-Foxc1 binding area
100% 100%
6%6% 7%
13%
C
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The analysis showed that after amplification of the (TTTGT)n repeat motif area, the 
amount of chromatin precipitated with the anti-Foxc1 antibody is twice as high as 
IgG-precipitated chromatin (6% and 13% compared to the Input, Fig. 22C). In 
contrast, when the Non-Foxc1 binding area is amplified on the chromatin, no 
difference between anti-Foxc1- and IgG-precipitated chromatin was observed (Fig. 
22C).  
 
In brief, ChIP analysis confirmed binding of Foxc1 protein at the (TTTGT)n repeat 
motif on the chromatin in support of the reporter studies. It is noteworthy to mention 
that I also tried to analyze Foxc1 binding to the ‘TTTGT’ repeats by means of 
electrophoretic mobility shift assays (EMSA). Although we were able to induce a shift 
of a biotin-labeled probe consisting of four ‘TTTGT’ repeats with nuclear extract from 
Foxc1-expressing eEPCs, we could not definitively show that the shift was caused 
specifically by Foxc1 protein.  
Thus, we took the in vivo promoter analysis one step further and attempted to study 
the specificity of this transcriptional mechanism in transgenic mice. To this end, LacZ 
Pecam-1-promoter constructs were cloned and used for pro-nucleus injections. 
However, attempts to create transient transgenic mouse embryos carrying the 5’-
Figure 22.  Chromatin Immunoprecipitation (ChIP) to assess Foxc1 binding to the repetitive (TTTGT)n
element in vivo. A) Distal 5’-flanking sequence (-11,497 to -10,063) of the mouse Pecam-1 locus 
containing the two blocks of ‘TTTGT’ pentanucleotide repeats (-10,995 to -10,478 and -10,390 to -
10,188). Underlined red nucleotides point out the binding sites for the primers used to amplify 
immunoprecipitated eEPC chromatin. The primers amplify a 599bp fragment (-11,039 to -10,441) that 
contains the larger block of ‘TTTGT’ pentanucleotide repeats. B) For chromatin immunoprecipitation, 
4x107 eEPCs were transiently transfected with 20 µg of CMV-Foxc1, followed by chromatin purification 
and immunoprecipitation with goat IgG Isotype as a negative control and anti-Foxc1 goat polyclonal. 
Sonicated total eEPC chromatin (Input) was used as positive PCR control. Chromatin was amplified by 
(1) PCR primers that span the major stretch of the (TTTGT)n repeat motif area in the distal 5’-flanking 
area of Pecam-1 (as described in A); (2) PCR primers that amplify a 171bp fragment located in the 5’-
flanking area of Pecam-1 and upstream of the (TTTGT)n repeat motif (-13,021 to -12,851) and served 
as negative control non-binding site. H2O was also used as negative control. Foxc1 binds to the 
(TTTGT)n repeat motif, as indicated by the PCR-signal observed with anti-Foxc1 precipitated 
chromatin (1). The negative control primer do not amplify anti-Foxc1 precipitated chromatin, indicated 
by the missing PCR signal (2).  Input chromatin is amplified by both PCR primers - Input chromatin 
was diluted to 10% in PCR-reaction (1). C) Quantification of PCR bands by means of gel densitometry. 
The intensity of the PCR signal from the Input was calculated for undiluted chromatin and set to an 
arbitrary value of 100%. All other values were normalized accordingly. ChIPs were performed twice. 
All nucleotide numbering is relative to the transcription initiation site (+1) and is based on the UCSC 
Genome Bioinformatics Database (http://www.genome.ucsc.edu). 
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flanking 1.5kb fragment (-11,520 to -10,063) in combination with the minimal 
promoter (-88 to +57) cloned in front of the LacZ reporter gene were not successful, 
thus not allowing further conclusions about the specificity and activity of the Pecam-1 
distal element transcriptional mechanism. 
 
 
3.18 Results – Summary  
 
The data presented in this Ph.D. project have identified Pecam-1 as a direct target of 
Foxc1 in embryonic endothelial progenitor cells. Promoter deletion analysis identified 
a fragment around 11kb upstream of the transcription initiation site that contains a 
Foxc1 responsive element. Sequence analysis identified a microsatellite sequence 
consisting of a (TTTGT)n pentanucleotide repeat motif that is arranged in two 
neighboring blocks. A stepwise deletion of this repeat motif causes a stepwise 
decrease in the ability of Foxc1 to drive reporter gene expression. Bioinformatics 
analysis revealed that this microsatellite sequence is also found randomly distributed 
in short blocks in the distal 5’-flanking area of the human PECAM-1 gene. In 
accordance with the promoter activity assays, ChIP analysis showed that Foxc1 
transcription factor binds to the (TTTGT)n repeat motif upstream of mouse Pecam-1 
on the chromosome in vivo. It is noteworthy that this molecular interaction was not 
observed in mature endothelial lines, such as mouse pancreatic and cardiac ECs, as 
well as bovine aortic ECs, nor in undifferentiated ES cells and Cos7 kidney cells, 
suggesting a specific role in the early stages of endothelial cell differentiation.  
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4. DISCUSSION 
 
Vascular development is a highly organized sequence of events requiring the spatial 
and temporal expression of specific genes. Endothelial differentiation from pluripotent 
stem cells through committed endothelial progenitors is one of the initial steps during 
blood vessel formation. Thereby, the expression of endothelial specific marker genes 
such as Pecam-1 and VE-cadherin is associated with the differentiation process 
toward the endothelial lineage. In addition, recruitment and incorporation of EPCs at 
sites of adult neo-vascularization takes place as a multi-step process consisting of 
attraction, adherence, transendothelial migration and eventually differentiation.  
In the last years, the identification of genomic regulatory sites of vascular specific 
genes has progressed the understanding about the transcriptional mechanisms 
required for vascular specific gene expression, although the mechanisms governing 
the transition from endothelial progenitor cells to endothelial cells are not well 
understood. In order to identify new molecular players during endothelial gene 
expression and differentiation, this Ph.D. thesis took advantage of embryonic EPC 
lines to study the involvement of the Forkhead transcription factor Foxc1 in the EPC-
differentiation process.  The characterization of a Foxc1 binding site embedded 
within a ‘TTTGT’ pentanucelotide microsatellite motif that drives endothelial-specific 
transcription of the Pecam-1 gene preferentially in eEPCs is described herein and 
discussed below.  
 
4.1 Pecam-1 basal promoter activity reflects endogenous transc ript levels  
 
Pecam-1 promoter activity was driven by a 4.5kb-intronic fragment combined with the 
minimal promoter in mature aortic ECs, as well as at lower levels in pancreatic 
endothelial cells (MS1-ECs) and ES cells (Fig. 9A). Vascular-specific genes such as 
Flk-1 and Tie2 were shown to require an intronic enhancer for their endothelial-
directed expression [87, 225], and Pecam-1 may represent another example for this 
type of endothelial-specific gene expression regulation. The strong transcriptional 
activity of the 4.5kb intronic fragment is consistent with the high endogenous 
Pecam-1 expression levels in BAECs, MS1-ECs and ES cells, whereas expression is 
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not seen in kidney cells and immature eEPCs, paralleled by a lack of activity of all 
four promoter plasmids (Fig. 9A,B). Further, reporter gene expression and 
endogenous Pecam-1 activity are in accordance with Pecam-1 expression being 
restricted primarily to the vascular endothelium and certain types of blood cells in 
adult life, whereas it is not expressed on the surface of epithelial cells, muscle cells, 
and fibroblasts, as well as other non-vascular cell lineages [62].  
ES cells, which are derived from the inner cell mass of day 3.5 mouse embryos [222] 
express Pecam-1 and, in addition to the intronic 4.5kb fragment, the long proximal 
promoter areas also drove reporter gene activity (Fig. 9A). Since pluripotent ES cells 
and terminally differentiated endothelial lineages represent different developmental 
stages, it is not unexpected that they may use different combinations of gene 
regulatory elements to drive stage-specific expression of Pecam-1. Overall, it is 
possible that the proximal promoter sequences and also the distal 5’-flanking 3.5kb-
fragment are capable to drive expression during eEPC differentiation, but the strong 
cis-active elements that regulate transcription in mature endothelium are located 
within the intronic 4.5kb-fragemnt. 
 
4.2 Foxc1 induced Pecam-1 expression reflects an eEPC-specific mechanism  
 
Transcriptional activation through the genomic 5’-3.5kb element might represent a 
stage-specific mechanism through a remote regulatory site in embryonic EPCs where 
Foxc1 is required to activate de novo Pecam-1 expression. Consistent with this 
proposition, alterations in endogenous Pecam-1 transcript levels in response to 
Foxc1 gain-of-function are only seen in eEPCs, but not in aortic, pancreatic and 
cardiac ECs, as well as undifferentiated ES cells (Fig. 13). It is also in agreement with 
the lack of significant Foxc1 expression in these cell types. 
In general, gene expression is regulated by genomic sites that are located in close 
proximity of the transcription initiation site (TIS) of a gene, such as cis-active 
elements in the core promoter region. In addition, gene expression is also controlled 
by enhancer/silencer elements, which can be located within introns and upstream or 
downstream of the transcript and at great distances of up to one megabase from the 
TIS [226, 227]. It is possible that Foxc1 transcription factor plays a more significant 
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role activating gene transcription through enhancer regulatory sequences rather than 
being bound by regulatory elements within the core promoter of a target gene. 
Support of this suggestion comes from recent publications that identified Foxc1 
binding sites at remote DNA loci upstream of the T-box transcription factor Tbx1 or 
the Notch-ligand Delta-like 4 (Dll4) gene [181, 195].  
In general, genes are expressed in different tissues or during distinct stages of 
development.  In addition, gene expression can be activated in response to various 
external stimuli under normal or pathophysiological conditions. Extensive studies of 
how gene expression is regulated have established the model that the combined 
activity of multiple regulatory sites controls gene expression in a temporal and spatial 
manner [228, 229]. The identified Foxc1 binding site might represent such a tissue-
and time-specific regulatory element that allows Pecam-1 induction in early 
embryonic angioblasts (eEPCs). This would indicate an analogous situation as with 
the transcriptional control of Tbx1 through Foxc1 and Foxc2, which exclusively drive 
its expression in the head mesenchyme and the pharyngeal endoderm of the embryo 
[195].  
Moreover, cellular heterogeneity is an important factor of endothelial function. The 
vasculature has to adopt organ and tissue-specific characteristics, since every organ 
shares a specific interaction with the blood vessel system to meet its local 
requirements [14]. The phenotypic endothelial heterogeneity is mediated in part by 
temporal and spatial differences in gene expression and regulation [4], and also 
depends on the vascular bed the cells originate from.  For example, lung, kidney and 
brain ECs were shown to have specific patterns of cell surface proteins [230, 231]. 
This molecular diversity is also regulated at the transcriptional level through tissue-
specific regulatory elements [4]. 
 
4.3 Pecam-1 expression is controlled by multiple factors  
 
Past studies showed that specific elements of the human PECAM-1 promoter are 
capable to drive cell-line specific transcription of a reporter gene in vitro. For 
instance, a 1.3kb proximal 5’-flanking sequence of the human PECAM-1 gene is 
lacking consensus TATA or CAAT binding elements, but contains multiple consensus 
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binding sites for different trans-acting factors, such as 2 NF-κB-sites, 4 Ets-sites, 3 
Sp1-sites, 2 E-box-domains, 2 tandem GATA-associated sites, 4 GATA elements 
and 3 shear-stress responsive elements (SSRE) [94]. In addition, two retinoic-acid 
responsive elements are located in the core promoter and might be involved during 
transcriptional regulation. In vitro studies showed that NF-kB is involved in regulating 
PECAM-1 expression in human myeloid cells, such as human promonocytic U937 
cells and macrophages. TNFα elevated human PECAM-1 promoter activity by 2.5-
fold, and NF-κB was shown to function as downstream activator of this process in 
promonocytic cells. [232]. In turn, the transcription factor GATA-2 binds to a cis-
acting GATA element at position -24 in the human PECAM-1 promoter and drives 
optimal lineage specific expression in the megakoryocitic lines HEL and Dami [94]. 
Although activity of this core promoter element was described in megakaryocytes, it 
remained elusive if the same cis-regulatory elements are capable to drive human 
PECAM-1 expression in endothelial cells and cells of the myeloid precursor lineage. 
Regardless, the studies showed that different transcription factors are responsible for 
Pecam-1 expression in different lineages, showing that the tight restriction of 
Pecam-1 gene expression to endothelial cells and certain leukocytes is most likely 
regulated on multiple levels and depends on the action of a multitude of trans-acting 
regulatory factors. This notion is further supported by transgenic mouse studies, 
which showed that the majority of endothelial-specific gene promoter constructs 
direct transcription of reporter genes to endothelial subpopulations in specific 
vascular beds. For example, short pieces of the promoter of vWF or Tie2 only have 
the capacity to drive reporter gene expression in limited endothelial subpopulations 
[233, 234], whereas longer fragments of the 5’-or 3’-flanking loci extend the 
expression patterns to wider areas of the vascular tree [225, 235]. In that respect, the 
distal 5’-flanking Foxc1 binding site could be required to regulate de novo Pecam-1 
expression in angioblasts during vasculogenesis. 
 
4.4 Expression of Pecam-1 in isolated embryonic angioblasts requires a 
specific upstream regulatory element  
 
Depending on the cell type, Pecam-1 is expressed constitutively – as in mature 
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endothelial cells - or requires the presence of special signals for inducible 
expression, as in monocytes, where Pecam-1 expression is regulated during the 
maturation and differentiation to macrophages [236-238]. During PECAM-1 activation 
in human myeloid cells, specific transcription factors, e.g. NF-κB in this case, account 
for its directed expression within the promonocytic lineage. This inducible expression 
most likely has a different type of molecular regulation than the constitutive 
expression found in mature endothelial cells [232]. In accordance, eEPCs may 
require the controlled activity of trans-acting factors such as Foxc1 to initiate 
Pecam-1 expression transiently in eEPCs during the transition from an 
undifferentiated to a differentiated cell stage, but this type of regulation is no longer 
required in mature endothelium of blood vessels. In mature endothelial cells 
constitutive Pecam-1 expression appears to be driven by Foxc1-independent 
mechanisms (Fig. 12 and Fig. 13), involving cis-regulatory elements that are located 
within the minimal promoter and in the 4.5kb intronic enhancer (Fig. 9A) that do not 
require bound Foxc1 protein for their activity. However, since mature endothelial lines 
– mouse and bovine alike - used in this project had Pecam-1 expression driven 
through the intronic 4.5kb-fragment element, it is reasonable to speculate that human 
endothelial cells, such as human umbilical vein endothelial cells (HUVECs) would 
regulate PECAM-1 expression by the same active promoter elements as mouse and 
bovine lines. Nevertheless, it appears that Foxc1 might have an opposite role in 
mature endothelial cells since down-regulation of both endogenous Pecam-1 
expression, as well as reporter gene expression through Pecam-1 promoter 
constructs, was observed after Foxc1 expression.  
In addition, Pecam-1 expression is insulin regulated [239] and Foxc2 has been 
implicated in insulin regulated PAI-1 expression [240]. Thus, it will be interestingly to 
test if FoxC genes are regulating Pecam-1 levels in hyperglycemia. 
  
To address these issues, we attempted to knock-down endogenous FOXC1 
expression in HUVECs by the means of sequence-specific siRNA molecules but 
without succes, likely because of the poor transfection efficiency of HUVECs cells, 
thus not allowing to assess a possible role of FOXC1 at the human PECAM-1 
promoter. Likewise, our attempts to knock-down Foxc1 expression during eEPC-
differentiation by means of siRNA were not realized, thus not allowing to observe a 
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direct effect of lacking endogenous Foxc1 activity on Pecam-1 activation in 
differentiated eEPCs. Alternative future approaches using viral vectors and shRNA 
(small-hairpin RNA) could overcome this problem and allow us to draw conclusions 
about this particular transcriptional mechanism.  
 
4.5 Loss of Foxc1 does not affect pan-endothelial Pecam-1 expression  
 
A stage and/or temporal specific function of Foxc1 at the Pecam-1 locus or a role 
under pathological conditions such as diabetes, might also explain why the 
vasculature of Foxc1-/- embryos still expresses Pecam-1 [180]. Because of the 
endothelial heterogeneity and the complex regulation of Pecam-1 expression, 
absence of one specific trans-factor might not result into an overall lack of gene 
expression. This notion gains further support by the fact that, although Gata-2 was 
implicated in Pecam-1 regulation in megakaryocytes and NF-κB is involved in 
Pecam-1 expression in cells of the monocytic lineage, Pecam-1 expression in 
endothelial cells is not affected by loss of either of these two genes. Studies in 
female Gata-2 +/- knock out mice showed that the vasculature of the placenta of 
Gata-2 -/- embryos still stains positive for Pecam-1, when compared with the 
placenta of wild-type embryos [241]. In addition, mice lacking Ikk1 and Ikk2, two 
genes encoding critical IκB kinases required to activate NF-κB, still display regular 
Pecam-1 staining of the embryonic vasculature, although NF-κB activity is absent 
[242]. Alongside, one could argue that loss of Foxc1 alleles in embryos does not 
affect the overall expression of Pecam-1 in the pan-vascular bed, because this 
transcriptional mechanism rather has specificity for an early endothelial progenitor 
population.   
Besides, transcriptional activation of vascular genes is considered to be under the 
control of a combinatorial interaction of different classes of transcription factors that 
might provide the molecular basis for the endothelial cell-specificity [84], as it has 
been shown for the e.g. Tie2 gene [243]. This might further explain why the absence 
of one trans-factor, i.e. Foxc1 in this case, might not lead to an overall loss of pan-
endothelial Pecam-1 expression, even if Foxc1 was required for Pecam-1 activity in 
mature vascular beds. Additionally, as mentioned in the Introduction, FoxC proteins 
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were shown to activate the arterial marker Delta-Like 4 (Dll4), a Notch ligand, through 
a Fox binding site around 3.5kb upstream of the transcription start site. However, the 
authors showed that mutations in the Fox binding site do not result into a complete 
loss of promoter activity, suggesting that further transcription factors account for the 
activation of Dll4 in arterial endothelium [181]. Likewise, loss of Foxc1 might be 
compensated by other transcription factors whose interaction with the Pecam-1 
regulatory sites might still be sufficient to drive Pecam-1 in mature endothelium.  
In addition, the presence of co-factors could support the specificity of a transcription 
factor thus allowing its activity at a certain promoter to be restricted to the vasculature 
or certain endothelial sub-compartments [4, 84]. 
In that light, the molecular basis for the eEPC-specificity of Foxc1 induced Pecam-1 
expression could be defined by a combination of Foxc1 and other transcription 
factors and/or co-activators, which in turn might be unavailable in ES cells and 
mature endothelial cells. For example, the transcriptional adaptor proteins p300 and 
CREB-binding protein (CBP) form a multiprotein/DNA complex with HIF1α while 
binding the VEGF gene, thus activating transcription in response to hypoxia [244], 
and FoxO transcription factors were shown to interact with CBP/p300 in mediating 
transcriptional activity [245]. However, an interaction of Foxc1 protein with CBP/p300 
during Pecam-1 activation in eEPCs was not seen (data not shown) and further 
putative co-activators of Foxc1 at the Pecam-1 locus were not identified in the frame 
of this Ph.D. project.  
 
 
4.6 Foxc1 binds a microsatellite repeat in the 5’-a rea of the mouse Pecam-1 
gene 
 
The Foxc1 binding site was identified within a microsatellite element that is 
comprised of a ‘TTTGT’ pentanucleotide repeat.  Microsatellites, also called simple 
sequence repeats (SSR), consist of tandem repeats of up to six very short nucleotide 
motifs [246], that in many cases show multiallelic polymorphism. In eukaryotic 
genomes, SSRs are widely dispersed in non-coding regions, and coding regions of 
mammalian genomes often include trinucleotide SSRs [247]. They are thought to 
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represent a source of quantitative genetic variation. Their polymorphic nature, due to 
variations in the number of the tandem repeat units caused by mutations in the DNA 
through slippage-like events during replication [248, 249], makes them suitable 
markers for genetic mapping and kinship studies [250, 251]. Next to coding 
sequences of genes, SSRs have been found within introns as well as 5’-and 3’-UTRs 
where they can serve as regulatory elements of transcription.  This is especially true 
for upstream promoter elements, where SSRs were shown to be involved in gene 
regulation.  
Specifically, the human epidermal growth factor receptor (EGF-R) gene contains two 
blocks of (TCC)3 repeats in its upstream promoter elements that were suggested to 
bind Sp1 and to be involved in regulation of EGF-R transcription [252]. Likewise, a 
motif of seven ‘TCCC’ repeats in the human proto-oncogene c-KI-ras promoter [253] 
is involved in transcriptional regulation, and the transcription factor p53 was 
described to activate the expression of the tumor-suppressor gene PIG3 through 
binding to a (TGYCC)n (Y= C or T) pentanucleotide repeat sequence within the 
human PIG3 promoter [254]. Another polymorphic (CCT)n trinucleotide repeat, 
located around 100 nucleotides upstream of the major transcription initiation site of 
the human paired box gene-7 (PAX7) gene, was shown to confer high transcriptional 
efficiency to the PAX7 promoter [255]. Those studies and others (reviewed in [256]) 
underscore the capability of repeated short sequence motifs to direct gene 
transcription.  
Additional support comes from a recent publication that aimed at identifying 
transcription factor binding sites within microsatellite sequences across the entire 
human genome [251]. Iglesias and co-workers investigated the functionality of 
microsatellites located near the transcription initiation site  (TIS - around the first 
exon) and the first intron of all annotated genes of the human genome and assessed 
their effect on gene expression as cis-regulatory elements. Among others, the 
pentanucleotide ‘AAACA’ (reverse sequence of ‘TTTGT’) was found in 12 
polymorphic microsatellites in the human genome. It was shown that the ‘TTTGT’ 
repeats have the capacity to bind DNA associated proteins in band shift assays, 
indicating that this repeat-motif sequence can indeed serve as a binding-site and cis-
regulatory element in gene promoters [251]. Although this study did not further 
investigate the precise nature of putative DNA binding proteins at the ‘AAACA’ 
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microsatellite repeat, we propose that Foxc1 might be among the group of yet to be 
identified proteins that has the ability to bind at ‘AAACA’ repeats on the chromatin 
and induce transcription of neighbouring genes. We found a similar scenario in band 
shift assays by using a biotin-labeled probe comprising four ‘TTTGT’ repeats that is 
shifted in presence of eEPC nuclear exract (data not shown), arguing that this 
pentanucleotide repeat is able to act as Fox protein binding site. However, the data 
obtained in these assays require further evaluation before being presented in a final 
conclusive form.  
Further, it is plausible that the promoter activation through the repeat motif has 
biological relevance, since, if there was unspecific binding of ectopically expressed 
Foxc1 to the (TTTGT)n repeat motifs, it would likely occur in all the co-transfection 
experiments with the different cell lines included in this study. Alongside, the 
decreased Pecam-1 mRNA levels in mature pancreatic endothelial cells (MS1-ECs) 
and ES cells in response to Foxc1 (Fig. 12B) indicate that the transcriptional effect of 
Foxc1 at the Pecam-1 promoter may be biphasic. Foxc1 could carry out a 
repressional effect in mature endothelial cells and ES cells, whereas a potential 
specific function as transcriptional activator specifically takes place in eEPCs (Fig. 
13). This is in accordance with the general notion that Fox transcription factors can 
act as trans-activators and trans-repressors [116].  
 
4.7 The activity of the upstream element depends on  the number of 
microsatellite repeat motifs  
 
Consistent with the observed drop in reporter expression after the (TTTGT)n motif is 
shortened, Iglesias et al. showed that protein binding capacity increased with higher 
numbers of AAACA repeats, with 7 repeats displaying about twice the binding 
capacity as four repeats [251]. In this respect, the ‘TGYCC’ repeat-motif in the human 
PIG3 promoter displays polymorphism in 117 human individuals, with four different 
motif lengths consisting of either 10,15,16, or 17 repeats [254]. Decreased numbers 
of ‘TGYCC’ repeats derived from the PIG3 promoter of different human individuals 
conferred a decreased degree of responsiveness to p53 when combined with a 
minimal promoter. Parallel overexpression of p53 showed that a motif comprising of 
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17 repeats confers an about 4-fold higher promoter activity compared to the allele 
containing only 10 repeats [254].  
Moreover, the binding affinity of the transcription factor Sp1 for (CCT)n-repeats in the 
human PAX7 promoter directly correlated with the repeat numbers of different alleles 
[255]. Genotype analysis showed that the polymorphic (CCT)n-repeat in the human 
PAX7 promoter has length variation in a Western European population and consists 
of three different alleles with 8,10, or 11 repeats in close proximity to the TIS and as 
for the ‘TTTGT’ and ‘TGYCC’ repeat motifs, alleles with a higher repeat number, in 
this case 11 repeats, drove higher reporter gene expression in rhabdomyosarcoma 
cells than alleles containing 8 or 10 repeats [255]. In similar fashion, I found that 
increasing numbers of ‘TTTGT’ repeats drive higher reporter activity in vitro in the 
Pecam-1 reporter gene studies. 
 
4.8 The repeat number compensates the loss of the c onsensus motif  
 
Despite its low similarity to the p53 consensus binding sequence, the ‘TGYCC’ 
repeat motif in the human PIG3 promoter was shown to be necessary and sufficient 
to activate PIG3 expression in response to p53 [254]. 
Alongside, Fox proteins were also shown to bind DNA motifs with only partial 
homology to the consensus core sequence and the efficient binding of Fox protein to 
their target DNA also depends on the flanking sequences of the core [116, 155]. In 
that respect, the ‘TTTGT’ pentanucleotide repeat might represent a sub-optimal 
recognition site, which is yet able to bind Foxc1 protein. However, the lower binding 
affinity could explain why high Foxc1 levels were necessary to induce promoter 
activity in the reporter gene assays. The same was true in the case of p53, where 
high amounts of p53 expression plasmid were required to induce a higher activation 
of the PIG3 promoter through binding to the (TGYCC)n repeats in the study of 
Contente and co-workers, compared to gene activation through a p53-consensus 
promoter site [254, 257].  
Next to requiring higher amounts of transcription factor, the deviation from the 
consensus sequence might be compensated by the large number of ‘TTTGT’ motif 
repeats, as found in the mouse Pecam-1 5’-flanking area, thus allowing to pass a 
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threshold level to initiate gene expression. This would also explain that a large 
number of repeat units has to be deleted to significantly decrease reporter gene 
expression, with each single repeat unit contributing weakly to the overall activity.  
 
4.9 Fox proteins can bind low-affinity sides  
 
FoxC expression levels are regarded as a key factor during the precise temporal and 
spatial control of target gene expression, e.g. the progressive loss of functional FoxC 
alleles in embryos is associated with an increasing lateralization of paraxial and 
somite mesoderm, showing a dose-dependent function of the proteins at the DNA 
regulatory sites [192]. Thus, it is speculated that suboptimal Fox binding sites, such 
as the ‘TTTGT’ repeats in our case, need high levels of endogenous Foxc1 protein 
for binding in order to be functionally active.  
Further support for a crucial dose dependent regulation of target genes by Fox 
transcription factors comes from in vivo studies in C.elegans. During development, 
the FoxA orthologue pha-4 controls pharyngeal development and the concentration 
of Pha-4 protein increases during development, thus activating target genes with low-
affinity binding site in their promoters, whereas during the onset of pha-4 
transcription, low protein concentrations are only able to activate target genes with 
high affinity binding sites within their regulatory sequences [258]. If target gene 
expression depends on a fine balanced level of Fox protein under certain 
circumstances, the presence of low-affinity sites such as the ‘TTTGT’ repeat motif 
described herein may allow a mechanism by which Pecam-1 transcript levels depend 
on the intracellular concentration of Foxc1 protein, thus allowing a dose-dependent 
control of gene expression. 
 
 
4.10 Microsatellite repeats represent species-speci fic transcriptional elements  
 
The lack of a similar arrangement of the (TTTGT)n repeat motif at the human locus 
makes the two blocks of repeat units a unique feature of the mouse Pecam-1 locus 
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(Fig. 19). However, a total of 45 ‘TTTGT’ repeat units was identified further upstream 
of the transcriptional start site of human PECAM-1 (Fig. 20). Unlike in the mouse, 
those repeats were shown to be distributed more randomly in shorter blocks of up to 
6 repeat units. As a general rule, microsatellite repeats are considered to have 
evolved differently between closely related species, e.g., the human genome 
contains more and longer polymorphic repeats (especially dinucleotides), compared 
to the genome of chimpanzees or other related primates [259].  Thus, it is unlikely to 
expect a similar microsatellite motif – consisting of a comparable number and 
arrangement of ‘TTTGT’ pentanucleotides – directly at the corresponding genomic 
locus in orthologue species. Further support for a cis-regulatory role of the (TTTGT)n 
repeat motif comes from our Bioinformatics analysis, that identified an experimentally 
verified Foxc1 binding site at the Tbx1 locus [195], containing the same ‘TTTG’ core 
sequence that was also as identified by the software within the ‘TTTGT’ repeats at 
the mouse and human Pecam-1 locus (Fig. 18, Fig. 20). Hence, we suggest that this 
microsatellite motif is involved in regulating the transcriptional activity of mouse and 
human Pecam-1.  
Functional conservation of a transcriptional regulatory activity of a microsatellite 
repeat sequence has also been described for the human PAX7 promoter, where the 
microsatellite shows a high conservation to the orthologue sequence in the mouse, 
which, interestingly, does not consist of a (CCT)n repeat motif, but rather a C/T rich 
sequence that might serve as a Sp1 binding site in vitro [255].  
As a general assumption, mutational processes that lead to the diversity of simple 
sequence repeats include replication slippage, point mutation, and recombination. If 
DNA changes are not corrected by the DNA mismatch repair system, then new 
alleles at the microsatellite loci are generated and eventually result into alternate 
phenotypes and contribute to the species specificity of microsatellites. This kind of 
divergence has been proposed to be responsible, at least in part, for temporal and 
quantitative differences in gene expression between species [251].  
 
In conclusion, we speculate that a cis-regulatory potential of a sequence repeat motif 
can be contained between related species, although there might be differences and 
variations on the nucleotide level or the position of the microsatellite repeat relative to 
the transcription initiation site of a gene. 
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4.11 Variation in transcription factor binding site s across species  
 
In general, binding sites for highly conserved transcription factors can vary 
significantly between mouse and human, as shown in a recent study that used 
custom DNA microarrays which analyzed 10kb of sequences surrounding the known 
transcription start sites of 4000 orthologue gene pairs from mouse and human [260]. 
The DNA was precipitated from primary mouse and human hepatocytes using 
antibodies against liver-specific transcription factors, since hepatocytes and the 
transcription factors that control their development and function are highly conserved 
among mammals [261]. Interestingly, the study showed that up to 89% of orthologue 
promoter regions bound by a protein in one species were not recognized by the 
same protein in the second species, depending on the individual factor. For example 
only 26% of orthologue genes bound by hepatocyte nuclear factor 6 (HNF6) in 
human hepatocytes were recognized by this transcription factor in mouse 
hepatocytes. Moreover, the location of binding events varied widely between the two 
species, e.g. the binding of HNF6 at a certain locus was shifted about 4 kb from the 
promoter region in human DNA to the first intron in the mouse DNA [260]. 
Furthermore, 41 orthologue pairs were bound by the related transcription factor 
HNF1A in both species, but only 20 binding events occurred in sequences that were 
aligned between mouse and human. This high mobility was regarded to account for 
the most notable feature of the divergent transcription factor binding sites.  
 
Generally, comparison of mouse and human genomic regulatory regions is used to 
identify putative binding sites for different classes of transcription factors. And 
conservation of sequence motifs suggests that a family of transcription factors might 
be important in regulating the e.g. vascular-specific expression of a certain gene [84]. 
However, bioinformatics studies suggest that comparative genomics may not always 
be sufficient to decode putative regulatory elements in promoter areas. Smith et al. 
showed that fewer than 10% of orthologue promoter pairs from mouse and human 
retain significant conservation, suggesting that tissue-specific sites would be difficult 
to identify by relying purely on traditional cross-species analysis through co-linear 
promoter alignment, which may result into high false-negative detection rates [229, 
260]. In order to identify putative Foxc1 binding sites at the human PECAM-1 locus 
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that might not match with the mouse sequence in co-linear alignments, we took 
advantage of the MatInspector and DiAlign Tools [219, 220]. In accordance with the 
above mentioned study [260], we suggest that the identified dispersed (TTTGT)n 
repeat motifs upstream of the human PECAM-1 gene might present another example 
of a transcription factor binding site that has a shifted position at the human locus, as 
compared to the mouse locus.  
In addition, it cannot be excluded that the human PECAM-1 locus contains Foxc1 
binding motifs, which might be embedded inside regular consensus sequences that 
are not in alignment with the repeat motif in the mouse genome and were not 
identified by the bioinformatics analysis applied in this study. Besides this notion, it is 
possible that further (TTTGT)n repeat motifs, other ‘TG’-rich sequences or regular 
Foxc1 consensus binding sites are located in genomic areas of the human locus that 
were not analyzed at all for the presence of such sites, e.g. areas far upstream of the 
transcription initiation site, as well as downstream of the PECAM-1 gene or within 
intronic regions.  This is making it hard to speculate about the possible existence of 
further Foxc1 sites with reasonable accuracy.   
In conclusion, the lack of identified Foxc1 binding sites in areas of the human locus 
that correspond to the microsatellite in the mouse sequence, does not rule out the 
possibility that putative functional Foxc1 sites, such as the already identified ‘TTTGT’ 
repeats in the human sequence, are present in distinct areas of the human PECAM-1 
locus. 
 
 
4.12 Difference between Foxc1 and Foxc2 functions  
 
Although the biological functions of the two closely related members of the FoxC 
subfamily are often conserved during evolution, their activities differ in some 
instances. For example, the congenital hydrocephalus phenotype in Foxc1 -/- mice is 
not seen in Foxc2 -/- mice [187, 189]. In turn, Foxc2 was shown to have stronger 
transcriptional activity in the cardiovascular system than Foxc1. [181, 190, 240].  For 
instance, the formation of the cardiac outflow tract, the right ventricle and the inflow 
tract is severely impaired in compound Foxc1+/-; Foxc2-/- and Foxc1-/-;Foxc2-/- 
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embryos, whereas compound Foxc1-/-;Foxc2+/- embryos do not display this kind of 
developmental abnormalities [190]. Moreover, Foxc2, but not Foxc1, was shown to 
bind and transactivate the promoter of the plasminogen activator inhibitor-1 (PAI-1) 
gene in endothelial cells [240].  
 
Although Foxc1 and Foxc2 differ considerably in their sequence, the DNA binding 
domains are almost 100% identical [116]. In this respect, it is surprising that only 
Foxc1 leads to transcriptional activation of the endogenous Pecam-1 gene as well as 
of the upstream 5’-flanking 3.5kb element in the reporter construct. This likely occurs 
because Foxc1 might be able to bind to other proteins within the transcriptional 
complex forming on the Pecam-1 promoter, but Foxc2 does not. This in turn would 
not be surprising since the two FoxC homologues differ extensively in the non-DNA 
binding domains [116].  This selective activation of Pecam-1 through Foxc1 likely 
represents another example of a functional difference between the closely related 
FoxC proteins, leading to gene target specificity under certain conditions;  this in turn 
is consistent with the fact that the two genes cannot compensate for each other in 
many developmental stages. 
 
 
4.13 Foxc1 as regulator of vascular adhesion molecu les?  
 
Myeloid cells regulate Pecam-1 activity through involvement of the transcriptional 
regulator NF-κB (Nuclear Factor-kappa B), which has also been implicated in the 
transcriptional regulation of other members of the Ig (Immunglobuline) superfamily, 
such as Icam-1 (Intercellular Adhesion Molecule-1) and Vcam-1 (Vascular Cell 
Adhesion Molecule-1) [262, 263], that are both implicated in endothelial-leukocyte 
adhesion during pathological conditions. These finding suggest a broad role of NF-κB 
in regulating the expression of cell adhesion molecules on the endothelium in 
response to environmental stimuli such as those occuring during inflammation. In 
accordance, in the frame of this project, Foxc1 and Foxc2 were shown to induce 
expression of Icam-1 and the chemokine receptor Cxcr4 (Fig. 4) in mouse eEPCs. 
Others have shown the induction of Cxcr4 by FoxC proteins in endothelial cells (Tom 
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Kume, personal communication) and Vcam-1 was identified as a target gene of 
Foxc1 and Foxc2 (Tom Kume, unpublished observations). As for NF-κB, our findings 
of Pecam-1 as well as Icam-1 and Cxcr4 as target genes could indicate a role of 
FoxC transcription factors in regulating the expression of genes encoding for surface 
proteins that typically are involved in the recruitment and adhesion of bone marrow-
derived peripheral blood cells of the leukocytic lineage to target organ sites during 
pathological conditions such as inflammation. However, further studies such as gain 
of function analysis in endothelial cell cultures or in vivo studies using FoxC knock-
out animal models will be necessary to verify this hypothesis.   
 
4.14 Conclusion  
 
In summary, transgenic overexpression of the transcription factor Foxc1 in eEPCs 
identified a transcriptional mechanism that up-regulates mouse Pecam-1 expression 
in undifferentiated embryonic endothelial progenitor cells, which represent an early 
angioblast population [108]. Most likely, Foxc1-induced Pecam-1 expression is active 
as a stage-specific mechanism in eEPCs as part of the molecular endothelial 
heterogeneity and may not reflect a general pan-endothelial transcriptional 
mechanism of Pecam-1 in mature vascular beds. Alternatively, Foxc1 might play a 
role in suppressing Pecam-1 expression under special circumstances like during 
inflammatory conditions or hyperglycemia. It was shown that the induction of Pecam-
1 expression by Foxc1 is direct, thus suggesting that Foxc1 may be involved in the 
initial control of endothelial differentiation by inducing Pecam-1. The results 
presented here indicate that Foxc1 regulates Pecam-1 induction through a distal 5’-
flanking binding site composed of a tandem repeated ‘TTTGT’ microsatellite motif 
that reflects the core-pentanucleotide of the Fox consensus binding site [224]. 
Microsatellites repeats have gained increasing importance as regulatory elements in 
gene expression and in human genetic diseases [251]. Yet, it is not entirely clear how 
they function during transcriptional regulation compared to single transcription factor 
binding sites with strong affinities. The data herein provide a new model of gene 
expression regulation involving a cis-active microsatellite repeat. In the future, it will 
be of interest to study the dispersed (TTTGT)n repeat motifs upstream of the human 
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PECAM-1 gene for cis-regulatory activity by an experimental approach in vitro and in 
vivo, through e.g. ChIP analysis. This will add further data about a role of this repeat 
motif in endothelial gene regulation.  
The presented data provide new insight into the regulation of vascular-specific gene 
expression.  Identifying additional targets of Foxc1 and also Foxc2 in endothelial cells 
will also extend our understanding of the role of these transcription factors during 
cardiovascular development and disease.  
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SUPPLEMENTAL TABLE  
 
Gene Symbol Gene Name 
    
Category - Transcription Factors 
Ascl2 Achaete-scute complex homolog-like 2 
Cited4 Cbp/p300-interacting transactivator, with Glu/Asp-r ich carboxy-terminal domain, 4 
c-myc Myelocytomatosis oncogene 
Egr1 Early growth response 1 
Foxa2 Forkhead box A2 
Foxc1 Forkhead box C1 
Foxc2 Forkhead box C2 
Gata4 GATA binding protein 4 
Gata5 GATA binding protein 5 
Gata6 GATA binding protein 6 
Hes5 Hairy and enhancer of split 5 (Drosophila) 
Id1 Inhibitor of DNA binding 1 
Id3 Inhibitor of DNA binding 3 
Klf2 Kruppel like Factor 2 
Klf4 Kruppel like Factor 4 
Sox7 SRY-box containing gene 7 
Sox17 SRY-box containing gene 17 
Sox18 SRY-box containing gene 18 
    
Category - Ligands 
Ang2 Angiopoietin-2 
Bmp2 Bone morphogenetic protein 2 
Bmp4 Bone morphogenetic protein 4 
Dkk1 Dickkopf homolog 1 
Dkk2 Dickkopf homolog 2 
Dkk3 Dickkopf homolog 3 
Dll1 Delta-like 1 (Drosophila) 
Dll4 Delta-like 4 (Drosophila) 
ESL E-selectin Ligand 
Fgf2 Fibroblast growth factor 2 (basic) 
PDGFB Platelet-derived growth factor beta polypeptide  
PSGL-1 Selectin P ligand 
TGFβ1 Transforming growth factor, beta 1 
VEGFA Vascular endothelial growth factor A 
 
 
 
 
 
 
 
 
 
 
Supplemental Table. Gain of function analysis in eEPCs after transient transfection with CMV-
Foxc1 and/or CMV-Foxc2. Table lists genes whose expression was analyzed by RT-PCR 
(continues next page). 
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Gene Symbol Gene Name 
    
Category - Receptors/Adhesion Molecules 
c-Kit Proto-oncogene tyrosine-protein kinase Kit 
Cxcr4 Chemokine (C-X-C motif) receptor 4 
Eng Endoglin 
EphA1 EPH receptor A1 
EphB4 EPH receptor B4 
Efnb2 Ephrin B2 
E-selectin Selectin E  
Flk-1 VEGF Receptor-2 
Flt-1 VEGF Receptor-1 
Icam-1 Intercellular adhesion molecule 1 
Interginav Integrin, alpha V 
Integrinb5 Integrin, beta 5 
Notch1 Notch homolog 1 (Drosophila) 
Notch2 Notch homolog 2 (Drosophila) 
Notch3 Notch homolog 3 (Drosophila) 
PDGFRα Platelet-derived growth factor receptor aplha 
Pecam-1 Platelet/endothelial cell adhesion molecule  
P-selectin Selectin P 
TGFβRII Transforming growth factor, beta receptor II  
Vcam-1 Vascular Cell Adhesion Molecule-1 
VE-Cadherin Cadherin 5, type 2, (vascular epithelium) 
    
Category - Extracellular Matrix 
lamininα Laminin, alpha 2  
lamininβ Laminin, beta 1 
MMP2 Matrix metalloproteinase 2  
MMP9 Matrix metalloproteinase 9 
MMP13 Matrix metallopeptidase 13  
TIMP-2 Tissue inhibitor of metalloproteinase 2 
    
Category - Miscellaneous 
eNos Endothelial Nitric Oxide Synthase 
Tsp-2 Thrombospondin 2 
tPA Plasminogen activator, tissue 
uPA Plasminogen activator, urokinase 
Dvl1    Dishevelled, dsh homolog 1 (Drosophila) 
Dvl2  Dishevelled, dsh homolog 2 (Drosophila) 
Dvl3  Dishevelled, dsh homolog 3 (Drosophila) 
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ABBREVIATIONS  
 
3T3  mouse fibroblast cell line 
BAECs Bovine Aortic Endothelial Cells 
C57/BL6 mouse strain 
cAMP  cyclic Adenosine-Monophosphate 
CD  Cluster of Differentiation (leukocyte surface antigens) 
CGR8  mouse embryonic stem cell line 
ChIP  Chromatin Immunoprecipitation 
Cos7  green monkey kidney cell line 
Cy3  red fluorescence dye, conjugated to secondary antibodies 
DNase Deoxyribonuclease 
dNTP  Deoxyribonucleosidtriphosphate/Deoxyribonucleotide 
ECs  Endothelial Cells 
EDTA  Ethylenediaminetetraacetate  
eEPCs Embryonic Endothelial Progenitor Cells 
EGFP  Enhanced Green Fluorescence Protein 
EMSA  Electrophoretic Mobility Shift Assay 
EPCs  Endothelial Progenitor Cells 
ES  Embryonic Stem cells 
FACS  Fluorescence Activated Cell Sorting 
FITC Fluorescein-isothiocyanate (green dye conjugated to secondary 
antibodies) 
fmol femtomole (10-15 mole) 
g  constant of gravity (9,81 m/s2) or gram 
H5V-ECs mouse cardiac endothelial cell line 
HSCs  Hematopoetic Stem Cells 
HEPES N-(2-Hydroxyethyl)piperazin-N`-2-ethansufloacid  
IgG  Immunoglobuline 
l  liter 
M  molar (mol/l) 
min  minutes 
ml  milliliter (10-3 liter) 
Abbreviations 
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mM  millimolar (10-3 molar) 
mol  mole (6.022x1023  atoms or molecules) 
mmol  millimole (10-3 mole) 
µl  microliter (10-6 liter) 
µM  micromolar (10-6 molar) 
µmol  micromole (10-6 mole) 
MS1-EC mouse pancreatic endothelial cell line 
nmol  nanomole (10-9 mole) 
ng  nanogram (10-9 gram)  
o/n  overnight 
PBS  Phosphate buffered saline 
PCR  Polymerase Chain Reaction 
PE Phycoerythrin (red fluorescence dye conjugated to secondary  
antibodies) 
pmol  picomole (10-12 mole) 
qPCR quantitative real-time PCR 
RNase Ribonuclease 
RT-PCR Reverse Transcriptase Polymerase Chain Reaction 
sec  seconds 
SMCs  Smooth Muscle Cells 
FT4b  mouse eEPC line 
T17b  mouse eEPC line 
T19b  mouse eEPC line 
TBE  Tris-borate EDTA 
TIS  Transcription Initiation Site 
Tris  Tris(hydroxymethyl)-aminomethane 
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